Estimated HIV Incidence and Prevalence in the United States, 2017–2021: Tables

Print
Related Pages
All Tables

Report Contents

Other Reports

Table 1. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2017
Assigned sex at birth
Male 29,700 2.1 28,500—30,900 22.3 21.4—23.2
Female 6,800 4.1 6,200—7,300 4.9 4.5—5.3
Age at infection (yr)
13–24 9,300 3.7 8,600—10,000 18.0 16.7—19.4
25–34 13,600 3.1 12,700—14,400 29.9 28.1—31.8
35–44 6,500 4.5 5,900—7,000 15.8 14.5—17.2
45–54 4,300 5.5 3,900—4,800 10.3 9.1—11.4
≥55 2,800 7.0 2,400—3,200 3.0 2.6—3.5
Race/ethnicity
American Indian/Alaska Native 190 26.3 90—290 9.6 4.7—14.6
Asian 600 15.3 420—780 3.9 2.7—5.0
Black/African American 15,100 2.9 14,300—16,000 45.3 42.8—47.8
Hispanic/Latinoc 10,100 3.8 9,400—10,900 22.5 20.9—24.2
Native Hawaiian/other Pacific Islander 60 *49.1 0—110 11.7 0.4—22.9
White 9,000 3.7 8,400—9,700 5.3 4.9—5.6
Multiracial 1,400 10.1 1,100—1,600 30.0 24.1—36.0
Transmission categoryd
Male-to-male sexual contacte 24,500 2.3 23,400—25,600 — —
Injection drug usef 2,400 6.6 2,100—2,700 — —
Male 1,300 9.7 1,100—1,600 — —
Female 1,100 8.9 930—1,300 — —
Male-to-male sexual contacte and injection drug usef 1,400 8.8 1,200—1,600 — —
Heterosexual contactg 8,100 4.2 7,400—8,800 — —
Male 2,500 9.1 2,100—3,000 — —
Female 5,600 4.7 5,100—6,100 — —
Region of residence
Northeast 5,100 5.1 4,600—5,600 10.7 9.6—11.8
Midwest 4,900 5.1 4,400—5,300 8.5 7.7—9.3
South 19,000 2.6 18,000—20,000 18.4 17.5—19.4
West 7,500 4.2 6,900—8,100 11.6 10.7—12.6
Totalh 36,500 1.9 35,100—37,800 13.4 12.9—13.9

 

Table 1. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2018
Assigned sex at birth
Male 29,400 2.4 28,000—30,800 21.9 20.9—23.0
Female 6,700 4.7 6,100—7,300 4.8 4.3—5.2
Age at infection (yr)
13–24 8,400 4.4 7,700—9,200 16.5 15.0—17.9
25–34 13,800 3.5 12,900—14,800 30.3 28.2—32.4
35–44 6,700 5.0 6,000—7,300 16.2 14.6—17.8
45–54 4,200 6.4 3,700—4,800 10.2 8.9—11.5
≥55 2,900 7.6 2,500—3,400 3.1 2.6—3.6
Race/ethnicity
American Indian/Alaska Native 180 *31.2 70—280 8.9 3.5—14.4
Asian 560 18.2 360—760 3.5 2.3—4.8
Black/African American 15,000 3.3 14,000—15,900 44.4 41.6—47.3
Hispanic/Latinoc 10,100 4.3 9,200—10,900 21.9 20.1—23.8
Native Hawaiian/other Pacific Islander … … … … …
White 9,000 4.2 8,200—9,700 5.2 4.8—5.7
Multiracial 1,300 11.6 1,000—1,600 27.8 21.5—34.1
Transmission categoryd
Male-to-male sexual contacte 23,900 2.7 22,700—25,200 — —
Injection drug usef 2,600 7.6 2,200—3,000 — —
Male 1,500 10.3 1,200—1,800 — —
Female 1,100 10.6 910—1,400 — —
Male-to-male sexual contacte and injection drug usef 1,500 9.2 1,200—1,800 — —
Heterosexual contactg 8,000 4.8 7,200—8,800 — —
Male 2,500 10.3 2,000—3,000 — —
Female 5,500 5.3 5,000—6,100 — —
Region of residence
Northeast 5,000 5.8 4,400—5,500 10.4 9.2—11.5
Midwest 4,800 5.8 4,300—5,300 8.4 7.4—9.3
South 18,800 3.0 17,700—19,900 18.0 16.9—19.1
West 7,600 4.7 6,900—8,300 11.7 10.6—12.8
Totalh 36,100 2.2 34,600—37,700 13.2 12.6—13.7

 

Table 1. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2019
Assigned sex at birth
Male 28,500 2.8 26,900—30,000 21.1 19.9—22.3
Female 6,400 5.4 5,700—7,000 4.5 4.0—5.0
Age at infection (yr)
13–24 7,700 5.4 6,900—8,500 15.0 13.5—16.6
25–34 13,500 4.0 12,500—14,600 29.4 27.1—31.7
35–44 6,800 5.7 6,000—7,500 16.2 14.4—18.0
45–54 3,900 7.5 3,400—4,500 9.7 8.2—11.1
≥55 2,900 8.7 2,400—3,400 3.0 2.5—3.6
Race/ethnicity
American Indian/Alaska Native 210 *32.7 70—340 10.4 3.7—17.0
Asian 540 20.3 330—760 3.4 2.0—4.7
Black/African American 14,400 3.8 13,300—15,400 42.3 39.1—45.4
Hispanic/Latinoc 9,600 5.1 8,600—10,600 20.5 18.4—22.5
Native Hawaiian/other Pacific Islander … … … … …
White 8,800 4.8 8,000—9,600 5.1 4.7—5.6
Multiracial 1,300 13.3 930—1,600 26.0 19.2—32.7
Transmission categoryd
Male-to-male sexual contacte 23,100 3.1 21,700—24,500 — —
Injection drug usef 2,600 8.6 2,200—3,000 — —
Male 1,400 12.4 1,100—1,800 — —
Female 1,200 11.6 890—1,400 — —
Male-to-male sexual contacte and injection drug usef 1,500 10.4 1,200—1,800 — —
Heterosexual contactg 7,600 5.5 6,800—8,400 — —
Male 2,400 11.5 1,900—3,000 — —
Female 5,200 6.1 4,600—5,800 — —
Region of residence
Northeast 4,700 6.9 4,100—5,300 9.8 8.5—11.2
Midwest 4,500 6.9 3,900—5,200 7.9 6.8—9.0
South 18,400 3.5 17,100—19,600 17.4 16.3—18.6
West 7,200 5.5 6,500—8,000 11.0 9.8—12.2
Totalh 34,800 2.5 33,100—36,600 12.6 12.0—13.2

 

Table 1. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2020 (COVID-19 Pandemic)b
Assigned sex at birth
Male 27,700 3.4 25,900—29,600 20.2 18.8—21.6
Female 5,900 6.6 5,100—6,700 4.2 3.6—4.7
Age at infection (yr)
13–24 6,900 6.8 6,000—7,800 13.3 11.5—15.1
25–34 13,700 4.8 12,400—14,900 29.9 27.1—32.7
35–44 6,700 6.9 5,800—7,600 15.5 13.4—17.6
45–54 3,700 9.2 3,000—4,400 9.0 7.4—10.6
≥55 2,700 10.6 2,200—3,300 2.8 2.2—3.4
Race/ethnicity
American Indian/Alaska Native 230 *35.9 70—390 11.3 3.3—19.2
Asian 510 25.2 260—760 3.1 1.5—4.6
Black/African American 13,900 4.7 12,600—15,200 40.3 36.5—44.0
Hispanic/Latinoc 9,100 6.3 8,000—10,200 18.9 16.5—21.2
Native Hawaiian/other Pacific Islander … … … … …
White 8,800 5.6 7,800—9,700 5.1 4.5—5.7
Multiracial 1,100 17.0 730—1,500 21.6 14.4—28.8
Transmission categoryd
Male-to-male sexual contacte 22,700 3.8 21,000—24,400 — —
Injection drug usef 2,600 10.9 2,000—3,100 — —
Male 1,500 14.7 1,100—2,000 — —
Female 1,000 15.6 700—1,300 — —
Male-to-male sexual contacte and injection drug usef 1,400 13.2 1,000—1,700 — —
Heterosexual contactg 6,900 6.8 6,000—7,800 — —
Male 2,100 15.1 1,400—2,700 — —
Female 4,900 7.4 4,200—5,600 — —
Region of residence
Northeast 4,600 8.4 3,800—5,300 9.3 7.8—10.9
Midwest 4,700 8.1 3,900—5,400 8.1 6.8—9.3
South 17,200 4.3 15,700—18,600 16.2 14.8—17.6
West 7,200 6.6 6,300—8,200 10.9 9.5—12.4
Totalh 33,600 3.1 31,600—35,700 12.1 11.3—12.8

 

Table 1. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2021b
Assigned sex at birth
Male 25,900i 4.0 23,900—27,900 18.8 17.3—20.2
Female 6,200 6.9 5,400—7,000 4.4 3.8—5.0
Age at infection (yr)
13–24 6,100i 8.0 5,200—7,100 11.8 10.0—13.7
25–34 12,600 5.6 11,200—14,000 27.7 24.7—30.7
35–44 6,800 7.6 5,800—7,800 15.6 13.3—18.0
45–54 3,600 10.3 2,900—4,300 8.8 7.0—10.6
≥55 3,000 11.3 2,300—3,600 3.0 2.3—3.7
Race/ethnicity
American Indian/Alaska Native 190 *45.8 20—360 9.2 0.9—17.4
Asian 470 29.6 200—750 2.8 1.2—4.5
Black/African American 13,000i 5.4 11,600—14,300 37.3 33.4—41.3
Hispanic/Latinoc 9,300 6.9 8,100—10,600 18.9 16.4—21.5
Native Hawaiian/other Pacific Islander … … … … …
White 8,200 6.5 7,100—9,200 4.8 4.2—5.4
Multiracial 890i 21.1 520—1,300 17.0 10.0—24.1
Transmission categoryd
Male-to-male sexual contacte 21,100i 4.4 19,300—23,000 — —
Injection drug usef 2,500 12.4 1,900—3,100 — —
Male 1,400 17.6 930—1,900 — —
Female 1,100 17.3 710—1,400 — —
Male-to-male sexual contacte and injection drug usef 1,300 15.2 890—1,600 — —
Heterosexual contactg 7,100 7.2 6,100—8,100 — —
Male 2,000 16.5 1,400—2,700 — —
Female 5,100 7.6 4,300—5,800 — —
Region of residence
Northeast 4,400 9.4 3,600—5,200 9.0 7.3—10.7
Midwest 4,400 9.2 3,600—5,200 7.6 6.2—9.0
South 16,700i 4.8 15,100—18,200 15.6 14.1—17.1
West 6,600 7.7 5,600—7,600 10.0 8.4—11.5
Totalh 32,100i 3.5 29,900—34,300 11.5 10.7—12.2

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE >50% are not shown and are replaced with an ellipsis (…).

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
bEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
cHispanic/Latino persons can be of any race.
dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
hIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
iIndicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2017
Male
Age at infection (yr)
13–24 3,900 5.6 3,500—4,400 106.6 94.9—118.2
25–34 4,300 5.4 3,900—4,800 139.9 125.2—154.6
35–44 1,500 9.5 1,200—1,800 60.1 48.9—71.2
45–54 920 12.4 700—1,100 37.3 28.3—46.4
≥55 690 14.9 490—890 17.1 12.1—22.1
Transmission categoryc
Male-to-male sexual contactd 9,300 3.6 8,600—9,900 — —
Injection drug usee 320 18.8 200—440 — —
Male-to-male sexual contactd and injection drug usee 260 20.2 150—360 — —
Heterosexual contactf 1,500 11.6 1,100—1,800 — —
Subtotalg 11,300 3.4 10,600—12,100 72.0 67.3—76.8
Female
Age at infection (yr)
13–24 670 13.3 500—850 18.7 13.8—23.6
25–34 1,100 10.4 860—1,300 34.2 27.2—41.2
35–44 790 12.1 600—980 28.8 22.0—35.7
45–54 670 13.3 490—840 23.9 17.7—30.1
≥55 560 14.4 400—720 10.6 7.6—13.6
Transmission categoryc
Injection drug usee 300 17.3 200—400 — —
Heterosexual contactf 3,400 5.9 3,000—3,900 — —
Subtotalg 3,800 5.6 3,400—4,200 21.4 19.1—23.8
Totalg 15,100 2.9 14,300—16,000 45.3 42.8—47.8

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2018
Male
Age at infection (yr)
13–24 3,600 6.7 3,100—4,000 98.0 85.2—110.9
25–34 4,600 5.9 4,000—5,100 144.2 127.5—161.0
35–44 1,500 10.8 1,200—1,800 59.2 46.7—71.7
45–54 930 13.9 680—1,200 38.3 27.8—48.7
≥55 740 15.9 510—970 17.8 12.2—23.3
Transmission categoryc
Male-to-male sexual contactd 9,200 4.1 8,400—9,900 — —
Injection drug usee 380 18.5 240—510 — —
Male-to-male sexual contactd and injection drug usee 270 21.8 150—380 — —
Heterosexual contactf 1,400 13.1 1,100—1,800 — —
Subtotalg 11,300 3.8 10,400—12,100 71.0 65.7—76.3
Female
Age at infection (yr)
13–24 620 15.4 430—810 17.6 12.3—23.0
25–34 1,000 12.1 770—1,200 31.3 23.9—38.7
35–44 830 13.4 610—1,000 29.9 22.0—37.7
45–54 620 15.3 440—810 22.6 15.8—29.4
≥55 600 15.7 410—780 10.9 7.5—14.2
Transmission categoryc
Injection drug usee 300 22.0 170—430 — —
Heterosexual contactf 3,300 6.8 2,900—3,800 — —
Subtotalg 3,700 6.3 3,200—4,100 20.7 18.1—23.3
Totalg 15,000 3.3 14,000—15,900 44.4 41.6—47.3

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2019
Male
Age at infection (yr)
13–24 3,400 8.0 2,800—3,900 93.7 79.0—108.5
25–34 4,500 6.9 3,900—5,100 137.1 118.4—155.7
35–44 1,600 11.9 1,200—2,000 62.7 48.0—77.3
45–54 850 16.7 570—1,100 35.5 23.9—47.2
≥55 730 18.5 470—990 17.0 10.9—23.2
Transmission categoryc
Male-to-male sexual contactd 9,000 4.9 8,100—9,800 — —
Injection drug usee 310 24.1 160—460 — —
Male-to-male sexual contactd and injection drug usee 250 25.2 130—380 — —
Heterosexual contactf 1,400 14.6 1,000—1,800 — —
Subtotalg 11,000 4.5 10,000—12,000 68.5 62.5—74.5
Female
Age at infection (yr)
13–24 540 18.6 340—740 15.5 9.8—21.1
25–34 960 13.9 700—1,200 29.2 21.3—37.2
35–44 730 16.1 500—960 26.1 17.8—34.3
45–54 540 18.5 350—740 20.0 12.7—27.2
≥55 600 17.6 400—810 10.7 7.0—14.4
Transmission categoryc
Injection drug usee 270 24.4 140—400 — —
Heterosexual contactf 3,100 7.9 2,600—3,500 — —
Subtotalg 3,400 7.4 2,900—3,900 18.8 16.1—21.5
Totalg 14,400 3.8 13,300—15,400 42.3 39.1—45.4

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2020 (COVID-19 Pandemic)b
Male
Age at infection (yr)
13–24 3,100 10.1 2,500—3,700 84.7 67.9—101.5
25–34 4,700 8.2 4,000—5,500 145.9 122.5—169.4
35–44 1,600 14.3 1,100—2,000 59.7 42.9—76.4
45–54 790 20.7 470—1,100 32.4 19.2—45.5
≥55 660 22.9 360—950 14.8 8.1—21.5
Transmission categoryc
Male-to-male sexual contactd 9,000 5.9 7,900—10,000 — —
Injection drug usee 300 29.8 130—480 — —
Male-to-male sexual contactd and injection drug usee 290 28.8 130—450 — —
Heterosexual contactf 1,300 18.1 820—1,700 — —
Subtotalg 10,800 5.4 9,700—12,000 66.1 59.1—73.2
Female
Age at infection (yr)
13–24 480 23.2 260—700 13.6 7.4—19.8
25–34 1,000 15.9 690—1,300 30.6 21.1—40.2
35–44 660 19.8 400—920 23.1 14.1—32.1
45–54 450 23.8 240—670 16.8 9.0—24.7
≥55 440 24.0 230—650 7.7 4.1—11.3
Transmission categoryc
Injection drug usee 260 29.9 110—410 — —
Heterosexual contactf 2,800 9.8 2,200—3,300 — —
Subtotalg 3,000 9.2 2,500—3,600 16.8 13.8—19.9
Totalg 13,900 4.7 12,600—15,200 40.3 36.5—44.0

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2021b
Male
Age at infection (yr)
13–24 2,800h 11.9 2,200—3,500 77.9 59.7—96.0
25–34 4,000 10.0 3,200—4,700 121.6 97.6—145.5
35–44 1,500 16.3 1,000—2,000 57.0 38.7—75.2
45–54 670 24.9 340—1,000 28.1 14.4—41.8
≥55 770 23.6 410—1,100 17.0 9.1—24.9
Transmission categoryc
Male-to-male sexual contactd 8,100 7.0 7,000—9,200 — —
Injection drug usee 280 *34.7 90—470 — —
Male-to-male sexual contactd and injection drug usee 230 *36.7 60—390 — —
Heterosexual contactf 1,200 20.8 700—1,700 — —
Subtotalg 9,800h 6.4 8,500—11,000 59.2 51.7—66.7
Female
Age at infection (yr)
13–24 440 25.6 220—660 12.5 6.2—18.7
25–34 960 17.3 640—1,300 29.3 19.4—39.3
35–44 700 20.3 420—980 24.3 14.6—33.9
45–54 540 23.0 300—790 20.3 11.1—29.5
≥55 540 23.2 290—780 9.2 5.0—13.4
Transmission categoryc
Injection drug usee 250 *34.4 80—420 — —
Heterosexual contactf 2,900 10.0 2,300—3,500 — —
Subtotalg 3,200 9.5 2,600—3,800 17.5 14.2—20.8
Totalg 13,000h 5.4 11,600—14,300 37.3 33.4—41.3

 

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE >50% are not shown and are replaced with an ellipsis (…).

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
bEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
cTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
dIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
eIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
hIndicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 3. Estimated HIV incidence among Hispanic/Latino persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2017
Male
Age at infection (yr)
13–24 2,400 7.8 2,000—2,800 40.0 33.8—46.1
25–34 3,700 6.2 3,200—4,100 75.7 66.5—85.0
35–44 1,600 9.5 1,300—1,900 37.7 30.6—44.8
45–54 880 13.1 650—1,100 25.7 19.1—32.3
≥55 370 21.2 210—520 9.1 5.3—12.8
Transmission categoryc
Male-to-male sexual contactd 7,800 4.3 7,200—8,500 — —
Injection drug usee 280 22.0 160—400 — —
Male-to-male sexual contactd and injection drug usee 340 20.0 200—470 — —
Heterosexual contactf 520 21.6 300—740 — —
Subtotalg 8,900 4.0 8,200—9,700 39.5 36.4—42.7
Female
Age at infection (yr)
13–24 220 23.6 120—320 3.8 2.0—5.6
25–34 370 18.1 240—500 8.4 5.4—11.4
35–44 270 20.9 160—380 6.7 3.9—9.4
45–54 200 24.8 100—290 5.8 3.0—8.7
≥55 130 *30.7 50—200 2.7 1.1—4.3
Transmission categoryc
Injection drug usee 190 21.4 110—260 — —
Heterosexual contactf 990 11.4 770—1,200 — —
Subtotalg 1,200 10.1 950—1,400 5.3 4.2—6.3
Totalg 10,100 3.8 9,400—10,900 22.5 20.9—24.2

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2018
Male
Age at infection (yr)
13–24 2,200 9.3 1,800—2,600 36.4 29.8—43.1
25–34 3,800 7.1 3,200—4,300 76.5 65.8—87.1
35–44 1,700 10.7 1,300—2,100 38.7 30.6—46.8
45–54 860 15.3 600—1,100 24.4 17.1—31.7
≥55 390 23.2 210—570 9.2 5.0—13.4
Transmission categoryc
Male-to-male sexual contactd 7,800 4.9 7,000—8,500 — —
Injection drug usee 290 24.0 160—430 — —
Male-to-male sexual contactd and injection drug usee 360 21.1 210—510 — —
Heterosexual contactf 520 24.3 270—760 — —
Subtotalg 8,900 4.6 8,100—9,700 38.5 35.0—42.1
Female
Age at infection (yr)
13–24 190 28.3 90—300 3.3 1.5—5.2
25–34 340 21.3 200—490 7.7 4.5—10.9
35–44 310 22.1 180—450 7.5 4.3—10.8
45–54 180 28.9 80—290 5.3 2.3—8.3
≥55 130 *34.9 40—220 2.6 0.8—4.3
Transmission categoryc
Injection drug usee 160 26.8 80—250 — —
Heterosexual contactf 990 12.7 740—1,200 — —
Subtotalg 1,200 11.5 900—1,400 5.1 3.9—6.2
Totalg 10,100 4.3 9,200—10,900 21.9 20.1—23.8

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2019
Male
Age at infection (yr)
13–24 2,000 11.3 1,500—2,400 32.2 25.0—39.4
25–34 3,700 8.3 3,100—4,300 73.4 61.4—85.4
35–44 1,700 12.3 1,300—2,100 37.9 28.7—47.0
45–54 860 17.6 570—1,200 24.1 15.8—32.4
≥55 380 26.7 180—580 8.6 4.1—13.1
Transmission categoryc
Male-to-male sexual contactd 7,400 5.9 6,500—8,200 — —
Injection drug usee 290 27.8 130—450 — —
Male-to-male sexual contactd and injection drug usee 420 21.1 250—590 — —
Heterosexual contactf 480 28.4 210—750 — —
Subtotalg 8,600 5.5 7,600—9,500 36.3 32.4—40.1
Female
Age at infection (yr)
13–24 160 *34.9 50—270 2.8 0.9—4.6
25–34 330 24.7 170—480 7.2 3.7—10.6
35–44 280 26.6 130—420 6.6 3.1—10.0
45–54 180 *33.4 60—290 5.0 1.7—8.4
≥55 100 *43.7 10—190 2.0 0.3—3.7
Transmission categoryc
Injection drug usee 160 *31.2 60—260 — —
Heterosexual contactf 880 15.4 620—1,100 — —
Subtotalg 1,000 13.8 760—1,300 4.5 3.3—5.7
Totalg 9,600 5.1 8,600—10,600 20.5 18.4—22.5

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2020 (COVID-19 Pandemic)b
Male
Age at infection (yr)
13–24 1,700 14.9 1,200—2,100 26.1 18.5—33.8
25–34 3,600 10.2 2,900—4,300 72.7 58.2—87.2
35–44 1,700 14.7 1,200—2,200 37.6 26.8—48.4
45–54 820 21.6 470—1,200 21.8 12.6—31.0
≥55 350 *34.0 120—580 7.3 2.4—12.2
Transmission categoryc
Male-to-male sexual contactd 7,200 7.2 6,200—8,200 — —
Injection drug usee 260 *35.6 80—450 — —
Male-to-male sexual contactd and injection drug usee 330 28.7 150—520 — —
Heterosexual contactf 370 *39.8 80—660 — —
Subtotalg 8,200 6.8 7,100—9,200 33.4 29.0—37.8
Female
Age at infection (yr)
13–24 180 *39.6 40—330 3.0 0.7—5.4
25–34 340 28.8 150—530 7.4 3.2—11.5
35–44 200 *37.6 50—350 4.7 1.2—8.1
45–54 130 *46.5 10—250 3.7 0.3—7.0
≥55 … … … … …
Transmission categoryc
Injection drug usee 160 *39.1 40—280 — —
Heterosexual contactf 790 19.4 490—1,100 — —
Subtotalg 960 17.3 630—1,300 4.0 2.6—5.4
Totalg 9,100 6.3 8,000—10,200 18.9 16.5—21.2

 

Table 2. Estimated HIV incidence among Black/African American persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2021b
Male
Age at infection (yr)
13–24 1,500h 17.7 950—2,000 22.6 14.8—30.5
25–34 3,600 11.2 2,800—4,400 73.7 57.5—89.9
35–44 1,800 16.0 1,300—2,400 38.9 26.7—51.1
45–54 830 24.0 440—1,200 21.6 11.5—31.8
≥55 450 *33.0 160—740 9.0 3.2—14.7
Transmission categoryc
Male-to-male sexual contactd 7,200 7.9 6,100—8,400 — —
Injection drug usee 270 *39.9 60—480 — —
Male-to-male sexual contactd and injection drug usee 280 *36.5 80—480 — —
Heterosexual contactf 420 *40.4 90—750 — —
Subtotalg 8,200 7.5 7,000—9,400 32.9 28.1—37.8
Female
Age at infection (yr)
13–24 180 *40.7 40—330 3.0 0.6—5.4
25–34 320 *30.8 130—520 7.0 2.8—11.2
35–44 310 *31.5 120—500 7.2 2.7—11.6
45–54 180 *41.5 30—320 4.8 0.9—8.8
≥55 120 *49.8 0—240 2.2 0.0—4.4
Transmission categoryc
Injection drug usee 150 *45.4 20—280 — —
Heterosexual contactf 960 17.9 620—1,300 — —
Subtotalg 1,100 16.6 760—1,500 4.6 3.1—6.1
Totalg 9,300 6.9 8,100—10,600 18.9 16.4—21.5

 

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE >50% are not shown and are replaced with an ellipsis (…).
Hispanic/Latino persons can be of any race.

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
bEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
cTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
dIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
eIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
hIndicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 4. Estimated HIV incidence among White persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2017
Male
Age at infection (yr)
13–24 1,300 9.9 1,000—1,500 9.2 7.4—10.9
25–34 2,700 6.8 2,400—3,100 21.3 18.4—24.1
35–44 1,500 9.1 1,200—1,800 12.8 10.5—15.1
45–54 1,200 10.2 960—1,400 9.0 7.2—10.8
≥55 820 12.5 620—1,000 2.6 1.9—3.2
Transmission categoryc
Male-to-male sexual contactd 5,800 4.7 5,300—6,300 — —
Injection drug usee 640 13.8 470—820 — —
Male-to-male sexual contactd and injection drug usee 710 11.7 550—870 — —
Heterosexual contactf 390 22.3 220—560 — —
Subtotalg 7,500 4.1 6,900—8,100 9.0 8.2—9.7
Female
Age at infection (yr)
13–24 230 21.5 140—330 1.8 1.0—2.5
25–34 510 14.4 360—650 4.1 2.9—5.2
35–44 360 16.8 240—480 3.1 2.1—4.2
45–54 240 21.3 140—340 1.8 1.0—2.5
≥55 140 28.4 60—210 0.4 0.2—0.6
Transmission categoryc
Injection drug usee 570 12.5 430—710 — —
Heterosexual contactf 900 11.2 700—1,100 — —
Subtotalg 1,500 8.4 1,200—1,700 1.7 1.4—2.0
Totalg 9,000 3.7 8,400—9,700 5.3 4.9—5.6

 

Table 4. Estimated HIV incidence among White persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2018
Male
Age at infection (yr)
13–24 1,100 12.0 860—1,400 8.1 6.2—10.0
25–34 2,800 7.5 2,400—3,200 21.7 18.5—24.9
35–44 1,600 10.0 1,300—1,900 13.7 11.0—16.4
45–54 1,100 12.0 880—1,400 8.8 6.7—10.9
≥55 810 14.3 580—1,000 2.5 1.8—3.2
Transmission categoryc
Male-to-male sexual contactd 5,500 5.4 5,000—6,100 — —
Injection drug usee 740 14.9 520—960 — —
Male-to-male sexual contactd and injection drug usee 780 12.2 590—970 — —
Heterosexual contactf 410 24.2 220—610 — —
Subtotalg 7,500 4.6 6,800—8,200 8.9 8.1—9.7
Female
Age at infection (yr)
13–24 200 25.8 100—310 1.5 0.8—2.3
25–34 520 15.9 360—680 4.2 2.9—5.5
35–44 400 18.3 250—540 3.4 2.2—4.6
45–54 240 24.0 130—350 1.8 1.0—2.7
≥55 140 *31.6 50—220 0.4 0.1—0.6
Transmission categoryc
Injection drug usee 610 14.1 440—770 — —
Heterosexual contactf 880 12.9 660—1,100 — —
Subtotalg 1,500 9.4 1,200—1,800 1.7 1.4—2.0
Totalg 9,000 4.2 8,200—9,700 5.2 4.8—5.7

 

Table 4. Estimated HIV incidence among White persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2019
Male
Age at infection (yr)
13–24 990 14.4 710—1,300 7.1 5.1—9.2
25–34 2,700 8.6 2,300—3,200 21.4 17.8—25.0
35–44 1,600 11.3 1,300—2,000 13.8 10.7—16.8
45–54 1,000 14.1 760—1,300 8.3 6.0—10.7
≥55 820 16.1 560—1,100 2.5 1.7—3.3
Transmission categoryc
Male-to-male sexual contactd 5,300 6.2 4,600—5,900 — —
Injection drug usee 770 17.5 510—1,000 — —
Male-to-male sexual contactd and injection drug usee 740 14.4 530—950 — —
Heterosexual contactf 430 26.3 210—650 — —
Subtotalg 7,200 5.4 6,500—8,000 8.6 7.7—9.5
Female
Age at infection (yr)
13–24 200 29.2 90—310 1.5 0.7—2.4
25–34 560 17.2 370—750 4.5 3.0—6.1
35–44 390 20.6 230—550 3.4 2.0—4.7
45–54 270 25.1 140—400 2.1 1.1—3.2
≥55 160 *33.0 60—260 0.4 0.1—0.7
Transmission categoryc
Injection drug usee 650 15.5 450—840 — —
Heterosexual contactf 930 14.0 670—1,200 — —
Subtotalg 1,600 10.3 1,300—1,900 1.8 1.4—2.2
Totalg 8,800 4.8 8,000—9,600 5.1 4.7—5.6

 

Table 4. Estimated HIV incidence among White persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2020 (COVID-19 Pandemic)b
Male
Age at infection (yr)
13–24 890 17.6 580—1,200 6.4 4.2—8.6
25–34 2,700 10.2 2,200—3,300 21.8 17.4—26.1
35–44 1,700 13.2 1,200—2,100 13.5 10.0—17.0
45–54 1,000 16.6 710—1,400 8.3 5.6—11.0
≥55 870 18.1 560—1,200 2.6 1.7—3.5
Transmission categoryc
Male-to-male sexual contactd 5,200 7.2 4,500—6,000 — —
Injection drug usee 920 19.6 570—1,300 — —
Male-to-male sexual contactd and injection drug usee 680 18.0 440—920 — —
Heterosexual contactf 350 *35.5 110—600 — —
Subtotalg 7,200 6.3 6,300—8,100 8.5 7.4—9.5
Female
Age at infection (yr)
13–24 200 *34.2 70—340 1.5 0.5—2.6
25–34 520 21.6 300—740 4.2 2.4—6.0
35–44 410 24.3 220—610 3.4 1.8—5.1
45–54 230 *32.1 90—380 1.9 0.7—3.1
≥55 200 *34.8 60—330 0.5 0.2—0.9
Transmission categoryc
Injection drug usee 540 22.1 310—780 — —
Heterosexual contactf 1,000 15.2 710—1,300 — —
Subtotalg 1,600 12.4 1,200—1,900 1.8 1.4—2.2
Totalg 8,800 5.6 7,800—9,700 5.1 4.5—5.7

 

Table 4. Estimated HIV incidence among White persons aged ≥13 years, by year of infection, assigned sex at birth, and selected characteristics, 2017–2021—United States
No RSE (%) 95% CI Ratea 95% CI
2021b
Male
Age at infection (yr)
13–24 720h 21.8 410—1,000 5.2 3.0—7.4
25–34 2,600 11.6 2,000—3,200 20.7 16.0—25.4
35–44 1,600 15.1 1,100—2,100 12.8 9.0—16.6
45–54 930 19.6 570—1,300 7.5 4.6—10.4
≥55 770 21.7 440—1,100 2.3 1.3—3.2
Transmission categoryc
Male-to-male sexual contactd 4,800h 8.4 4,000—5,500 — —
Injection drug usee 810 24.4 420—1,200 — —
Male-to-male sexual contactd and injection drug usee 680 19.7 410—940 — —
Heterosexual contactf 340 *38.7 80—600 — —
Subtotalg 6,600 7.3 5,600—7,500 7.8 6.7—8.9
Female
Age at infection (yr)
13–24 200 *38.1 50—350 1.5 0.4—2.7
25–34 470 25.4 230—700 3.9 1.9—5.8
35–44 430 26.2 210—660 3.6 1.7—5.4
45–54 290 *32.0 110—480 2.4 0.9—3.9
≥55 200 *37.9 50—350 0.5 0.1—0.9
Transmission categoryc
Injection drug usee 610 23.3 330—890 — —
Heterosexual contactf 970 16.9 650—1,300 — —
Subtotalg 1,600 13.6 1,200—2,000 1.8 1.3—2.3
Totalg 8,200 6.5 7,100—9,200 4.8 4.2—5.4

 

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE >50% are not shown and are replaced with an ellipsis (…).

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
bEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
cTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
dIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
eIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
hIndicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 5. Estimated HIV incidence among males, based on assigned sex at birth, with HIV attributed to male-to-male sexual contact, by year of infection, race/ethnicity, and age at infection, 2017–2021—United States
No. RSE (%) 95% CI
2017
Black/African American
Age at infection (yr)
13–24 3,700 5.7 3,300—4,100
25–34 3,700 5.6 3,300—4,200
35–44 1,000 10.6 820—1,300
45–54 540 14.8 380—700
≥55 270 21.0 160—390
Subtotal 9,300 3.6 8,600—9,900
Hispanic/Latinob
Age at infection (yr)
13–24 2,200 8.1 1,900—2,600
25–34 3,300 6.5 2,900—3,700
35–44 1,400 10.2 1,100—1,600
45–54 710 14.2 510—910
≥55 240 24.2 130—350
Subtotal 7,800 4.3 7,200—8,500
White
Age at infection (yr)
13–24 1,100 11.0 840—1,300
25–34 2,100 7.7 1,800—2,400
35–44 1,100 10.8 840—1,300
45–54 920 11.7 710—1,100
≥55 650 13.9 470—820
Subtotal 5,800 4.7 5,300—6,300
Allc
Age at infection (yr)
13–24 7,400 4.2 6,800—8,000
25–34 9,800 3.6 9,100—10,500
35–44 3,700 5.9 3,300—4,200
45–54 2,300 7.5 2,000—2,700
≥55 1,200 10.3 960—1,500
Totalc 24,500 2.3 23,400—25,600

 

Table 5. Estimated HIV incidence among males, based on assigned sex at birth, with HIV attributed to male-to-male sexual contact, by year of infection, race/ethnicity, and age at infection, 2017–2021—United States
No. RSE (%) 95% CI
2018
Black/African American
Age at infection (yr)
13–24 3,300 6.8 2,900—3,800
25–34 3,900 6.3 3,500—4,400
35–44 1,000 12.3 780—1,300
45–54 550 17.1 360—730
≥55 320 23.2 170—460
Subtotal 9,200 4.1 8,400—9,900
Hispanic/Latinob
Age at infection (yr)
13–24 2,100 9.6 1,700—2,500
25–34 3,300 7.5 2,800—3,800
35–44 1,400 11.5 1,100—1,700
45–54 670 16.8 450—890
≥55 270 26.5 130—410
Subtotal 7,800 4.9 7,000—8,500
White
Age at infection (yr)
13–24 950 13.1 710—1,200
25–34 2,000 9.0 1,600—2,300
35–44 1,100 12.0 840—1,400
45–54 860 13.7 630—1,100
≥55 660 15.6 450—860
Subtotal 5,500 5.4 5,000—6,100
Allc
Age at infection (yr)
13–24 6,800 5.0 6,100—7,400
25–34 9,900 4.1 9,100—10,700
35–44 3,700 6.7 3,300—4,200
45–54 2,200 8.8 1,800—2,600
≥55 1,300 11.4 1,000—1,600
Totalc 23,900 2.7 22,700—25,200

 

Table 5. Estimated HIV incidence among males, based on assigned sex at birth, with HIV attributed to male-to-male sexual contact, by year of infection, race/ethnicity, and age at infection, 2017–2021—United States
No. RSE (%) 95% CI
2019
Black/African American
Age at infection (yr)
13–24 3,200 8.2 2,600—3,700
25–34 3,900 7.4 3,300—4,400
35–44 1,100 13.6 840—1,400
45–54 510 20.6 300—710
≥55 320 26.0 160—490
Subtotal 9,000 4.9 8,100—9,800
Hispanic/Latinob
Age at infection (yr)
13–24 1,800 11.8 1,400—2,200
25–34 3,200 8.9 2,600—3,800
35–44 1,400 13.5 1,000—1,800
45–54 680 19.4 420—930
≥55 260 *31.3 100—420
Subtotal 7,400 5.9 6,500—8,200
White
Age at infection (yr)
13–24 830 15.7 570—1,100
25–34 1,900 10.2 1,600—2,300
35–44 1,100 13.6 800—1,400
45–54 780 16.2 530—1,000
≥55 650 17.8 420—870
Subtotal 5,300 6.2 4,600—5,900
Allc
Age at infection (yr)
13–24 6,200 6.0 5,400—6,900
25–34 9,600 4.8 8,700—10,500
35–44 3,900 7.5 3,400—4,500
45–54 2,100 10.4 1,600—2,500
≥55 1,300 13.1 960—1,600
Totalc 23,100 3.1 21,700—24,500

 

Table 5. Estimated HIV incidence among males, based on assigned sex at birth, with HIV attributed to male-to-male sexual contact, by year of infection, race/ethnicity, and age at infection, 2017–2021—United States
No. RSE (%) 95% CI
2020 (COVID-19 Pandemic)a
Black/African American
Age at infection (yr)
13–24 2,800 10.5 2,300—3,400
25–34 4,200 8.7 3,400—4,900
35–44 1,200 16.2 810—1,600
45–54 480 25.7 240—720
≥55 300 *32.6 110—500
Subtotal 9,000 5.9 7,900—10,000
Hispanic/Latinob
Age at infection (yr)
13–24 1,500 15.5 1,100—2,000
25–34 3,200 10.8 2,500—3,900
35–44 1,500 15.6 1,100—2,000
45–54 670 23.5 360—970
≥55 260 *37.9 70—450
Subtotal 7,200 7.2 6,200—8,200
White
Age at infection (yr)
13–24 780 18.7 490—1,100
25–34 1,900 11.8 1,500—2,400
35–44 1,000 16.5 680—1,300
45–54 790 18.6 500—1,100
≥55 730 19.3 460—1,000
Subtotal 5,200 7.2 4,500—6,000
Allc
Age at infection (yr)
13–24 5,500 7.7 4,700—6,300
25–34 9,800 5.7 8,700—11,000
35–44 4,000 9.0 3,300—4,700
45–54 2,000 12.4 1,600—2,500
≥55 1,400 14.9 960—1,800
Totalc 22,700 3.8 21,000—24,400

 

Table 5. Estimated HIV incidence among males, based on assigned sex at birth, with HIV attributed to male-to-male sexual contact, by year of infection, race/ethnicity, and age at infection, 2017–2021—United States
No. RSE (%) 95% CI
2021a
Black/African American
Age at infection (yr)
13–24 2,700d 12.2 2,000—3,300
25–34 3,500 10.7 2,800—4,200
35–44 1,100 19.1 690—1,500
45–54 420 *30.8 170—670
≥55 390 *32.0 140—630
Subtotal 8,100 7.0 7,000—9,200
Hispanic/Latinob
Age at infection (yr)
13–24 1,400d 18.2 880—1,900
25–34 3,300 11.8 2,500—4,000
35–44 1,600 16.9 1,100—2,100
45–54 660 26.3 320—1,000
≥55 320 *38.0 80—560
Subtotal 7,200 7.9 6,100—8,400
White
Age at infection (yr)
13–24 610d 23.3 330—890
25–34 1,900 13.4 1,400—2,400
35–44 1,100 17.8 680—1,400
45–54 650 22.7 360—940
≥55 580 24.0 310—850
Subtotal 4,800d 8.4 4,000—5,500
Allc
Age at infection (yr)
13–24 4,900d 9.1 4,000—5,800
25–34 9,100 6.7 7,900—10,300
35–44 4,000 10.0 3,200—4,800
45–54 1,800 14.8 1,300—2,300
≥55 1,400 16.9 900—1,800
Totalc 21,100d 4.4 19,300—23,000

 

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%-50%, preceded by an asterisk(*), should be used with caution.

aEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
bHispanic/Latino persons can be of any race.
cIncludes data for all race/ethnicities.
dIndicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 6. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2021—United States and Puerto Rico
Area of residence No. RSE (%) 95% CI Ratea 95% CI
2017
Alabama 620 13.9 450 790 15.1 11.0 19.3
Alaska … … … … … … …
Arizona 800 13.0 590 1,000 13.6 10.1 17.1
Arkansas 300 23.7 160 430 11.9 6.4 17.4
California 4,600 5.2 4,200 5,100 14.1 12.7 15.6
Colorado 440 17.1 290 580 9.3 6.1 12.4
Connecticut 250 22.5 140 350 8.0 4.5 11.6
Delaware 120 *33.1 40 200 15.1 5.3 24.9
District of Columbia 230 24.8 120 340 38.6 19.8 57.4
Florida 4,400 5.3 3,900 4,800 24.4 21.9 27.0
Georgia 2,600 7.4 2,200 3,000 29.9 25.5 34.2
Hawaii 80 *41.5 10 150 6.7 1.2 12.2
Idaho … … … … … … …
Illinois 1,300 9.8 1,000 1,500 11.9 9.6 14.2
Indiana 510 16.0 350 670 9.2 6.3 12.2
Iowa 100 *36.8 30 180 4.0 1.1 6.8
Kansas 90 *43.0 10 170 3.9 0.6 7.2
Kentucky 330 19.9 200 460 8.9 5.4 12.3
Louisiana 920 12.0 700 1,100 23.7 18.1 29.3
Maine … … … … … … …
Maryland 770 13.4 570 970 15.2 11.2 19.2
Massachusetts 500 15.1 350 650 8.4 6.0 10.9
Michigan 660 13.7 480 840 7.8 5.7 9.9
Minnesota 250 22.6 140 360 5.4 3.0 7.8
Mississippi 420 18.6 270 580 17.1 10.9 23.4
Missouri 540 13.4 400 690 10.6 7.8 13.4
Montana … … … … … … …
Nebraska 110 *35.2 30 180 6.7 2.1 11.3
Nevada 530 16.1 370 700 21.6 14.8 28.4
New Hampshire … … … … … … …
New Jerseyc 1,100 12.2 820 1,300 14.4 10.9 17.8
New Mexico 140 26.3 70 210 7.9 3.8 12.0
New York 2,200 7.6 1,900 2,600 13.4 11.4 15.4
North Carolina 1,300 9.5 1,000 1,500 14.8 12.0 17.5
North Dakota … … … … … … …
Ohio 920 11.7 710 1,100 9.4 7.2 11.5
Oklahoma 340 18.9 220 470 10.6 6.7 14.6
Oregon 190 26.1 90 290 5.4 2.6 8.1
Pennsylvaniac 980 12.9 740 1,200 9.0 6.7 11.3
Puerto Ricoc 410 18.6 260 560 14.3 9.1 19.6
Rhode Island 80 *34.5 30 140 9.1 2.9 15.2
South Carolina 690 15.0 480 890 16.2 11.4 21.0
South Dakota … … … … … … …
Tennessee 750 12.0 570 930 13.3 10.2 16.4
Texas 4,400 5.5 3,900 4,800 19.0 17.0 21.1
Utah 130 *34.1 40 220 5.4 1.8 8.9
Vermont … … … … … … …
Virginia 850 12.8 630 1,100 11.9 8.9 14.9
Washington 450 17.1 300 600 7.2 4.8 9.7
West Virginia 110 *37.7 30 200 7.3 1.9 12.6
Wisconsin 250 23.1 130 360 5.0 2.8 7.3
Wyoming … … … … … … …
Table 6. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2021—United States and Puerto Rico
Area of residence No. RSE (%) 95% CI Ratea 95% CI
2018
Alabama 570 16.7 390 760 14.0 9.4 18.5
Alaska … … … … … … …
Arizona 820 14.9 580 1,100 13.7 9.7 17.7
Arkansas 260 29.6 110 410 10.3 4.3 16.4
California 4,700 5.9 4,100 5,200 14.2 12.5 15.8
Colorado 400 21.0 230 560 8.3 4.9 11.7
Connecticut 210 28.6 90 320 6.7 2.9 10.5
Delaware 90 *48.7 0 170 10.6 0.5 20.8
District of Columbia 230 26.7 110 350 38.2 18.2 58.3
Florida 4,100 6.3 3,600 4,700 22.7 19.9 25.5
Georgia 2,500 8.7 2,100 3,000 29.0 24.1 34.0
Hawaii … … … … … … …
Idaho … … … … … … …
Illinois 1,300 11.1 1,000 1,600 12.2 9.5 14.8
Indiana 550 17.4 360 740 9.9 6.5 13.2
Iowa 120 *37.7 30 210 4.7 1.2 8.2
Kansas 120 *40.8 20 210 4.9 1.0 8.9
Kentucky 440 18.9 270 600 11.7 7.4 16.0
Louisiana 950 13.3 700 1,200 24.6 18.1 31.0
Maine … … … … … … …
Maryland 840 13.8 610 1,100 16.5 12.0 20.9
Massachusetts 590 15.0 420 760 9.9 7.0 12.8
Michigan 640 15.7 440 840 7.6 5.3 9.9
Minnesota 310 22.7 170 450 6.6 3.7 9.6
Mississippi 440 21.2 260 630 17.9 10.5 25.3
Missouri 480 16.8 320 640 9.4 6.3 12.5
Montana … … … … … … …
Nebraska … … … … … … …
Nevada 590 17.7 380 790 23.2 15.1 31.3
New Hampshire … … … … … … …
New Jerseyc 920 15.2 650 1,200 12.3 8.6 15.9
New Mexico 190 25.6 90 280 10.7 5.3 16.0
New York 2,000 9.1 1,700 2,400 12.2 10.1 14.4
North Carolina 1,200 11.0 970 1,500 14.2 11.1 17.2
North Dakota … … … … … … …
Ohio 890 13.6 660 1,100 9.1 6.7 11.5
Oklahoma 340 22.3 190 480 10.3 5.8 14.8
Oregon 170 *31.4 70 280 4.9 1.9 7.9
Pennsylvaniac 1,000 13.3 760 1,300 9.4 6.9 11.8
Puerto Ricoc 350 22.4 200 510 12.7 7.1 18.2
Rhode Island 60 *47.7 0 120 6.6 0.4 12.9
South Carolina 700 17.2 460 930 16.2 10.7 21.6
South Dakota … … … … … … …
Tennessee 740 13.8 540 940 12.9 9.4 16.5
Texas 4,500 6.2 3,900 5,000 19.1 16.8 21.4
Utah 140 *37.1 40 240 5.7 1.5 9.8
Vermont … … … … … … …
Virginia 820 14.9 580 1,100 11.4 8.1 14.7
Washington 540 17.5 360 730 8.6 5.6 11.5
West Virginia 170 *35.4 50 300 11.3 3.5 19.2
Wisconsin 210 29.5 90 330 4.3 1.8 6.8
Wyoming … … … … … … …
Table 6. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2021—United States and Puerto Rico
Area of residence No. RSE (%) 95% CI Ratea 95% CI
2019
Alabama 540 19.9 330 750 13.1 8.0 18.2
Alaska … … … … … … …
Arizona 760 18.1 490 1,000 12.4 8.0 16.8
Arkansas 330 28.5 150 510 13.0 5.8 20.3
California 4,300 7.1 3,700 4,900 13.1 11.3 14.9
Colorado 460 21.9 260 650 9.4 5.4 13.4
Connecticut 160 *37.9 40 290 5.4 1.4 9.4
Delaware … … … … … … …
District of Columbia 190 *33.5 70 320 32.0 11.0 53.0
Florida 3,900 7.4 3,400 4,500 21.3 18.2 24.4
Georgia 2,400 10.3 1,900 2,900 27.3 21.8 32.8
Hawaii … … … … … … …
Idaho … … … … … … …
Illinois 1,200 13.6 850 1,500 10.8 7.9 13.7
Indiana 500 21.5 290 710 8.9 5.1 12.7
Iowa 140 *39.2 30 250 5.5 1.3 9.6
Kansas 190 *33.4 60 310 7.8 2.7 12.9
Kentucky 380 24.3 200 560 10.0 5.3 14.8
Louisiana 840 16.8 560 1,100 21.8 14.6 28.9
Maine … … … … … … …
Maryland 730 16.9 490 970 14.3 9.6 19.1
Massachusetts 460 19.8 280 640 7.8 4.7 10.8
Michigan 600 18.7 380 820 7.1 4.5 9.7
Minnesota 270 27.8 120 420 5.8 2.6 8.9
Mississippi 470 23.9 250 690 18.8 10.0 27.6
Missouri 460 19.2 290 630 8.9 5.6 12.3
Montana … … … … … … …
Nebraska … … … … … … …
Nevada 590 21.0 350 830 22.8 13.4 32.2
New Hampshire … … … … … … …
New Jerseyc 1,000 16.0 680 1,300 13.3 9.1 17.4
New Mexico 160 *32.1 60 270 9.3 3.5 15.2
New York 1,900 10.6 1,500 2,300 11.5 9.1 13.9
North Carolina 1,400 11.5 1,100 1,700 15.7 12.1 19.2
North Dakota … … … … … … …
Ohio 860 15.8 590 1,100 8.7 6.0 11.4
Oklahoma 430 21.9 250 620 13.3 7.6 19.0
Oregon 190 *33.2 70 320 5.3 1.8 8.8
Pennsylvaniac 860 15.8 600 1,100 7.9 5.4 10.3
Puerto Ricoc 320 26.7 150 490 11.3 5.4 17.3
Rhode Island … … … … … … …
South Carolina 670 20.2 400 930 15.3 9.2 21.3
South Dakota … … … … … … …
Tennessee 800 14.5 570 1,000 14.0 10.0 18.0
Texas 4,500 7.0 3,900 5,100 18.9 16.3 21.5
Utah 140 *42.0 30 260 5.6 1.0 10.3
Vermont … … … … … … …
Virginia 800 17.1 530 1,100 11.0 7.3 14.7
Washington 510 21.0 300 720 8.0 4.7 11.3
West Virginia 260 *34.1 90 430 16.8 5.6 28.0
Wisconsin 220 *33.1 80 360 4.4 1.5 7.2
Wyoming … … … … … … …
Table 6. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2021—United States and Puerto Rico
Area of residence No. RSE (%) 95% CI Ratea 95% CI
2020 (COVID-19 Pandemic)b
Alabama 590 21.3 340 830 13.9 8.1 19.7
Alaska … … … … … … …
Arizona 720 22.9 390 1,000 11.9 6.5 17.2
Arkansas 360 *32.2 130 580 14.1 5.2 23.1
California 4,300 8.3 3,600 5,000 13.1 11.0 15.2
Colorado 370 *30.3 150 590 7.5 3.0 12.0
Connecticut 200 *40.4 40 360 6.5 1.3 11.6
Delaware … … … … … … …
District of Columbia 140 *47.9 10 280 24.3 1.5 47.1
Florida 3,800 9.0 3,100 4,500 20.6 17.0 24.3
Georgia 2,300 12.9 1,700 2,900 25.7 19.2 32.3
Hawaii … … … … … … …
Idaho … … … … … … …
Illinois 1,100 16.5 780 1,500 10.6 7.2 14.1
Indiana 630 22.4 350 900 11.1 6.2 16.0
Iowa … … … … … … …
Kansas 160 *43.7 20 300 6.6 1.0 12.3
Kentucky 390 29.3 170 620 10.4 4.4 16.4
Louisiana 880 19.6 540 1,200 22.6 13.9 31.3
Maine … … … … … … …
Maryland 680 20.3 410 940 13.0 7.8 18.2
Massachusetts 350 26.6 170 530 5.8 2.8 8.8
Michigan 630 21.6 360 890 7.3 4.2 10.4
Minnesota 240 *34.9 80 410 5.1 1.6 8.6
Mississippi 460 28.9 200 720 18.7 8.1 29.3
Missouri 440 24.6 230 660 8.6 4.4 12.8
Montana … … … … … … …
Nebraska … … … … … … …
Nevada 610 25.3 300 910 23.2 11.7 34.7
New Hampshire … … … … … … …
New Jerseyc 970 20.3 580 1,400 12.3 7.4 17.3
New Mexico 140 *43.0 20 260 7.9 1.2 14.5
New York 1,900 12.4 1,400 2,400 11.0 8.4 13.7
North Carolina 1,200 15.5 800 1,500 13.0 9.1 17.0
North Dakota … … … … … … …
Ohio 810 18.7 510 1,100 8.1 5.1 11.1
Oklahoma 390 28.4 170 610 11.9 5.3 18.5
Oregon 210 *38.8 50 370 5.9 1.4 10.3
Pennsylvaniac 850 18.8 540 1,200 7.7 4.9 10.6
Puerto Ricoc 280 *33.6 100 470 9.7 3.3 16.1
Rhode Island … … … … … … …
South Carolina 630 23.7 340 920 14.5 7.7 21.3
South Dakota … … … … … … …
Tennessee 700 19.1 440 960 12.0 7.5 16.5
Texas 4,200 8.8 3,500 5,000 17.8 14.7 20.8
Utah … … … … … … …
Vermont … … … … … … …
Virginia 720 21.3 420 1,000 9.9 5.7 14.0
Washington 450 27.2 210 690 6.9 3.2 10.6
West Virginia … … … … … … …
Wisconsin 300 *31.9 110 490 6.1 2.3 9.9
Wyoming … … … … … … …
Table 6. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2021—United States and Puerto Rico
Area of residence No. RSE (%) 95% CI Ratea 95% CI
2021b
Alabama 670 22.3 380 970 15.8 8.9 22.7
Alaska … … … … … … …
Arizona 780 24.0 410 1,200 12.7 6.7 18.7
Arkansas 380 *33.4 130 640 15.2 5.2 25.1
California 4,000 9.8 3,200 4,700 12.0 9.7 14.4
Colorado 490 28.6 210 760 9.8 4.3 15.3
Connecticut 180 *44.4 20 330 5.7 0.7 10.6
Delaware … … … … … … …
District of Columbia 150 *46.8 10 300 26.9 2.2 51.7
Florida 3,700 9.9 3,000 4,400 19.7 15.9 23.6
Georgia 2,300 14.1 1,700 2,900 25.4 18.4 32.5
Hawaii … … … … … … …
Idaho … … … … … … …
Illinois 1,100 18.8 680 1,500 10.0 6.3 13.7
Indiana 540 26.4 260 810 9.4 4.5 14.3
Iowa … … … … … … …
Kansas … … … … … … …
Kentucky 420 *31.7 160 680 11.1 4.2 18.0
Louisiana 760 23.1 420 1,100 19.8 10.8 28.8
Maine … … … … … … …
Maryland 630 23.3 340 910 12.0 6.5 17.5
Massachusetts 370 28.6 160 570 6.1 2.7 9.5
Michigan 590 24.7 310 880 7.0 3.6 10.3
Minnesota 230 *39.9 50 420 4.9 1.1 8.8
Mississippi 420 *36.4 120 730 17.2 4.9 29.5
Missouri 470 24.2 250 700 9.1 4.8 13.5
Montana … … … … … … …
Nebraska … … … … … … …
Nevada 520 *31.3 200 840 19.7 7.6 31.7
New Hampshire … … … … … … …
New Jerseyc 1,100 18.9 670 1,500 13.5 8.5 18.5
New Mexico 130 *48.8 10 260 7.5 0.3 14.6
New York 1,700 14.5 1,200 2,200 10.1 7.3 13.0
North Carolina 1,100 17.3 700 1,400 11.9 7.9 15.9
North Dakota … … … … … … …
Ohio 850 20.8 500 1,200 8.6 5.1 12.1
Oklahoma 370 *33.5 130 610 11.2 3.8 18.5
Oregon 230 *42.6 40 420 6.3 1.0 11.5
Pennsylvaniac 650 23.8 350 950 5.9 3.1 8.6
Puerto Ricoc 280 *35.4 90 470 9.6 2.9 16.3
Rhode Island … … … … … … …
South Carolina 650 27.5 300 1,000 14.8 6.8 22.7
South Dakota … … … … … … …
Tennessee 720 20.2 430 1,000 12.2 7.3 17.0
Texas 4,000 10.0 3,300 4,800 16.7 13.4 19.9
Utah … … … … … … …
Vermont … … … … … … …
Virginia 640 24.4 330 950 8.8 4.6 13.0
Washington 470 *30.2 190 750 7.2 2.9 11.5
West Virginia … … … … … … …
Wisconsin 230 *41.5 40 430 4.7 0.9 8.5
Wyoming … … … … … … …

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE > 50% are not shown and are replaced with an ellipsis (…).

aRates are per 100,000 population.
bEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
cEstimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania, and Puerto Rico.

Table 7. Estimated HIV prevalence and undiagnosed infection among persons aged ≥13 years, by selected characteristics, 2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with undiagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No. RSE (%) 95% CI % RSE (%) 95% CI
Assigned sex at birth
Male 946,500 0.4 939,400 953,500 686.1 681.0 691.3 127,300 2.8 120,300 134,400 13.5 2.5 12.8 14.1
Female 265,900 0.7 262,500 269,300 186.9 184.5 189.3 26,200 6.7 22,700 29,600 9.8 6.0 8.7 11.0
Age (yr)
13–24 41,900 2.1 40,200 43,700 80.7 77.4 84.0 18,300 4.8 16,500 20,000 43.6 2.7 41.1 45.8
25–34 217,100 0.7 214,000 220,200 477.2 470.3 484.0 60,100 2.6 56,900 63,200 27.7 1.9 26.6 28.7
35–44 238,300 0.6 235,700 241,000 549.1 543.1 555.1 36,300 3.7 33,700 38,900 15.2 3.1 14.3 16.2
45–54 263,000 0.4 260,700 265,300 646.4 640.7 652.1 20,000 5.9 17,700 22,300 7.6 5.5 6.8 8.4
≥ 55 452,000 0.4 448,600 455,400 458.2 454.7 461.7 18,800 9.3 15,400 22,300 4.2 8.9 3.4 4.9
Race/ethnicity
American Indian/Alaska Native 4,100 6.1 3,600 4,500 198.7 174.8 222.5 810 *30.7 320 1,300 19.9 25.0 9.0 28.5
Asianb 18,600 2.4 17,700 19,400 110.3 105.0 115.6 2,100 21.6 1,200 3,000 11.3 19.2 6.9 15.4
Black/African American 487,500 0.5 482,500 492,500 1404.2 1389.9 1418.6 62,000 4.1 57,000 67,000 12.7 3.6 11.8 13.6
Hispanic/Latinoc 297,200 0.7 293,400 301,100 603.0 595.2 610.8 44,900 4.4 41,000 48,700 15.1 3.7 14.0 16.2
Native Hawaiian/other Pacific Islander 1,200 11.1 950 1,400 229.2 185.1 279.1 … … … … 19.3 *44.6 0.0 33.7
White 342,000 0.6 337,800 346,300 199.3 196.8 201.8 37,200 5.9 32,900 41,400 10.9 5.2 9.7 12.0
Multiracial 61,200 1.3 59,600 62,800 1168.6 1138.6 1198.6 6,300 12.6 4,800 7,900 10.4 11.4 8.0 12.6
Transmission categoryd
Male-to-male sexual contacte 716,900 0.4 710,900 722,900 — — — 101,900 3.0 95,900 107,900 14.2 2.6 13.5 14.9
Injection drug usef 121,900 1.2 119,200 124,700 — — — 9,600 14.9 6,800 12,400 7.8 13.8 5.7 9.9
      Male 70,400 1.6 68,100 72,600 — — — 5,900 19.5 3,600 8,100 8.3 17.9 5.3 11.2
      Female 51,600 1.6 49,900 53,200 — — — 3,700 22.9 2,000 5,400 7.2 21.3 4.1 10.1
Male-to-male sexual contacte and injection drug usef 62,900 1.4 61,100 64,600 — — — 5,300 16.9 3,500 7,100 8.4 15.5 5.8 10.9
Heterosexual contactg 306,700 0.6 303,000 310,500 — — — 36,500 5.2 32,700 40,200 11.9 4.6 10.8 13.0
      Male 94,100 1.2 91,800 96,400 — — — 14,100 8.3 11,800 16,400 15.0 7.1 12.9 17.1
      Female 212,600 0.7 209,600 215,600 — — — 22,300 6.8 19,400 25,300 10.5 6.1 9.2 11.7
Region of residence
Northeast 250,600 0.7 247,100 254,200 512.4 505.0 519.7 19,900 9.2 16,400 23,500 8.0 8.5 6.6 9.3
Midwest 148,800 0.9 146,000 151,500 256.5 251.8 261.2 21,300 6.6 18,600 24,100 14.3 5.6 12.7 15.9
South 567,800 0.5 562,400 573,200 530.7 525.7 535.8 79,800 3.4 74,500 85,200 14.1 2.9 13.2 14.9
West 245,200 0.7 241,700 248,700 369.8 364.5 375.1 32,400 5.5 28,900 35,900 13.2 4.8 12.0 14.4
Totalh 1,212,400 0.3 1,204,500 1,220,200 432.7 429.9 435.5 153,500 2.6 145,600 161,300 12.7 2.3 12.1 13.2

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE >50% are not shown and are replaced with an ellipsis (…).
Estimates for the year 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.

a Rates are per 100,000 population.
b Includes Asian/Pacific Islander legacy cases.
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2017
Assigned sex at birth
Male 886,200 0.3 880,100 892,200 665.4 660.8 670.0 753,766 85.1 0.4 84.5 85.6
Female 256,600 0.6 253,500 259,600 184.3 182.1 186.5 228,901 89.2 0.6 88.2 90.3
Age (yr)
13–24 65,200 1.0 63,900 66,500 126.7 124.2 129.2 27,742 42.6 1.0 41.7 43.4
25–34 203,900 0.5 201,900 206,000 450.0 445.5 454.5 148,377 72.8 0.5 72.0 73.5
35–44 216,800 0.4 214,900 218,600 531.7 527.2 536.2 186,686 86.1 0.4 85.4 86.9
45–54 313,600 0.3 311,400 315,700 742.6 737.5 747.7 291,493 93.0 0.3 92.3 93.6
≥ 55 343,200 0.4 340,400 346,100 370.6 367.5 373.6 328,369 95.7 0.4 94.9 96.5
Race/ethnicity
American Indian/Alaska Native 3,500 5.6 3,100 3,900 180.4 160.8 200.1 2,730 77.3 5.6 69.7 86.7
Asiand 16,500 2.3 15,800 17,300 106.1 101.3 110.8 13,516 81.8 2.3 78.3 85.7
Black/African American 461,000 0.5 456,700 465,400 1382.0 1369.0 1395.1 395,740 85.8 0.5 85.0 86.7
Hispanic/Latinoe 268,800 0.6 265,700 272,000 598.0 591.0 605.1 223,165 83.0 0.6 82.0 84.0
Native Hawaiian/Other Pacific Islander 990 9.9 800 1,200 210.7 169.8 251.7 739 74.4 10.3 62.3 92.3
White 329,600 0.6 325,700 333,400 192.1 189.9 194.4 291,194 88.4 0.6 87.3 89.4
Multiple races 61,600 1.2 60,200 63,000 1352.8 1321.9 1383.6 54,920 89.2 1.2 87.2 91.3
Transmission categoryf
Male-to-male sexual contactg 655,100 0.4 650,000 660,200 — — — 549,064 83.8 0.4 83.2 84.5
Injection drug useh 125,900 1.1 123,300 128,500 — — — 116,784 92.8 1.1 90.9 94.7
     Male 73,200 1.5 71,100 75,300 — — — 67,774 92.6 1.5 90.1 95.3
     Female 52,700 1.5 51,200 54,200 — — — 49,011 93.0 1.5 90.4 95.8
Male-to-male sexual contactg and Injection drug useh 63,400 1.3 61,800 65,000 — — — 58,001 91.5 1.3 89.2 93.9
Heterosexual contacti 294,500 0.6 291,200 297,700 — — — 255,234 86.7 0.6 85.7 87.7
     Male 92,200 1.1 90,300 94,200 — — — 76,847 83.3 1.1 81.6 85.1
     Female 202,200 0.7 199,600 204,800 — — — 178,387 88.2 0.7 87.1 89.4
Region of residence
Northeast 248,600 0.7 245,300 251,800 520.2 513.3 527.0 226,712 91.2 0.7 90.0 92.4
Midwest 139,100 0.9 136,800 141,500 243.7 239.6 247.9 117,129 84.2 0.9 82.8 85.6
South 527,000 0.4 522,500 531,600 510.9 506.5 515.4 443,937 84.2 0.4 83.5 85.0
West 228,000 0.7 225,000 231,000 354.1 349.4 358.8 194,889 85.5 0.7 84.4 86.6
Totalj 1,142,700 0.3 1,135,900 1,149,500 419.5 417.0 422.0 982,667 86.0 0.3 85.5 86.5
TTable 8. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2018
Assigned sex at birth
Male 904,500 0.4 898,300 910,800 674.5 669.8 679.1 772,969 85.5 0.4 84.9 86.1
Female 259,800 0.6 256,700 263,000 185.4 183.1 187.6 232,542 89.5 0.6 88.4 90.6
Age (yr)
13–24 59,200 1.2 57,800 60,600 115.5 112.8 118.2 26,607 45.0 1.2 43.9 46.0
25–34 211,200 0.5 209,000 213,500 462.4 457.5 467.3 153,232 72.5 0.5 71.8 73.3
35–44 220,200 0.5 218,300 222,200 534.1 529.4 538.8 189,167 85.9 0.5 85.1 86.7
45–54 301,000 0.4 298,800 303,100 724.0 718.8 729.2 279,604 92.9 0.4 92.2 93.6
≥ 55 372,800 0.4 369,800 375,800 394.2 391.0 397.3 356,901 95.7 0.4 95.0 96.5
Race/ethnicity
American Indian/Alaska Native 3,700 5.6 3,300 4,100 185.2 164.9 205.5 2,853 77.9 5.7 70.2 87.5
Asiand 17,100 2.3 16,300 17,900 107.4 102.6 112.2 14,375 84.1 2.3 80.5 88.1
Black/African American 469,600 0.5 465,100 474,100 1394.8 1381.5 1408.0 404,951 86.2 0.5 85.4 87.1
Hispanic/Latinoe 277,000 0.6 273,700 280,200 602.2 595.0 609.3 231,101 83.4 0.6 82.5 84.4
Native Hawaiian/Other Pacific Islander 1,000 10.1 830 1,200 214.8 172.4 257.2 784 75.8 10.5 63.3 94.4
White 333,600 0.6 329,600 337,500 194.4 192.2 196.7 295,534 88.6 0.6 87.6 89.7
Multiple races 61,800 1.2 60,400 63,300 1313.9 1283.3 1344.5 55,250 89.4 1.2 87.3 91.5
Transmission categoryf
Male-to-male sexual contactg 673,000 0.4 667,700 678,200 — — — 567,472 84.3 0.4 83.7 85.0
Injection drug useh 125,200 1.1 122,500 127,800 — — — 115,950 92.6 1.1 90.7 94.6
     Male 72,600 1.5 70,500 74,700 — — — 67,101 92.4 1.5 89.8 95.2
     Female 52,600 1.5 51,000 54,100 — — — 48,850 92.9 1.5 90.2 95.8
Male-to-male sexual contactg and Injection drug useh 63,500 1.3 61,900 65,200 — — — 58,116 91.5 1.3 89.2 93.9
Heterosexual contacti 298,900 0.6 295,500 302,200 — — — 260,362 87.1 0.6 86.1 88.1
     Male 93,200 1.1 91,200 95,300 — — — 78,210 83.9 1.1 82.1 85.8
     Female 205,600 0.7 202,900 208,300 — — — 182,152 88.6 0.7 87.4 89.8
Region of residence
Northeast 250,000 0.7 246,700 253,400 522.7 515.8 529.7 228,784 91.5 0.7 90.3 92.7
Midwest 142,000 0.9 139,600 144,400 248.1 243.9 252.4 120,165 84.6 0.9 83.2 86.1
South 538,900 0.4 534,200 543,600 517.3 512.8 521.8 456,294 84.7 0.4 83.9 85.4
West 233,400 0.7 230,300 236,500 358.9 354.1 363.7 200,268 85.8 0.7 84.7 87.0
Totalj 1,164,400 0.3 1,157,400 1,171,400 424.5 422.0 427.1 1,005,511 86.4 0.3 85.8 86.9
Table 8. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2019
Assigned sex at birth
Male 921,900 0.4 915,400 928,400 683.0 678.2 687.8 791,399 85.8 0.4 85.2 86.5
Female 262,900 0.6 259,700 266,100 186.4 184.1 188.7 236,166 89.8 0.6 88.7 90.9
Age (yr)
13–24 53,500 1.4 52,000 55,000 104.8 101.8 107.7 25,934 48.5 1.4 47.2 49.9
25–34 216,200 0.6 213,800 218,700 470.1 464.6 475.5 156,651 72.4 0.6 71.6 73.3
35–44 225,100 0.5 223,000 227,200 540.1 535.0 545.2 192,529 85.5 0.5 84.7 86.4
45–54 287,400 0.4 285,300 289,600 703.5 698.2 708.8 266,664 92.8 0.4 92.1 93.5
≥ 55 402,600 0.4 399,500 405,700 417.3 414.1 420.6 385,787 95.8 0.4 95.1 96.6
Race/ethnicity
American Indian/Alaska Native 3,800 5.7 3,400 4,200 191.0 169.7 212.3 2,990 78.4 5.8 70.6 88.2
Asiand 17,700 2.3 16,900 18,500 108.8 103.8 113.7 15,118 85.6 2.3 81.9 89.7
Black/African American 477,600 0.5 473,000 482,200 1405.5 1392.0 1419.1 413,920 86.7 0.5 85.8 87.5
Hispanic/Latinoe 284,700 0.6 281,200 288,100 606.3 599.0 613.6 239,069 84.0 0.6 83.0 85.0
Native Hawaiian/Other Pacific Islander 1,100 10.2 850 1,300 216.6 173.1 260.1 830 78.0 10.7 64.9 97.6
White 337,300 0.6 333,300 341,300 196.6 194.3 199.0 299,443 88.8 0.6 87.7 89.8
Multiple races 62,000 1.2 60,600 63,500 1275.9 1245.5 1306.3 55,536 89.5 1.2 87.4 91.7
Transmission categoryf
Male-to-male sexual contactg 689,900 0.4 684,500 695,300 — — — 585,215 84.8 0.4 84.2 85.5
Injection drug useh 124,500 1.1 121,900 127,200 — — — 115,253 92.6 1.1 90.6 94.6
     Male 72,100 1.5 69,900 74,200 — — — 66,494 92.2 1.5 89.6 95.1
     Female 52,400 1.5 50,900 54,000 — — — 48,759 93.0 1.5 90.2 95.9
Male-to-male sexual contactg and Injection drug useh 63,600 1.3 62,000 65,300 — — — 58,324 91.6 1.3 89.3 94.1
Heterosexual contacti 302,900 0.6 299,400 306,300 — — — 265,124 87.5 0.6 86.5 88.6
     Male 94,100 1.1 92,000 96,200 — — — 79,292 84.3 1.1 82.4 86.2
     Female 208,800 0.7 206,000 211,500 — — — 185,832 89.0 0.7 87.8 90.2
Region of residence
Northeast 250,900 0.7 247,500 254,300 524.8 517.7 531.9 230,293 91.8 0.7 90.6 93.0
Midwest 144,500 0.9 142,000 147,000 251.8 247.4 256.2 122,883 85.0 0.9 83.6 86.5
South 550,900 0.5 546,000 555,800 523.4 518.8 528.1 468,902 85.1 0.5 84.4 85.9
West 238,500 0.7 235,300 241,700 363.5 358.6 368.4 205,487 86.2 0.7 85.0 87.3
Totalj 1,184,800 0.3 1,177,600 1,192,100 429.2 426.6 431.8 1,027,565 86.7 0.3 86.2 87.3
Table 8. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2020 (COVID-19 Pandemic)c
Assigned sex at birth
Male 932,300 0.4 925,600 939,100 678.8 673.9 683.7 802,910 86.1 0.4 85.5 86.7
Female 263,600 0.6 260,300 267,000 186.1 183.8 188.5 237,346 90.0 0.6 88.9 91.2
Age (yr)
13–24 46,900 1.7 45,300 48,500 90.5 87.4 93.6 24,027 51.3 1.8 49.6 53.1
25–34 217,100 0.7 214,300 219,900 475.2 469.1 481.3 156,512 72.1 0.7 71.2 73.0
35–44 230,200 0.5 227,900 232,600 536.6 531.2 542.1 195,916 85.1 0.5 84.2 86.0
45–54 273,800 0.4 271,600 276,000 666.2 660.8 671.6 253,579 92.6 0.4 91.9 93.4
≥ 55 428,000 0.4 424,700 431,200 438.9 435.5 442.2 410,222 95.9 0.4 95.1 96.6
Race/ethnicity
American Indian/Alaska Native 3,900 5.9 3,500 4,400 194.5 172.0 217.1 3,099 78.8 6.0 70.6 89.1
Asiand 18,100 2.4 17,200 18,900 108.7 103.6 113.8 15,721 87.1 2.4 83.2 91.3
Black/African American 481,700 0.5 476,900 486,500 1397.2 1383.3 1411.1 418,714 86.9 0.5 86.1 87.8
Hispanic/Latinoe 289,500 0.6 285,900 293,200 599.0 591.5 606.5 244,303 84.4 0.6 83.3 85.5
Native Hawaiian/Other Pacific Islander 1,100 10.7 880 1,300 219.3 175.0 265.1 882 79.8 10.9 66.0 100.0
White 339,300 0.6 335,100 343,400 197.3 194.9 199.7 301,619 88.9 0.6 87.8 90.0
Multiple races 61,700 1.3 60,200 63,200 1218.1 1188.0 1248.3 55,260 89.6 1.3 87.4 91.8
Transmission categoryf
Male-to-male sexual contactg 701,900 0.4 696,200 707,600 — — — 598,237 85.2 0.4 84.5 85.9
Injection drug useh 123,000 1.1 120,200 125,700 — — — 113,525 92.3 1.1 90.3 94.4
     Male 71,100 1.6 68,900 73,300 — — — 65,327 91.9 1.6 89.1 94.8
     Female 51,800 1.6 50,200 53,500 — — — 48,198 93.0 1.6 90.1 96.0
Male-to-male sexual contactg and Injection drug useh 63,200 1.4 61,500 64,900 — — — 57,858 91.5 1.4 89.1 94.1
Heterosexual contacti 304,000 0.6 300,400 307,600 — — — 267,001 87.8 0.6 86.8 88.9
     Male 93,900 1.2 91,700 96,100 — — — 79,440 84.6 1.2 82.6 86.6
     Female 210,100 0.7 207,200 212,900 — — — 187,561 89.3 0.7 88.1 90.5
Region of residence
Northeast 250,200 0.7 246,700 253,700 509.4 502.3 516.5 229,844 91.9 0.7 90.6 93.2
Midwest 146,400 0.9 143,800 149,000 252.7 248.2 257.3 124,830 85.3 0.9 83.8 86.8
South 558,000 0.5 552,900 563,100 526.6 521.8 531.4 476,871 85.5 0.5 84.7 86.3
West 241,400 0.7 238,100 244,800 365.8 360.7 370.9 208,711 86.4 0.7 85.3 87.7
Totalj 1,196,000 0.3 1,188,400 1,203,500 428.7 426.0 431.4 1,040,256 87.0 0.3 86.4 87.5
Table 8. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2021c
Assigned sex at birth
Male 946,500 0.4 939,400 953,500 686.1 681.0 691.3 819,141 86.5k 0.4 85.9 87.2
Female 265,900 0.7 262,500 269,300 186.9 184.5 189.3 239,759 90.2 0.7 89.0 91.3
Age (yr)
13–24 41,900 2.1 40,200 43,700 80.7 77.4 84.0 23,671 56.4k 2.1 54.2 58.9
25–34 217,100 0.7 214,000 220,200 477.2 470.3 484.0 157,035 72.3 0.7 71.3 73.4
35–44 238,300 0.6 235,700 241,000 549.1 543.1 555.1 202,019 84.8k 0.6 83.8 85.7
45–54 263,000 0.4 260,700 265,300 646.4 640.7 652.1 243,001 92.4 0.4 91.6 93.2
≥ 55 452,000 0.4 448,600 455,400 458.2 454.7 461.7 433,174 95.8 0.4 95.1 96.6
Race/ethnicity
American Indian/Alaska Native 4,100 6.1 3,600 4,500 198.7 174.8 222.5 3,245 80.1 6.2 71.5 91.0
Asiand 18,600 2.4 17,700 19,400 110.3 105.0 115.6 16,455 88.7k 2.5 84.6 93.1
Black/African American 487,500 0.5 482,500 492,500 1404.2 1389.9 1418.6 425,519 87.3k 0.5 86.4 88.2
Hispanic/Latinoe 297,200 0.7 293,400 301,100 603.0 595.2 610.8 252,342 84.9k 0.7 83.8 86.0
Native Hawaiian/Other Pacific Islander 1,200 11.1 950 1,400 229.2 185.1 279.1 948 80.7 10.6 66.3 100.0
White 342,000 0.6 337,800 346,300 199.3 196.8 201.8 304,871 89.1 0.6 88.0 90.3
Multiple races 61,200 1.3 59,600 62,800 1168.6 1138.6 1198.6 54,864 89.6 1.3 87.4 92.0
Transmission categoryf
Male-to-male sexual contactg 716,900 0.4 710,900 722,900 — — — 615,019 85.8k 0.4 85.1 86.5
Injection drug useh 121,900 1.2 119,200 124,700 — — — 112,395 92.2 1.2 90.1 94.3
     Male 70,400 1.6 68,100 72,600 — — — 64,530 91.7 1.6 88.8 94.7
     Female 51,600 1.6 49,900 53,200 — — — 47,864 92.8 1.6 89.9 95.9
Male-to-male sexual contactg and Injection drug useh 62,900 1.4 61,100 64,600 — — — 57,559 91.6 1.4 89.1 94.2
Heterosexual contacti 306,700 0.6 303,000 310,500 — — — 270,255 88.1 0.6 87.0 89.2
     Male 94,100 1.2 91,800 96,400 — — — 79,991 85.0 1.2 82.9 87.1
     Female 212,600 0.7 209,600 215,600 — — — 190,265 89.5 0.7 88.3 90.8
Region of residence
Northeast 250,600 0.7 247,100 254,200 512.4 505.0 519.7 230,704 92.0 0.7 90.7 93.4
Midwest 148,800 0.9 146,000 151,500 256.5 251.8 261.2 127,435 85.7 0.9 84.1 87.3
South 567,800 0.5 562,400 573,200 530.7 525.7 535.8 487,976 85.9k 0.5 85.1 86.8
West 245,200 0.7 241,700 248,700 369.8 364.5 375.1 212,785 86.8 0.7 85.6 88.0
Totalj 1,212,400 0.3 1,204,500 1,220,200 432.7 429.9 435.5 1,058,900 87.3k 0.3 86.8 87.9

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.

a Rates are per 100,000 population.
b Reported to the National HIV Surveillance System.
c Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
d Includes Asian/Pacific Islander legacy cases.
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
k Indicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 9. Estimated HIV prevalence among Black/African American persons aged ≥ 13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2017
Male 
    Age (yr)
    13–24 29,200 1.5 28,400 30,100 790.7 767.7 813.7 12,666 43.4 1.5 42.1 44.7
    25–34 73,600 0.8 72,400 74,800 2,389.1 2,350.6 2,427.5 55,620 75.6 0.8 74.4 76.8
    35–44 52,200 0.9 51,300 53,100 2,118.2 2,082.1 2,154.4 45,328 86.9 0.9 85.4 88.4
    45–54 71,600 0.7 70,500 72,600 2,913.1 2,870.2 2,955.9 66,888 93.4 0.8 92.1 94.8
    ≥55 85,800 0.9 84,300 87,300 2,119.7 2,082.4 2,157.0 82,058 95.7 0.9 94.0 97.4
    Transmission categoryd
    Male-to-male sexual contacte 204,900 0.7 202,100 207,700 — — — 166,582 81.3 0.7 80.2 82.4
    Injection drug usef 33,400 2.3 31,900 34,900 — — — 31,874 95.5 2.3 91.5 99.9
Male-to-male sexual contacte and injection drug usef 17,000 2.6 16,100 17,900 — — — 15,979 93.9 2.6 89.3 99.0
    Heterosexual contactg 56,400 1.4 54,900 58,000 — — — 47,587 84.4 1.4 82.1 86.7
Subtotalh 312,300 0.6 308,700 316,000 1,984.1 1,961.0 2,007.2 262,560 84.1 0.6 83.1 85.1
Female
    Age (yr)
    13–24 4,800 3.7 4,500 5,200 135.1 125.2 144.9 2,529 52.2 3.7 48.6 56.3
    25–34 19,500 1.5 18,900 20,100 617.0 598.2 635.7 15,267 78.2 1.5 75.9 80.7
    35–44 34,300 1.0 33,600 35,000 1,250.9 1,225.6 1,276.2 30,713 89.6 1.0 87.8 91.5
    45–54 44,600 0.9 43,800 45,400 1,601.9 1,572.7 1,631.1 41,659 93.5 0.9 91.8 95.2
    ≥55 45,500 1.1 44,500 46,500 851.4 833.1 869.8 43,012 94.5 1.1 92.6 96.6
    Transmission categoryd
    Injection drug usef 24,500 2.3 23,400 25,600 — — — 23,358 95.2 2.3 91.1 99.8
    Heterosexual contactg 123,300 0.9 121,300 125,400 — — — 109,088 88.4 0.9 87.0 89.9
Subtotalh 148,700 0.8 146,300 151,100 844.1 830.6 857.5 133,180 89.6 0.8 88.2 91.0
Totalh 461,000 0.5 456,700 465,400 1,382.0 1,369.0 1,395.1 395,740 85.8 0.5 85.0 86.7
Table 9. Estimated HIV prevalence among Black/African American persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2018
Male 
    Age (yr)
    13–24 26,700 1.7 25,800 27,600 734.7 709.9 759.5 12,152 45.5 1.7 44.0 47.1
    25–34 77,900 0.9 76,600 79,200 2,456.8 2,415.3 2,498.4 58,599 75.2 0.9 74.0 76.5
    35–44 54,200 0.9 53,300 55,200 2,175.7 2,137.2 2,214.3 47,121 86.9 0.9 85.3 88.4
    45–54 68,200 0.8 67,200 69,300 2,809.8 2,766.5 2,853.1 63,765 93.5 0.8 92.1 94.9
    ≥55 92,100 0.9 90,500 93,600 2,210.2 2,172.4 2,248.0 88,074 95.7 0.9 94.1 97.3
    Transmission categoryd
    Male-to-male sexual contacte 212,100 0.7 209,200 215,000 — — — 173,802 81.9 0.7 80.8 83.1
    Injection drug usef 32,700 2.3 31,300 34,200 — — — 31,259 95.5 2.3 91.4 100.0
Male-to-male sexual contacte and injection drug usef 16,800 2.7 16,000 17,700 — — — 15,828 94.0 2.7 89.3 99.2
    Heterosexual contactg 56,800 1.4 55,300 58,400 — — — 48,281 84.9 1.4 82.6 87.4
Subtotalh 319,100 0.6 315,400 322,900 2,008.1 1,984.5 2,031.7 269,711 84.5 0.6 83.5 85.5
Female 
    Age (yr)
    13–24 4,400 4.3 4,000 4,800 124.3 113.8 134.7 2,357 53.6 4.3 49.4 58.5
    25–34 18,900 1.7 18,300 19,600 587.1 567.6 606.7 14,696 77.7 1.7 75.2 80.3
    35–44 33,800 1.1 33,000 34,500 1,221.7 1,195.6 1,247.7 30,257 89.6 1.1 87.7 91.6
    45–54 43,800 1.0 43,000 44,700 1,591.2 1,561.4 1,621.0 41,014 93.6 1.0 91.8 95.3
    ≥55 49,500 1.1 48,500 50,600 901.4 882.6 920.2 46,916 94.7 1.1 92.8 96.7
    Transmission categoryd
    Injection drug usef 24,300 2.4 23,100 25,400 — — — 23,121 95.3 2.4 91.0 99.9
    Heterosexual contactg 125,300 0.9 123,200 127,400 — — — 111,350 88.8 0.9 87.4 90.4
Subtotalh 150,500 0.8 148,000 152,900 846.4 832.8 860.1 135,240 89.9 0.8 88.5 91.3
Totalh 469,600 0.5 465,100 474,100 1,394.8 1,381.5 1,408.0 404,951 86.2 0.5 85.4 87.1
Table 9. Estimated HIV prevalence among Black/African American persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2019
Male 
    Age (yr)
    13–24 24,400 2.0 23,400 25,400 679.5 652.5 706.6 11,920 48.9 2.0 47.0 50.9
    25–34 81,200 0.9 79,700 82,600 2,496.2 2,451.0 2,541.3 60,775 74.9 0.9 73.5 76.3
    35–44 57,000 0.9 56,000 58,100 2,254.1 2,212.5 2,295.8 49,434 86.7 0.9 85.1 88.3
    45–54 64,700 0.8 63,700 65,800 2,708.9 2,664.6 2,753.1 60,419 93.3 0.8 91.8 94.9
    ≥55 98,300 0.9 96,700 100,000 2,296.4 2,258.0 2,334.7 94,175 95.8 0.9 94.2 97.4
    Transmission categoryd
    Male-to-male sexual contacte 219,000 0.7 216,000 222,000 — — — 180,843 82.6 0.7 81.5 83.7
    Injection drug usef 32,100 2.4 30,700 33,600 — — — 30,721 95.7 2.3 91.4 100.0
Male-to-male sexual contacteand injection drug usef 16,700 2.7 15,800 17,600 — — — 15,717 94.3 2.8 89.5 99.7
    Heterosexual contactg 57,300 1.5 55,600 58,900 — — — 48,884 85.4 1.5 83.0 87.9
Subtotalh 325,600 0.6 321,800 329,500 2,029.8 2,005.6 2,054.0 276,723 85.0 0.6 84.0 86.0
Female 
    Age (yr)
    13–24 4,000 5.0 3,600 4,400 113.8 102.8 124.9 2,219 55.7 5.0 50.7 61.7
    25–34 18,300 1.9 17,700 19,000 559.3 538.8 579.7 14,228 77.6 1.9 74.9 80.6
    35–44 32,800 1.2 32,000 33,500 1,173.8 1,146.9 1,200.6 29,335 89.5 1.2 87.5 91.5
    45–54 43,100 1.0 42,300 44,000 1,588.2 1,557.5 1,618.8 40,458 93.8 1.0 92.0 95.6
    ≥55 53,700 1.0 52,600 54,800 951.1 931.8 970.4 50,957 94.8 1.0 93.0 96.8
    Transmission categoryd
    Injection drug usef 24,000 2.4 22,900 25,100 — — — 22,895 95.6 2.3 91.3 100.0
    Heterosexual contactg 127,100 0.9 124,900 129,300 — — — 113,502 89.3 0.9 87.8 90.8
Subtotalh 152,000 0.8 149,500 154,500 847.2 833.4 861.0 137,197 90.3 0.8 88.8 91.8
Totalh 477,600 0.5 473,000 482,200 1,405.5 1,392.0 1,419.1 413,920 86.7 0.5 85.8 87.5
Table 9. Estimated HIV prevalence among Black/African American persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2020 (COVID-19 Pandemic)c
Male 
    Age (yr)
    13–24 21,800 2.5 20,700 22,900 602.0 572.5 631.5 11,276 51.7 2.5 49.3 54.3
    25–34 82,900 1.0 81,200 84,600 2,548.3 2,497.0 2,599.5 61,640 74.3 1.0 72.9 75.9
    35–44 60,200 1.0 59,000 61,400 2,282.6 2,238.1 2,327.2 52,029 86.4 1.0 84.8 88.1
    45–54 61,100 0.9 60,100 62,200 2,516.7 2,472.4 2,561.1 56,952 93.1 0.9 91.5 94.8
    ≥55 103,500 0.8 101,800 105,200 2,330.8 2,292.2 2,369.4 99,102 95.8 0.8 94.2 97.4
    Transmission categoryd
    Male-to-male sexual contacte 224,200 0.7 221,000 227,400 — — — 186,280 83.1 0.7 81.9 84.3
    Injection drug usef 31,200 2.5 29,800 32,700 — — — 29,844 95.7 2.3 91.3 100.0
Male-to-male sexual contacte and injection drug usef 16,400 2.8 15,500 17,400 — — — 15,479 94.1 2.8 89.2 99.6
    Heterosexual contactg 57,100 1.5 55,300 58,800 — — — 48,836 85.6 1.5 83.1 88.2
Subtotalh 329,500 0.6 325,500 333,600 2,011.4 1,986.6 2,036.2 280,999 85.3 0.6 84.2 86.3
Female
    Age (yr)
    13–24 3,400 6.1 3,000 3,800 97.1 85.6 108.7 1,969 57.3 6.2 51.2 65.1
    25–34 17,600 2.1 16,900 18,400 535.9 513.6 558.2 13,518 76.7 2.1 73.7 80.0
    35–44 31,800 1.3 31,000 32,600 1,113.3 1,085.6 1,140.9 28,324 89.1 1.3 87.0 91.4
    45–54 42,000 1.0 41,200 42,900 1,555.8 1,524.4 1,587.2 39,511 94.0 1.0 92.1 95.9
    ≥55 57,300 1.0 56,100 58,400 1,002.8 982.7 1,022.9 54,393 95.0 1.0 93.1 96.9
    Transmission categoryd
    Injection drug usef 23,500 2.5 22,500 24,700 — — — 22,495 95.7 2.3 91.2 100.0
    Heterosexual contactg 127,700 0.9 125,500 130,000 — — — 114,400 89.6 0.9 88.0 91.2
Subtotalh 152,200 0.9 149,600 154,700 841.0 826.9 855.0 137,715 90.5 0.9 89.0 92.0
Totalh 481,700 0.5 476,900 486,500 1,397.2 1,383.3 1,411.1 418,714 86.9 0.5 86.1 87.8
Table 9. Estimated HIV prevalence among Black/African American persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2021c
Male 
    Age (yr)
    13–24 19,800 3.0 18,600 21,000 544.7 512.6 576.8 11,207 56.6i 3.0 53.5 60.2
    25–34 83,400 1.1 81,600 85,300 2,556.7 2,500.1 2,613.2 62,019 74.3 1.1 72.7 76.0
    35–44 64,600 1.0 63,200 65,900 2,407.6 2,358.4 2,456.8 55,567 86.1 1.0 84.3 87.9
    45–54 58,100 1.0 57,000 59,200 2,421.8 2,375.7 2,468.0 53,955 92.9 1.0 91.2 94.7
    ≥55 108,600 0.8 106,800 110,300 2,400.6 2,360.9 2,440.2 103,910 95.7 0.8 94.2 97.3
    Transmission categoryd
    Male-to-male sexual contacte 230,100 0.8 226,700 233,500 — — — 192,625 83.7i 0.8 82.5 85.0
    Injection drug usef 30,400 2.5 29,200 32,000 — — — 29,183 95.8 2.3 91.3 100.0
Male-to-male sexual contacte and injection drug usef 16,200 2.9 15,300 17,100 — — — 15,249 94.1 2.9 89.0 99.8
    Heterosexual contactg 57,000 1.6 55,200 58,800 — — — 49,028 86.0 1.6 83.4 88.8
Subtotalh 334,400 0.6 330,200 338,700 2,027.0 2,001.2 2,052.8 286,658 85.7i 0.6 84.6 86.8
Female 
    Age (yr)
    13–24 3,000 7.1 2,600 3,500 85.9 73.9 97.9 1,866 61.3 7.3 53.8 71.2
    25–34 17,000 2.4 16,200 17,800 516.1 492.1 540.2 12,955 76.4 2.4 73.0 80.1
    35–44 31,200 1.4 30,300 32,000 1,077.2 1,048.3 1,106.2 27,708 88.9 1.4 86.6 91.4
    45–54 41,200 1.1 40,300 42,100 1,541.9 1,509.3 1,574.6 38,717 94.0 1.1 92.0 96.0
    ≥55 60,700 1.0 59,500 61,900 1,042.5 1,021.7 1,063.2 57,615 94.9 1.0 93.1 96.9
    Transmission categoryd
    Injection drug usef 23,100 2.5 22,100 24,300 — — — 22,134 95.8 2.3 91.2 100.0
    Heterosexual contactg 129,000 0.9 126,700 131,300 — — — 115,867 89.8 0.9 88.2 91.5
Subtotalh 153,100 0.9 150,400 155,700 840.2 825.9 854.6 138,861 90.7 0.9 89.2 92.3
Totalh 487,500 0.5 482,500 492,500 1,404.2 1,389.9 1,418.6 425,519 87.3i 0.5 86.4 88.2

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.

aRates are per 100,000 population.
bReported to the National HIV Surveillance System.
cEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
hIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
iIndicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 10. Estimated HIV prevalence among Hispanic/Latino persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2017
Male 
    Age (yr)
    13–24 16,000 2.2 15,300 16,600 266.6 255.2 278.0 5,878 36.8 2.2 35.3 38.5
    25–34 48,400 1.1 47,400 49,500 995.0 973.6 1,016.5 32,663 67.5 1.1 66.0 69.0
    35–44 50,100 0.9 49,200 51,000 1,163.7 1,142.7 1,184.7 41,961 83.8 0.9 82.3 85.3
    45–54 59,000 0.8 58,100 59,900 1,719.4 1,692.8 1,746.1 54,358 92.1 0.8 90.7 93.6
    ≥55 48,300 1.1 47,300 49,300 1,192.2 1,166.9 1,217.6 46,157 95.6 1.1 93.6 97.6
    Transmission categoryd
Male-to-male sexual contacte 167,300 0.7 164,900 169,800 — — — 132,912 79.4 0.7 78.3 80.6
Injection drug usef 20,600 2.6 19,500 21,600 — — — 19,161 93.2 2.6 88.7 98.1
Male-to-male sexual contacte and injection drug usef 14,900 2.5 14,100 15,600 — — — 13,326 89.7 2.5 85.5 94.3
Heterosexual contactg 18,700 2.4 17,800 19,500 — — — 15,311 82.0 2.4 78.3 86.0
Subtotalh 221,800 0.7 218,900 224,700 979.5 966.7 992.3 181,017 81.6 0.7 80.6 82.7
Female 
    Age (yr)
    13–24 1,400 7.0 1,200 1,600 24.3 20.9 27.6 671 48.5 7.2 42.6 56.3
    25–34 5,600 2.9 5,300 5,900 127.3 120.0 134.6 4,258 75.8 2.9 71.7 80.4
    35–44 10,600 1.8 10,200 11,000 260.0 250.8 269.1 9,428 88.7 1.8 85.7 92.0
    45–54 14,300 1.6 13,800 14,700 423.1 410.1 436.0 13,276 92.9 1.6 90.2 95.9
    ≥55 15,200 1.7 14,700 15,700 320.5 309.7 331.4 14,515 95.6 1.7 92.5 99.0
    Transmission categoryd
    Injection drug usef 10,200 3.2 9,600 10,900 — — — 9,628 94.2 3.1 88.7 100.0
    Heterosexual contactg 36,600 1.5 35,600 37,700 — — — 32,291 88.2 1.5 85.6 90.8
Subtotalh 47,100 1.4 45,800 48,400 211.0 205.4 216.7 42,148 89.5 1.4 87.2 92.0
Totalh 268,800 0.6 265,700 272,000 598.0 591.0 605.1 223,165 83.0 0.6 82.0 84.0
Table 10. Estimated HIV prevalence among Hispanic/Latino persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2018
Male 
    Age (yr)
    13–24 14,700 2.5 14,000 15,400 242.4 230.4 254.5 5,800 39.5 2.5 37.6 41.6
    25–34 50,800 1.2 49,700 52,000 1,031.4 1,007.6 1,055.3 34,289 67.4 1.2 65.9 69.0
    35–44 51,700 1.0 50,700 52,700 1,178.1 1,155.5 1,200.6 43,185 83.5 1.0 81.9 85.1
    45–54 58,600 0.8 57,700 59,600 1,670.1 1,643.3 1,696.9 53,977 92.1 0.8 90.6 93.6
    ≥55 53,300 1.0 52,200 54,400 1,249.5 1,224.1 1,274.9 50,942 95.6 1.0 93.7 97.6
    Transmission categoryd
Male-to-male sexual contacte 174,400 0.7 171,800 177,000 — — — 139,681 80.1 0.7 78.9 81.3
Injection drug usef 20,400 2.6 19,400 21,400 — — — 19,024 93.3 2.6 88.7 98.3
Male-to-male sexual contacte and injection drug usef 15,000 2.5 14,200 15,700 — — — 13,456 89.9 2.5 85.7 94.6
Heterosexual contactg 19,000 2.4 18,100 19,900 — — — 15,721 82.6 2.4 78.8 86.7
Subtotalh 229,100 0.7 226,100 232,200 989.7 976.7 1,002.8 188,193 82.1 0.7 81.1 83.2
Female 
    Age (yr)
    13–24 1,300 8.1 1,100 1,500 22.2 18.7 25.8 644 50.0 8.3 43.2 59.4
    25–34 5,500 3.2 5,100 5,800 121.9 114.2 129.6 4,097 74.9 3.2 70.5 80.0
    35–44 10,500 1.9 10,100 10,900 253.8 244.3 263.4 9,272 88.0 1.9 84.8 91.5
    45–54 14,100 1.6 13,600 14,500 406.7 393.8 419.5 13,098 93.2 1.6 90.3 96.2
    ≥55 16,500 1.7 15,900 17,000 331.9 321.0 342.8 15,797 95.9 1.7 92.8 99.2
    Transmission categoryd
    Injection drug usef 10,200 3.2 9,600 10,800 — — — 9,588 94.3 3.1 88.7 100.0
    Heterosexual contactg 37,400 1.5 36,300 38,500 — — — 33,087 88.4 1.5 85.9 91.1
Subtotalh 47,800 1.4 46,500 49,100 209.3 203.7 215.0 42,908 89.7 1.4 87.4 92.2
Totalh 277,000 0.6 273,700 280,200 602.2 595.0 609.3 231,101 83.4 0.6 82.5 84.4
Table 10. Estimated HIV prevalence among Hispanic/Latino persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2019
Male 
    Age (yr)
    13–24 13,300 3.0 12,500 14,100 217.0 204.1 229.8 5,809 43.7 3.0 41.2 46.4
    25–34 52,800 1.3 51,500 54,100 1,060.2 1,033.7 1,086.7 35,727 67.6 1.3 66.0 69.4
    35–44 53,700 1.0 52,600 54,800 1,205.5 1,181.0 1,230.0 44,682 83.3 1.0 81.6 85.0
    45–54 57,600 0.9 56,700 58,600 1,611.6 1,584.2 1,639.0 52,961 91.9 0.9 90.3 93.5
    ≥55 58,800 1.0 57,700 59,900 1,312.2 1,286.6 1,337.8 56,231 95.6 1.0 93.8 97.5
    Transmission categoryd
Male-to-male sexual contacte 181,300 0.8 178,500 184,000 — — — 146,598 80.9 0.8 79.7 82.1
Injection drug usef 20,200 2.7 19,200 21,300 — — — 18,866 93.2 2.7 88.6 98.4
Male-to-male sexual contacte and injection drug usef 15,100 2.6 14,300 15,900 — — — 13,599 90.0 2.6 85.6 94.8
Heterosexual contactg 19,300 2.5 18,400 20,200 — — — 16,030 83.0 2.5 79.2 87.3
Subtotalh 236,200 0.7 233,100 239,400 1,000.0 986.6 1,013.4 195,410 82.7 0.7 81.6 83.8
Female 
    Age (yr)
    13–24 1,100 9.7 900 1,300 19.0 15.4 22.6 620 55.6 10.0 46.7 68.6
    25–34 5,400 3.6 5,000 5,800 118.6 110.3 126.9 4,011 74.2 3.6 69.4 79.8
    35–44 10,300 2.1 9,900 10,700 246.4 236.4 256.4 9,045 87.6 2.1 84.2 91.3
    45–54 13,800 1.7 13,400 14,300 392.2 379.4 405.1 12,885 93.2 1.7 90.3 96.4
    ≥55 17,800 1.6 17,200 18,300 342.4 331.4 353.4 17,098 96.2 1.6 93.2 99.4
    Transmission categoryd
    Injection drug usef 10,100 3.3 9,500 10,800 — — — 9,533 94.4 3.1 88.7 100.0
    Heterosexual contactg 38,100 1.5 37,000 39,200 — — — 33,887 89.0 1.5 86.4 91.7
Subtotalh 48,400 1.4 47,100 49,800 207.6 201.9 213.3 43,659 90.1 1.4 87.7 92.7
Totalh 284,700 0.6 281,200 288,100 606.3 599.0 613.6 239,069 84.0 0.6 83.0 85.0
Table 10. Estimated HIV prevalence among Hispanic/Latino persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2020 (COVID-19 Pandemic)c
Male 
    Age (yr)
    13–24 11,500 3.8 10,600 12,300 181.3 167.9 194.8 5,366 46.8 3.8 43.6 50.5
    25–34 53,600 1.4 52,100 55,100 1,082.3 1,052.0 1,112.6 36,217 67.6 1.4 65.7 69.5
    35–44 55,700 1.1 54,500 56,900 1,202.8 1,176.2 1,229.3 46,067 82.7 1.1 80.9 84.6
    45–54 56,400 0.9 55,400 57,400 1,499.5 1,472.1 1,527.0 51,639 91.6 0.9 89.9 93.3
    ≥55 63,800 1.0 62,600 65,000 1,338.8 1,313.3 1,364.3 61,079 95.7 1.0 93.9 97.6
    Transmission categoryd
Male-to-male sexual contacte 186,300 0.8 183,400 189,200 — — — 151,711 81.4 0.8 80.2 82.7
Injection drug usef 19,900 2.7 18,900 21,000 — — — 18,617 93.4 2.8 88.6 98.7
Male-to-male sexual contact e and injection drug usef 15,100 2.7 14,300 15,900 — — — 13,567 90.0 2.7 85.5 95.0
Heterosexual contactg 19,300 2.6 18,400 20,300 — — — 16,160 83.5 2.6 79.4 88.0
Subtotalh 241,000 0.7 237,600 244,300 986.2 972.4 1,000.0 200,368 83.2 0.7 82.0 84.3
Female 
    Age (yr)
    13–24 1,000 12.0 760 1,200 16.5 12.6 20.4 566 56.6 12.7 45.8 74.0
    25–34 5,300 4.0 4,800 5,700 114.5 105.4 123.5 3,874 73.7 4.1 68.3 80.0
    35–44 9,900 2.3 9,500 10,400 232.2 221.8 242.5 8,719 87.9 2.3 84.2 92.0
    45–54 13,500 1.8 13,000 13,900 372.1 359.2 384.9 12,555 93.2 1.8 90.1 96.5
    ≥55 18,900 1.6 18,300 19,500 352.9 341.7 364.1 18,221 96.3 1.6 93.3 99.4
    Transmission categoryd
Injection drug usef 10,000 3.4 9,400 10,600 — — — 9,418 94.5 3.1 88.6 100.0
Heterosexual contactg 38,400 1.6 37,200 39,500 — — — 34,277 89.4 1.6 86.7 92.2
Subtotalh 48,600 1.4 47,200 49,900 203.2 197.5 208.9 43,935 90.4 1.4 88.0 93.1
Totalh 289,500 0.6 285,900 293,200 599.0 591.5 606.5 244,303 84.4 0.6 83.3 85.5
Table 10. Estimated HIV prevalence among Hispanic/Latino persons aged ≥13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2021c
Male 
    Age (yr)
    13–24 10,200 4.5 9,300 11,100 158.2 144.1 172.2 5,427 53.3i 4.6 48.9 58.5
    25–34 54,700 1.6 53,000 56,400 1,104.7 1,070.4 1,138.9 37,327 68.2 1.6 66.2 70.4
    35–44 58,400 1.2 57,000 59,800 1,244.9 1,215.3 1,274.5 48,144 82.5 1.2 80.5 84.5
    45–54 55,700 1.0 54,600 56,800 1,453.3 1,424.5 1,482.1 50,884 91.3 1.0 89.6 93.2
    ≥55 69,000 1.0 67,700 70,300 1,382.3 1,356.4 1,408.3 65,979 95.6 1.0 93.8 97.4
   Transmission categoryd
Male-to-male sexual contacte 193,400 0.8 190,200 196,500 — — — 159,035 82.2i 0.8 80.9 83.6
Injection drug usef 19,700 2.8 18,600 20,800 — — — 18,423 93.4 2.8 88.5 98.9
Male-to-male sexual contacte and injection drug usef 15,000 2.8 14,200 15,800 — — — 13,539 90.2 2.8 85.5 95.4
Heterosexual contactg 19,600 2.7 18,500 20,600 — — — 16,450 84.1 2.7 79.8 88.8
Subtotalh 248,000 0.7 244,400 251,600 995.8 981.4 1,010.2 207,761 83.8i 0.7 82.6 85.0
Female 
    Age (yr)
    13–24 960 13.8 700 1,200 15.5 11.3 19.7 551 57.6 14.8 45.4 78.9
    25–34 5,100 4.5 4,700 5,600 110.8 101.0 120.5 3,797 74.0 4.5 68.0 81.2
    35–44 9,800 2.5 9,300 10,300 228.1 216.8 239.3 8,560 87.2 2.5 83.1 91.7
    45–54 13,100 1.9 12,600 13,600 355.1 342.1 368.1 12,238 93.3 1.9 90.0 96.8
    ≥55 20,200 1.6 19,600 20,800 361.4 350.1 372.8 19,435 96.2 1.6 93.3 99.4
    Transmission categoryd
    Injection drug usef 9,900 3.5 9,300 10,600 — — — 9,349 94.5 3.1 88.4 100.0
    Heterosexual contactg 39,100 1.6 37,800 40,300 — — — 34,984 89.6 1.6 86.8 92.5
Subtotalh 49,200 1.5 47,800 50,600 201.8 196.0 207.7 44,581 90.6 1.5 88.0 93.3
Totalh 297,200 0.7 293,400 301,100 603.0 595.2 610.8 252,342 84.9i 0.7 83.8 86.0

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.

a Rates are per 100,000 population.
b Reported to the National HIV Surveillance System.
c Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
i Indicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 11. Estimated HIV prevalence among White persons aged ≥ 13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2017
Male 
    Age (yr)
    13–24 8,100 3.0 7,600 8,500 57.0 53.6 60.4 3,303 41.0 3.0 38.7 43.6
    25–34 34,700 1.3 33,800 35,500 270.6 263.7 277.5 23,931 69.0 1.3 67.3 70.9
    35–44 43,100 1.0 42,300 44,000 369.0 361.8 376.2 36,343 84.2 1.0 82.6 85.9
    45–54 87,900 0.7 86,800 89,100 657.8 649.2 666.4 81,600 92.8 0.7 91.6 94.0
    ≥ 55 112,900 0.8 111,200 114,700 352.1 346.8 357.5 108,600 96.2 0.8 94.7 97.6
    Transmission categoryd
Male-to-male sexual contacte 233,300 0.7 230,100 236,500 — — — 207,430 88.9 0.7 87.7 90.2
Injection drug usef 15,100 3.2 14,100 16,000 — — — 12,864 85.3 3.2 80.2 91.1
Male-to-male sexual contacte and injection drug usef 25,500 2.1 24,400 26,500 — — — 23,036 90.4 2.1 86.8 94.3
Heterosexual contactg 11,800 3.2 11,000 12,500 — — — 9,371 79.7 3.3 75.0 85.1
Subtotalh 286,700 0.6 283,100 290,300 341.1 336.8 345.4 253,777 88.5 0.6 87.4 89.6
Female
    Age (yr)
    13–24 1,200 7.4 1,000 1,400 9.2 7.8 10.5 557 45.5 7.6 39.7 53.2
    25–34 5,700 3.0 5,400 6,000 45.8 43.2 48.5 4,094 71.9 3.0 68.0 76.3
    35–44 8,900 2.1 8,500 9,300 77.1 74.0 80.2 7,499 84.3 2.1 81.0 87.9
    45–54 13,200 1.7 12,800 13,700 98.4 95.1 101.7 12,141 91.8 1.7 88.8 95.0
    ≥ 55 13,800 2.0 13,300 14,400 37.7 36.2 39.2 13,126 95.0 2.0 91.4 98.9
    Transmission categoryd
    Injection drug usef 13,900 2.8 13,100 14,700 — — — 12,194 87.8 2.8 83.2 93.0
    Heterosexual contactg 28,500 1.8 27,500 29,500 — — — 24,809 86.9 1.8 84.0 90.1
Subtotalh 42,900 1.5 41,600 44,100 49.0 47.5 50.5 37,417 87.3 1.5 84.8 90.0
Totalh 329,600 0.6 325,700 333,400 192.1 189.9 194.4 291,194 88.4 0.6 87.3 89.4
Table 11. Estimated HIV prevalence among White persons aged ≥ 13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2018
Male 
    Age (yr)
    13–24 7,100 3.6 6,600 7,600 50.7 47.1 54.2 3,158 44.7 3.6 41.7 48.0
    25–34 35,600 1.4 34,700 36,600 277.9 270.4 285.5 24,718 69.4 1.4 67.5 71.3
    35–44 43,400 1.1 42,500 44,300 368.6 360.9 376.3 36,326 83.7 1.1 82.0 85.4
    45–54 81,200 0.7 80,000 82,300 626.1 617.3 634.8 75,180 92.6 0.7 91.3 93.9
    ≥ 55 122,700 0.7 120,900 124,500 376.9 371.4 382.4 118,086 96.2 0.7 94.8 97.6
    Transmission categoryd
Male-to-male sexual contacte 235,900 0.7 232,600 239,200 — — — 210,596 89.3 0.7 88.1 90.5
Injection drug usef 15,400 3.2 14,400 16,400 — — — 13,025 84.5 3.3 79.5 90.3
Male-to-male sexual contacte and injection drug usef 25,700 2.1 24,600 26,800 — — — 23,210 90.3 2.1 86.7 94.3
Heterosexual contactg 11,900 3.3 11,200 12,700 — — — 9,578 80.2 3.3 75.4 85.8
Subtotalh 290,000 0.6 286,300 293,700 344.9 340.5 349.3 257,468 88.8 0.6 87.7 89.9
Female 
    Age (yr)
    13–24 1,100 8.5 950 1,300 8.6 7.2 10.0 543 47.8 8.8 40.9 57.3
    25–34 5,700 3.2 5,300 6,000 45.7 42.8 48.6 4,030 71.0 3.2 66.8 75.9
    35–44 9,000 2.2 8,600 9,300 77.0 73.7 80.3 7,524 84.1 2.2 80.6 87.9
    45–54 12,700 1.8 12,300 13,200 97.6 94.2 101.1 11,647 91.6 1.8 88.5 94.9
    ≥ 55 15,100 1.9 14,500 15,600 40.5 39.0 42.1 14,322 95.1 2.0 91.6 98.9
    Transmission categoryd
    Injection drug usef 14,100 2.9 13,300 14,900 — — — 12,349 87.6 2.9 82.9 92.8
    Heterosexual contactg 29,000 1.8 28,000 30,000 — — — 25,303 87.2 1.8 84.2 90.4
Subtotalh 43,500 1.5 42,200 44,800 49.8 48.3 51.3 38,066 87.4 1.5 84.9 90.2
Totalh 333,600 0.6 329,600 337,500 194.4 192.2 196.7 295,534 88.6 0.6 87.6 89.7
Table 11. Estimated HIV prevalence among White persons aged ≥ 13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2019
Male 
    Age (yr)
    13–24 6,200 4.2 5,700 6,700 45.0 41.3 48.7 3,025 48.7 4.2 45.0 53.1
    25–34 36,000 1.5 34,900 37,100 280.5 272.2 288.8 25,060 69.6 1.5 67.6 71.8
    35–44 44,300 1.1 43,300 45,300 373.3 365.1 381.6 36,760 82.9 1.1 81.1 84.8
    45–54 74,300 0.8 73,200 75,400 591.4 582.6 600.3 68,600 92.3 0.8 90.9 93.7
    ≥ 55 132,100 0.7 130,200 133,900 400.0 394.4 405.6 127,168 96.3 0.7 94.9 97.6
    Transmission categoryd
Male-to-male sexual contacte 238,100 0.7 234,800 241,400 — — — 213,222 89.6 0.7 88.3 90.8
Injection drug usef 15,800 3.3 14,700 16,800 — — — 13,209 83.9 3.3 78.8 89.6
Male-to-male sexual contacte and injection drug usef 25,900 2.2 24,800 27,000 — — — 23,416 90.4 2.2 86.7 94.4
Heterosexual contactg 12,100 3.4 11,300 12,900 — — — 9,727 80.3 3.4 75.3 86.0
Subtotalh 292,900 0.7 289,200 296,700 348.3 343.9 352.8 260,613 89.0 0.7 87.8 90.1
Female 
    Age (yr)
    13–24 1,100 9.8 860 1,300 8.2 6.6 9.7 544 50.9 10.1 42.8 63.0
    25–34 5,700 3.6 5,300 6,100 46.2 43.0 49.5 4,012 70.1 3.6 65.5 75.4
    35–44 9,000 2.4 8,600 9,400 77.0 73.4 80.6 7,559 83.7 2.4 80.0 87.8
    45–54 12,200 1.9 11,700 12,600 96.7 93.1 100.3 11,147 91.4 1.9 88.1 95.0
    ≥ 55 16,400 1.9 15,700 17,000 43.4 41.8 45.1 15,568 95.2 1.9 91.8 98.8
    Transmission categoryd
    Injection drug usef 14,400 2.9 13,600 15,200 — — — 12,570 87.3 2.9 82.6 92.6
    Heterosexual contactg 29,600 1.8 28,500 30,600 — — — 25,850 87.5 1.8 84.4 90.7
Subtotalh 44,400 1.6 43,000 45,700 50.7 49.2 52.3 38,830 87.5 1.6 84.9 90.3
Totalh 337,300 0.6 333,300 341,300 196.6 194.3 199.0 299,443 88.8 0.6 87.7 89.8
Table 11. Estimated HIV prevalence among White persons aged ≥ 13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2020 (COVID-19 Pandemic)c
Male 
    Age (yr)
    13–24 5,300 5.2 4,800 5,800 38.2 34.3 42.1 2,768 52.3 5.3 47.4 58.2
    25–34 35,700 1.7 34,500 36,900 282.7 273.4 292.1 24,805 69.5 1.7 67.3 71.9
    35–44 45,300 1.2 44,200 46,400 368.9 360.0 377.8 37,367 82.4 1.2 80.5 84.5
    45–54 68,200 0.8 67,100 69,400 540.2 531.3 549.1 62,758 92.0 0.8 90.5 93.5
    ≥ 55 139,900 0.7 138,000 141,800 417.2 411.4 422.9 134,636 96.3 0.7 94.9 97.6
    Transmission categoryd
Male-to-male sexual contacte 239,200 0.7 235,800 242,700 — — — 214,917 89.8 0.7 88.6 91.1
Injection drug usef 16,100 3.4 15,000 17,200 — — — 13,271 82.4 3.4 77.2 88.3
Male-to-male sexual contacte and injection drug usef 25,800 2.2 24,700 27,000 — — — 23,310 90.2 2.2 86.5 94.4
Heterosexual contactg 12,200 3.5 11,300 13,000 — — — 9,820 80.6 3.6 75.4 86.6
Subtotalh 294,400 0.7 290,500 298,300 346.6 342.0 351.2 262,334 89.1 0.7 87.9 90.3
Female 
    Age (yr)
    13–24 950 12.1 720 1,200 7.2 5.5 8.9 498 52.5 12.8 42.4 68.7
    25–34 5,700 4.0 5,200 6,100 46.5 42.8 50.2 3,945 69.3 4.1 64.3 75.3
    35–44 9,000 2.6 8,500 9,500 75.4 71.5 79.3 7,475 83.0 2.7 78.9 87.5
    45–54 11,800 2.0 11,300 12,300 95.5 91.7 99.4 10,771 91.2 2.1 87.7 95.0
    ≥ 55 17,400 1.9 16,800 18,100 46.7 45.0 48.4 16,596 95.3 1.9 91.9 98.9
    Transmission categoryd
    Injection drug usef 14,500 3.0 13,600 15,300 — — — 12,610 87.1 3.0 82.3 92.6
    Heterosexual contactg 30,000 1.9 28,900 31,100 — — — 26,273 87.6 1.9 84.5 91.0
Subtotalh 44,900 1.6 43,500 46,300 51.6 49.9 53.2 39,285 87.6 1.6 84.9 90.4
Totalh 339,300 0.6 335,100 343,400 197.3 194.9 199.7 301,619 88.9 0.6 87.8 90.0
Table 11. Estimated HIV prevalence among White persons aged ≥ 13 years, by assigned sex at birth and selected characteristics, 2017–2021—United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2021c
Male 
    Age (yr)
    13–24 4,500 6.3 4,000 5,100 32.8 28.7 36.8 2,616 57.7i 6.4 51.4 65.9
    25–34 35,500 1.9 34,200 36,800 283.7 273.3 294.1 24,900 70.2 1.9 67.7 72.9
    35–44 46,500 1.3 45,300 47,700 375.0 365.3 384.7 38,273 82.3 1.3 80.2 84.5
    45–54 63,300 0.9 62,200 64,500 513.0 503.7 522.4 58,032 91.6 0.9 90.0 93.3
    ≥ 55 146,600 0.7 144,600 148,600 435.2 429.3 441.1 141,132 96.3 0.7 95.0 97.6
    Transmission categoryd
Male-to-male sexual contacte 240,800 0.7 237,300 244,300 — — — 217,223 90.2 0.7 88.9 91.6
Injection drug usef 16,400 3.6 15,300 17,600 — — — 13,440 81.7 3.6 76.4 87.8
Male-to-male sexual contacte and injection drug usef 25,900 2.3 24,700 27,100 — — — 23,373 90.3 2.3 86.4 94.5
Heterosexual contactg 12,200 3.7 11,400 13,100 — — — 9,915 81.0 3.7 75.5 87.3
Subtotalh 296,400 0.7 292,400 300,400 349.8 345.0 354.5 264,953 89.4 0.7 88.2 90.6
Female 
    Age (yr)
    13–24 920 13.7 670 1,200 7.0 5.1 8.9 521 56.5 14.8 44.5 77.2
    25–34 5,500 4.6 5,000 6,000 45.7 41.6 49.8 3,820 69.0 4.6 63.4 75.8
    35–44 9,200 2.9 8,700 9,700 76.1 71.7 80.4 7,546 82.2 2.9 77.7 87.1
    45–54 11,500 2.2 11,000 12,000 95.1 90.9 99.2 10,424 90.7 2.2 86.9 94.8
    ≥ 55 18,500 1.9 17,800 19,200 49.4 47.6 51.2 17,607 95.2 1.9 91.8 98.8
    Transmission categoryd
    Injection drug usef 14,700 3.1 13,800 15,600 — — — 12,783 86.7 3.1 81.7 92.4
    Heterosexual contactg 30,500 1.9 29,300 31,700 — — — 26,736 87.7 1.9 84.5 91.2
Subtotalh 45,600 1.7 44,200 47,100 52.5 50.8 54.3 39,918 87.5 1.7 84.7 90.4
Totalh 342,000 0.6 337,800 346,300 199.3 196.8 201.8 304,871 89.1 0.6 88.0 90.3

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect model uncertainty.

a Rates are per 100,000 population.
b Reported to the National HIV Surveillance System.
c Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
i Indicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 12. Estimated HIV prevalence among males (based on sex assigned at birth) with HIV attributed to male-to-male sexual contact, by race/ethnicity and age, 2017–2021— United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI No.a % RSE (%) 95% CI
2017
Black/African American
    Age (yr)
    13–24 27,000 1.5 26,200 27,900 11,751 43.4 1.5 42.2 44.8
    25–34 64,400 0.9 63,300 65,500 49,334 76.6 0.9 75.3 77.9
    35–44 37,500 1.0 36,800 38,200 33,136 88.4 1.0 86.7 90.1
    45–54 41,300 1.0 40,500 42,100 38,941 94.3 1.0 92.5 96.1
    ≥ 55 34,600 1.3 33,700 35,600 33,421 96.5 1.3 94.0 99.1
Subtotal 204,900 0.7 202,100 207,700 166,582 81.3 0.7 80.2 82.4
Hispanic/Latinob
    Age (yr)
    13–24 14,700 2.3 14,100 15,400 5,410 36.7 2.3 35.2 38.4
    25–34 42,600 1.2 41,700 43,600 28,774 67.5 1.2 66.0 69.1
    35–44 39,500 1.0 38,700 40,300 32,996 83.6 1.0 81.9 85.3
    45–54 42,300 0.9 41,600 43,100 38,895 91.9 0.9 90.3 93.6
    ≥ 55 28,200 1.3 27,400 28,900 26,836 95.3 1.3 92.8 97.8
Subtotal 167,300 0.7 164,900 169,800 132,912 79.4 0.7 78.3 80.6
White
    Age (yr)
    13–24 6,900 3.3 6,500 7,400 2,847 41.1 3.3 38.7 44.0
    25–34 28,500 1.4 27,700 29,300 20,026 70.4 1.4 68.4 72.4
    35–44 34,400 1.1 33,600 35,100 29,247 85.1 1.1 83.3 87.0
    45–54 71,400 0.7 70,400 72,400 66,498 93.1 0.7 91.8 94.5
    ≥ 55 92,100 0.8 90,600 93,600 88,812 96.4 0.8 94.8 98.0
Subtotal 233,300 0.7 230,100 236,500 207,430 88.9 0.7 87.7 90.2
Allc
    Age (yr)
    13–24 52,300 1.1 51,200 53,500 21,699 41.5 1.1 40.5 42.4
    25–34 147,800 0.6 146,000 149,500 107,492 72.7 0.6 71.9 73.6
    35–44 121,900 0.6 120,500 123,300 104,570 85.8 0.6 84.8 86.8
    45–54 167,800 0.5 166,300 169,400 156,310 93.1 0.5 92.3 94.0
    ≥ 55 165,200 0.6 163,300 167,200 158,993 96.2 0.6 95.1 97.4
Totalc 655,100 0.4 650,000 660,200 549,064 83.8 0.4 83.2 84.5
Table 12. Estimated HIV prevalence among males (based on sex assigned at birth) with HIV attributed to male-to-male sexual contact, by race/ethnicity and age, 2017–2021— United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI No.a % RSE (%) 95% CI
2018
Black/African American
    Age (yr)
    13–24 24,900 1.8 24,000 25,700 11,293 45.4 1.8 43.9 47.1
    25–34 68,700 0.9 67,500 70,000 52,274 76.1 0.9 74.7 77.4
    35–44 39,900 1.0 39,100 40,700 35,300 88.4 1.0 86.6 90.2
    45–54 40,100 1.0 39,300 40,900 37,850 94.3 1.0 92.5 96.2
    ≥ 55 38,400 1.3 37,500 39,400 37,085 96.5 1.3 94.1 98.9
Subtotal 212,100 0.7 209,200 215,000 173,802 81.9 0.7 80.8 83.1
Hispanic/Latinob
    Age (yr)
    13–24 13,600 2.6 12,900 14,300 5,350 39.3 2.6 37.4 41.4
    25–34 45,100 1.2 44,000 46,200 30,446 67.5 1.2 65.9 69.2
    35–44 41,200 1.1 40,300 42,100 34,366 83.4 1.1 81.7 85.2
    45–54 42,700 0.9 41,900 43,500 39,256 91.8 1.0 90.2 93.6
    ≥ 55 31,700 1.3 30,900 32,500 30,263 95.4 1.3 93.1 97.8
Subtotal 174,400 0.7 171,800 177,000 139,681 80.1 0.7 78.9 81.3
White
    Age (yr)
    13–24 6,100 3.8 5,600 6,500 2,745 45.1 3.9 41.9 48.7
    25–34 29,100 1.5 28,200 29,900 20,562 70.7 1.5 68.7 72.9
    35–44 34,500 1.2 33,700 35,300 29,242 84.7 1.2 82.8 86.7
    45–54 65,900 0.8 64,900 66,900 61,263 93.0 0.8 91.6 94.5
    ≥ 55 100,300 0.8 98,800 101,900 96,784 96.4 0.8 95.0 98.0
Subtotal 235,900 0.7 232,600 239,200 210,596 89.3 0.7 88.1 90.5
Allc
    Age (yr)
    13–24 47,700 1.3 46,500 48,900 20,921 43.9 1.3 42.7 45.0
    25–34 155,600 0.6 153,700 157,500 112,957 72.6 0.6 71.7 73.5
    35–44 126,500 0.6 125,000 127,900 108,371 85.7 0.6 84.7 86.7
    45–54 161,300 0.5 159,700 162,800 150,081 93.1 0.5 92.2 94.0
    ≥ 55 181,900 0.6 179,900 184,000 175,144 96.3 0.6 95.2 97.4
Totalc 673,000 0.4 667,700 678,200 567,472 84.3 0.4 83.7 85.0
Table 12. Estimated HIV prevalence among males (based on sex assigned at birth) with HIV attributed to male-to-male sexual contact, by race/ethnicity and age, 2017–2021— United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI No.a % RSE (%) 95% CI
2019
Black/African American
    Age (yr)
    13–24 22,800 2.1 21,900 23,700 11,116 48.8 2.1 46.9 50.9
    25–34 72,100 1.0 70,700 73,500 54,447 75.5 1.0 74.1 77.0
    35–44 43,000 1.0 42,100 43,900 37,874 88.1 1.0 86.3 89.9
    45–54 38,900 1.0 38,100 39,700 36,608 94.2 1.0 92.3 96.2
    ≥ 55 42,200 1.2 41,200 43,300 40,798 96.6 1.2 94.3 99.0
Subtotal 219,000 0.7 216,000 222,000 180,843 82.6 0.7 81.5 83.7
Hispanic/Latinob
    Age (yr)
    13–24 12,400 3.1 11,600 13,100 5,383 43.5 3.1 41.0 46.4
    25–34 47,200 1.3 45,900 48,400 31,947 67.7 1.3 66.0 69.6
    35–44 43,300 1.2 42,300 44,300 36,042 83.2 1.2 81.4 85.1
    45–54 42,500 1.0 41,700 43,400 39,015 91.7 1.0 89.9 93.5
    ≥ 55 35,800 1.2 35,000 36,700 34,211 95.4 1.2 93.2 97.7
Subtotal 181,300 0.8 178,500 184,000 146,598 80.9 0.8 79.7 82.1
White
    Age (yr)
    13–24 5,400 4.5 4,900 5,800 2,630 49.0 4.6 45.0 53.7
    25–34 29,200 1.6 28,300 30,200 20,770 71.1 1.7 68.9 73.5
    35–44 35,100 1.2 34,300 36,000 29,579 84.2 1.2 82.2 86.3
    45–54 60,100 0.8 59,100 61,100 55,735 92.8 0.8 91.3 94.3
    ≥ 55 108,300 0.8 106,700 109,900 104,508 96.5 0.8 95.1 98.0
Subtotal 238,100 0.7 234,800 241,400 213,222 89.6 0.7 88.3 90.8
Allc
    Age (yr)
    13–24 43,300 1.6 41,900 44,600 20,546 47.5 1.6 46.1 49.0
    25–34 161,300 0.7 159,200 163,500 116,994 72.5 0.7 71.6 73.5
    35–44 132,600 0.6 131,000 134,300 113,255 85.4 0.6 84.3 86.5
    45–54 153,700 0.5 152,200 155,300 142,799 92.9 0.5 91.9 93.8
    ≥ 55 198,900 0.6 196,800 201,100 191,621 96.3 0.6 95.3 97.4
Totalc 689,900 0.4 684,500 695,300 585,215 84.8 0.4 84.2 85.5
Table 12. Estimated HIV prevalence among males (based on sex assigned at birth) with HIV attributed to male-to-male sexual contact, by race/ethnicity and age, 2017–2021— United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI No.a % RSE (%) 95% CI
2020 (COVID-19 Pandemic)b
Black/African American
    Age (yr)
    13–24 20,400 2.6 19,400 21,400 10,540 51.6 2.6 49.2 54.4
    25–34 74,100 1.1 72,600 75,700 55,524 74.9 1.1 73.4 76.5
    35–44 46,500 1.1 45,500 47,500 40,740 87.6 1.1 85.8 89.5
    45–54 37,400 1.1 36,600 38,300 35,270 94.2 1.1 92.2 96.3
    ≥ 55 45,800 1.2 44,700 46,800 44,207 96.6 1.2 94.4 98.9
Subtotal 224,200 0.7 221,000 227,400 186,280 83.1 0.7 81.9 84.3
Hispanic/Latinob
    Age (yr)
    13–24 10,700 3.9 9,900 11,500 5,003 46.8 3.9 43.4 50.6
    25–34 48,100 1.5 46,700 49,500 32,537 67.7 1.5 65.8 69.7
    35–44 45,700 1.2 44,600 46,900 37,767 82.6 1.2 80.6 84.6
    45–54 42,000 1.1 41,100 42,900 38,418 91.4 1.1 89.5 93.4
    ≥ 55 39,700 1.2 38,800 40,600 37,986 95.6 1.2 93.5 97.8
Subtotal 186,300 0.8 183,400 189,200 151,711 81.4 0.8 80.2 82.7
White
    Age (yr)
    13–24 4,600 5.6 4,100 5,100 2,415 52.5 5.7 47.3 59.0
    25–34 28,800 1.8 27,800 29,900 20,534 71.2 1.8 68.8 73.9
    35–44 35,700 1.3 34,800 36,700 30,072 84.1 1.3 82.0 86.4
    45–54 55,100 0.9 54,100 56,000 50,923 92.5 0.9 90.9 94.2
    ≥ 55 115,000 0.8 113,300 116,700 110,972 96.5 0.8 95.1 97.9
Subtotal 239,200 0.7 235,800 242,700 214,917 89.8 0.7 88.6 91.1
Allc
    Age (yr)
    13–24 38,000 1.9 36,600 39,500 19,201 50.5 1.9 48.6 52.5
    25–34 163,700 0.8 161,300 166,100 118,326 72.3 0.8 71.2 73.4
    35–44 139,700 0.7 137,800 141,500 118,723 85.0 0.7 83.9 86.1
    45–54 146,400 0.6 144,700 148,000 135,672 92.7 0.6 91.7 93.7
    ≥ 55 214,100 0.5 211,900 216,400 206,315 96.3 0.5 95.3 97.4
Totalc 701,900 0.4 696,200 707,600 598,237 85.2 0.4 84.5 85.9
Table 12. Estimated HIV prevalence among males (based on sex assigned at birth) with HIV attributed to male-to-male sexual contact, by race/ethnicity and age, 2017–2021— United States
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI No.a % RSE (%) 95% CI
2021b
Black/African American
    Age (yr)
    13–24 18,600 3.1 17,500 19,700 10,522 56.6d 3.1 53.3 60.2
    25–34 74,900 1.2 73,200 76,600 56,005 74.8 1.2 73.1 76.5
    35–44 51,000 1.1 49,800 52,100 44,414 87.1 1.1 85.2 89.1
    45–54 36,300 1.2 35,400 37,100 34,075 93.9 1.2 91.8 96.2
    ≥ 55 49,400 1.2 48,200 50,500 47,610 96.5 1.2 94.3 98.8
Subtotal 230,100 0.8 226,700 233,500 192,625 83.7d 0.8 82.5 85.0
Hispanic/Latinob
    Age (yr)
    13–24 9,500 4.7 8,700 10,400 5,072 53.2d 4.7 48.7 58.5
    25–34 49,300 1.7 47,700 50,900 33,736 68.4 1.7 66.2 70.7
    35–44 48,600 1.3 47,300 49,900 40,024 82.4 1.3 80.3 84.6
    45–54 42,000 1.2 41,100 43,000 38,343 91.2 1.2 89.2 93.3
    ≥ 55 43,800 1.1 42,900 44,800 41,861 95.5 1.1 93.4 97.7
Subtotal 193,400 0.8 190,200 196,500 159,035 82.2d 0.8 80.9 83.6
White
    Age (yr)
    13–24 4,000 6.7 3,400 4,500 2,304 58.2d 6.8 51.4 67.0
    25–34 28,500 2.0 27,400 29,700 20,531 71.9 2.0 69.2 74.9
    35–44 36,600 1.4 35,600 37,600 30,805 84.1 1.4 81.9 86.5
    45–54 50,900 1.0 49,900 51,900 47,012 92.3 1.0 90.5 94.2
    ≥ 55 120,700 0.7 119,000 122,500 116,570 96.5 0.7 95.2 98.0
Subtotal 240,800 0.7 237,300 244,300 217,223 90.2 0.7 88.9 91.6
Allc
    Age (yr)
    13–24 34,100 2.3 32,500 35,700 19,089 56.0d 2.3 53.5 58.7
    25–34 165,100 0.8 162,400 167,800 119,823 72.6 0.8 71.4 73.8
    35–44 148,500 0.7 146,400 150,500 125,834 84.8 0.7 83.6 86.0
    45–54 140,700 0.6 139,100 142,400 130,173 92.5 0.6 91.4 93.6
    ≥ 55 228,500 0.5 226,100 230,900 220,100 96.3 0.5 95.3 97.3
Totalc 716,900 0.4 710,900 722,900 615,019 85.8d 0.4 85.1 86.5

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.
Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

a Reported to the National HIV Surveillance System.
b Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
c Includes data for all race/ethnicities.
d Indicates that difference from 2017 estimate was deemed statistically significantly (P<.05).

Table 13. Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and Puerto Rico
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2017
Alabama 15,600 2.6 14,800 16,400 381.6 362.4 400.8 12,899 82.5 2.6 78.6 86.9
Alaska 820 10.8 710 1,000 136.2 116.7 165.0 705 85.7 8.7 70.7 100.0
Arizona 18,800 2.2 18,000 19,600 319.6 305.6 333.6 15,606 83.1 2.2 79.6 86.9
Arkansas 6,900 3.8 6,400 7,400 276.6 255.8 297.3 5,458 79.0 3.9 73.5 85.5
California 146,700 0.8 144,300 149,100 447.0 439.5 454.4 126,922 86.5 0.8 85.1 88.0
Colorado 13,800 2.6 13,100 14,500 293.1 278.3 307.8 11,969 86.7 2.6 82.5 91.3
Connecticut 11,200 3.1 10,500 11,900 365.8 343.4 388.1 10,138 90.5 3.1 85.3 96.4
Delaware 3,700 5.3 3,300 4,100 456.1 408.6 503.7 3,218 86.9 5.4 78.7 97.0
District of Columbia 15,100 2.7 14,300 15,900 2523.3 2391.2 2655.5 14,039 93.0 2.7 88.4 98.1
Florida 125,800 0.9 123,600 128,100 700.3 687.7 712.9 107,755 85.6 0.9 84.1 87.2
Georgia 63,600 1.2 62,100 65,100 736.6 719.3 754.0 52,255 82.2 1.2 80.3 84.2
Hawaii 2,700 6.4 2,400 3,000 224.0 198.1 252.1 2,376 88.5 6.2 78.6 100.0
Idaho 1,500 10.7 1,200 1,800 105.0 82.9 127.0 1,093 74.2 11.2 61.3 93.9
Illinois 39,800 1.6 38,600 41,100 371.4 359.5 383.3 34,336 86.2 1.6 83.5 89.1
Indiana 13,000 2.7 12,300 13,700 235.0 222.4 247.6 10,859 83.4 2.7 79.1 88.1
Iowa 3,100 5.1 2,800 3,400 119.2 107.2 131.2 2,634 84.4 5.2 76.7 93.9
Kansas 3,600 5.3 3,200 4,000 150.2 134.4 165.9 2,972 82.5 5.4 74.7 92.2
Kentucky 8,400 3.3 7,900 9,000 226.1 211.6 240.6 6,903 81.8 3.3 76.9 87.4
Louisiana 24,100 2.1 23,100 25,100 622.0 596.0 648.1 20,019 83.2 2.1 79.8 86.8
Maine 1,800 7.5 1,500 2,000 153.4 132.6 176.0 1,537 86.5 7.3 75.4 100.0
Maryland 36,100 1.7 34,900 37,300 712.8 689.0 736.6 32,102 89.0 1.7 86.1 92.0
Massachusetts 22,000 2.1 21,100 22,900 372.7 357.4 387.9 19,945 90.7 2.1 87.2 94.6
Michigan 18,300 2.5 17,400 19,200 216.6 206.2 227.0 15,449 84.5 2.5 80.6 88.8
Minnesota 9,300 3.0 8,800 9,900 201.7 189.7 213.7 8,140 87.1 3.1 82.2 92.7
Mississippic 11,000 3.1 10,300 11,700 444.3 416.9 471.6 9,089 82.5 3.2 77.7 87.9
Missouri 14,000 2.7 13,300 14,700 273.6 259.3 287.9 12,140 86.7 2.7 82.4 91.5
Montana 680 10.2 600 820 76.5 68.0 91.9 604 88.9 7.4 74.1 100.0
Nebraska 2,500 6.0 2,200 2,800 158.5 139.8 177.2 2,085 83.7 6.1 74.9 95.0
Nevada 11,600 2.8 10,900 12,200 466.7 441.2 492.1 9,397 81.2 2.8 77.0 85.9
New Hampshire 1,300 8.7 1,200 1,500 111.8 98.8 130.8 1,156 88.3 7.1 75.5 100.0
New Jerseyd 38,300 1.9 36,900 39,800 511.5 492.6 530.5 33,765 88.1 1.9 84.9 91.4
New Mexico 3,900 4.6 3,600 4,300 224.0 203.7 244.3 3,382 86.6 4.7 79.4 95.2
New York 133,000 0.9 130,600 135,300 799.2 784.9 813.4 122,472 92.1 0.9 90.5 93.8
North Carolina 35,600 1.6 34,500 36,700 412.1 399.0 425.1 30,380 85.4 1.6 82.8 88.2
North Dakota 630 13.7 460 800 100.7 73.5 127.8 404 64.3 14.8 50.7 88.1
Ohio 25,700 1.9 24,700 26,700 261.9 252.0 271.8 21,502 83.7 1.9 80.6 87.0
Oklahoma 7,300 3.8 6,800 7,900 225.8 209.1 242.4 5,930 81.1 3.8 75.5 87.6
Oregon 7,700 3.3 7,200 8,200 218.7 204.3 233.1 6,808 88.4 3.4 83.0 94.6
Pennsylvaniad 38,700 1.6 37,500 39,900 354.9 343.4 366.3 34,533 89.2 1.6 86.5 92.2
Puerto Ricod 17,500 3.0 16,500 18,500 606.3 570.9 641.8 15,628 89.3 3.0 84.4 94.9
Rhode Island 2,800 5.8 2,500 3,100 304.7 274.2 339.3 2,498 90.0 5.4 80.8 100.0
South Carolina 19,600 2.3 18,700 20,500 462.5 441.6 483.5 16,214 82.8 2.3 79.2 86.7
South Dakota 740 12.0 570 910 103.0 79.1 127.3 565 76.8 12.6 62.1 100.0
Tennessee 19,600 2.3 18,700 20,400 347.1 331.7 362.4 16,564 84.7 2.3 81.1 88.6
Texas 106,300 1.0 104,300 108,300 462.7 454.0 471.4 87,340 82.2 1.0 80.6 83.7
Utah 3,300 5.4 3,000 3,700 136.7 122.3 151.2 2,725 82.0 5.5 74.2 91.7
Vermont 730 10.0 670 880 135.1 122.9 161.8 668 91.0 6.7 76.0 100.0
Virginia 25,700 2.0 24,700 26,700 361.1 346.8 375.4 21,991 85.5 2.0 82.2 89.0
Washington 14,900 2.5 14,200 15,600 239.4 227.7 251.2 12,980 87.1 2.5 83.0 91.6
West Virginiac 2,200 6.8 1,900 2,500 143.5 124.4 162.6 1,781 79.8 6.9 70.4 92.0
Wisconsin 7,100 3.7 6,600 7,600 144.9 134.5 155.3 6,043 85.4 3.7 79.7 92.1
Wyoming 370 15.1 320 480 77.2 67.0 100.1 322 86.8 9.7 67.0 100.0
Table 13. Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and Puerto Rico
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2018
Alabama 16,000 2.6 15,200 16,800 390.0 370.3 409.8 13,331 83.2 2.6 79.1 87.6
Alaska 810 11.2 690 990 135.4 115.4 165.2 694 85.2 9.0 69.8 100.0
Arizona 19,500 2.2 18,600 20,300 325.1 310.8 339.4 16,246 83.4 2.3 79.9 87.2
Arkansas 7,000 3.9 6,500 7,600 280.7 259.1 302.3 5,614 79.8 4.0 74.1 86.4
California 149,300 0.9 146,800 151,800 452.7 445.1 460.3 129,640 86.8 0.9 85.4 88.3
Colorado 14,300 2.6 13,500 15,000 297.4 282.5 312.3 12,422 87.1 2.6 82.9 91.7
Connecticut 11,300 3.1 10,600 12,000 368.2 345.5 390.9 10,281 91.1 3.2 85.8 97.0
Delaware 3,700 5.4 3,300 4,100 453.3 405.2 501.5 3,240 87.1 5.5 78.7 97.4
District of Columbia 14,900 2.7 14,100 15,700 2473.5 2340.8 2606.3 13,917 93.2 2.7 88.5 98.5
Florida 127,700 0.9 125,400 130,000 700.7 687.9 713.4 109,843 86.0 0.9 84.5 87.6
Georgia 65,600 1.2 64,000 67,200 751.1 733.2 769.0 54,270 82.7 1.2 80.8 84.7
Hawaii 2,600 6.7 2,300 3,000 218.4 194.0 247.2 2,324 88.8 6.2 78.5 100.0
Idaho 1,500 11.2 1,200 1,900 107.0 83.5 130.4 1,143 74.4 11.8 61.1 95.4
Illinois 40,500 1.6 39,200 41,900 379.1 366.8 391.3 35,131 86.6 1.7 83.9 89.5
Indiana 13,400 2.8 12,700 14,100 240.4 227.4 253.5 11,209 83.6 2.8 79.3 88.4
Iowa 3,200 5.2 2,900 3,600 123.4 110.9 135.9 2,744 84.7 5.2 76.9 94.3
Kansas 3,600 5.5 3,200 4,000 151.2 134.9 167.5 3,043 83.7 5.6 75.6 93.8
Kentucky 8,700 3.3 8,200 9,300 233.8 218.7 249.0 7,154 81.8 3.3 76.8 87.4
Louisiana 24,500 2.2 23,500 25,600 634.6 607.7 661.5 20,491 83.5 2.2 80.1 87.2
Maine 1,800 7.6 1,600 2,100 156.3 136.1 179.6 1,585 87.0 7.1 75.7 100.0
Maryland 36,400 1.7 35,200 37,700 717.5 693.3 741.7 32,609 89.5 1.7 86.6 92.6
Massachusetts 22,200 2.1 21,300 23,100 375.2 359.7 390.7 20,248 91.1 2.1 87.5 95.0
Michigan 18,500 2.5 17,600 19,400 218.9 208.2 229.6 15,762 85.1 2.5 81.1 89.5
Minnesota 9,600 3.0 9,100 10,200 206.4 194.0 218.7 8,416 87.3 3.1 82.4 92.9
Mississippic 11,200 3.2 10,400 11,900 450.3 421.8 478.8 9,259 83.0 3.2 78.1 88.6
Missouri 14,300 2.7 13,600 15,100 279.3 264.6 293.9 12,445 86.7 2.7 82.4 91.5
Montana 700 10.2 630 840 77.7 70.1 93.3 628 90.2 7.1 75.1 100.0
Nebraska 2,500 6.1 2,200 2,800 158.9 139.8 178.1 2,128 84.7 6.2 75.6 96.4
Nevada 12,200 2.8 11,600 12,900 483.1 456.8 509.4 9,975 81.5 2.8 77.3 86.2
New Hampshire 1,400 8.5 1,200 1,600 116.7 104.0 136.1 1,224 89.1 6.8 76.4 100.0
New Jerseyd 38,400 1.9 36,900 39,800 511.3 492.0 530.6 33,888 88.3 1.9 85.1 91.8
New Mexico 4,100 4.5 3,800 4,500 236.2 215.2 257.1 3,579 86.6 4.6 79.5 95.0
New York 133,200 0.9 130,800 135,600 802.1 787.6 816.6 123,159 92.4 0.9 90.8 94.1
North Carolina 36,600 1.6 35,400 37,700 418.0 404.7 431.2 31,306 85.6 1.6 83.0 88.4
North Dakota 680 13.9 500 870 108.9 79.2 138.6 442 64.8 15.0 50.9 89.2
Ohio 26,200 2.0 25,200 27,200 266.2 256.0 276.4 22,066 84.3 2.0 81.2 87.6
Oklahoma 7,500 3.8 7,000 8,100 231.6 214.3 248.8 6,091 80.9 3.8 75.3 87.4
Oregon 7,800 3.4 7,300 8,300 219.7 205.2 234.3 6,983 89.3 3.4 83.7 95.6
Pennsylvaniad 39,300 1.7 38,100 40,600 360.0 348.3 371.7 35,164 89.4 1.7 86.6 92.4
Puerto Ricod 17,300 3.1 16,200 18,300 617.4 580.4 654.4 15,483 89.7 3.1 84.6 95.4
Rhode Island 2,800 5.8 2,500 3,100 307.7 278.8 342.8 2,549 90.6 5.3 81.3 100.0
South Carolina 20,000 2.3 19,100 20,900 466.2 444.8 487.6 16,683 83.3 2.3 79.6 87.3
South Dakota 770 12.3 600 960 107.3 83.3 133.1 600 77.7 12.3 62.6 100.0
Tennessee 20,200 2.2 19,300 21,000 353.9 338.3 369.6 17,166 85.2 2.3 81.6 89.1
Texas 109,800 1.0 107,800 111,900 471.3 462.3 480.2 90,838 82.7 1.0 81.2 84.3
Utah 3,500 5.3 3,200 3,900 142.0 127.2 156.8 2,910 82.5 5.4 74.7 92.1
Vermont 740 10.1 690 890 136.5 126.1 163.5 686 92.4 6.3 77.2 100.0
Virginia 26,300 2.0 25,200 27,300 366.8 352.1 381.4 22,597 86.0 2.0 82.7 89.5
Washington 15,400 2.5 14,600 16,100 242.9 231.0 254.9 13,381 87.1 2.5 83.1 91.7
West Virginiac 2,400 6.8 2,100 2,700 156.4 135.6 177.3 1,885 77.9 6.9 68.8 89.9
Wisconsin 7,200 3.7 6,700 7,700 147.1 136.4 157.8 6,179 85.7 3.7 79.9 92.4
Wyoming 390 14.7 340 510 81.8 71.2 105.4 343 87.1 9.5 67.6 100.0
Table 13. Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and Puerto Rico
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2019
Alabama 16,300 2.6 15,500 17,200 395.5 375.1 415.8 13,721 84.0 2.6 79.9 88.6
Alaska 840 11.3 710 1,000 139.9 118.4 171.0 711 84.6 9.3 69.2 100.0
Arizona 20,200 2.3 19,300 21,100 330.3 315.5 345.0 16,969 83.9 2.3 80.3 87.9
Arkansas 7,300 4.0 6,700 7,900 289.0 266.2 311.8 5,815 79.9 4.1 74.1 86.7
California 151,700 0.9 149,100 154,200 458.6 450.8 466.4 132,153 87.1 0.9 85.7 88.6
Colorado 14,600 2.6 13,900 15,400 300.6 285.3 315.9 12,790 87.5 2.6 83.2 92.2
Connecticut 11,400 3.2 10,600 12,100 370.6 347.5 393.7 10,392 91.5 3.2 86.2 97.6
Delaware 3,800 5.5 3,400 4,200 456.8 407.9 505.8 3,326 87.7 5.5 79.2 98.2
District of Columbia 14,800 2.8 14,000 15,700 2446.9 2313.0 2580.9 13,882 93.5 2.8 88.7 99.0
Florida 129,700 0.9 127,300 132,100 702.6 689.6 715.6 112,068 86.4 0.9 84.8 88.0
Georgia 67,500 1.2 65,900 69,100 762.6 744.1 781.2 56,154 83.2 1.2 81.2 85.3
Hawaii 2,600 6.9 2,300 3,000 219.3 196.0 248.9 2,339 89.4 6.1 78.8 100.0
Idaho 1,600 11.5 1,300 2,000 111.4 86.2 136.6 1,215 74.1 12.2 60.5 95.8
Illinois 40,500 1.7 39,200 41,900 379.9 367.2 392.6 35,248 86.9 1.7 84.1 89.9
Indiana 13,600 2.8 12,900 14,400 243.2 229.7 256.7 11,430 83.8 2.8 79.3 88.7
Iowa 3,400 5.3 3,000 3,700 127.8 114.6 140.9 2,832 84.0 5.3 76.2 93.7
Kansas 3,800 5.6 3,300 4,200 155.7 138.7 172.8 3,104 82.7 5.7 74.6 92.9
Kentucky 9,100 3.3 8,500 9,700 242.5 226.6 258.4 7,456 81.9 3.4 76.9 87.7
Louisiana 25,000 2.2 23,900 26,100 645.7 617.8 673.6 20,964 83.9 2.2 80.5 87.7
Maine 1,800 7.8 1,600 2,100 156.7 138.2 180.6 1,619 88.2 6.8 76.5 100.0
Maryland 36,400 1.8 35,200 37,700 715.2 690.6 739.9 32,785 90.0 1.8 87.0 93.2
Massachusetts 22,400 2.1 21,500 23,400 377.5 361.7 393.3 20,526 91.5 2.1 87.8 95.5
Michigan 19,100 2.5 18,100 20,000 225.0 214.0 236.1 16,367 85.9 2.5 81.9 90.3
Minnesota 9,900 3.1 9,300 10,500 210.4 197.7 223.0 8,679 87.7 3.1 82.7 93.3
Mississippic 11,400 3.3 10,700 12,200 460.6 430.7 490.5 9,528 83.4 3.3 78.3 89.2
Missouri 14,500 2.7 13,800 15,300 282.0 267.0 297.0 12,667 87.1 2.7 82.7 92.0
Montana 710 10.3 650 860 78.8 72.0 94.7 652 91.4 6.7 76.0 100.0
Nebraska 2,600 6.3 2,200 2,900 161.3 141.4 181.1 2,184 85.2 6.4 75.9 97.2
Nevada 12,900 2.8 12,200 13,600 497.0 469.5 524.5 10,538 81.8 2.8 77.6 86.6
New Hampshire 1,400 8.4 1,300 1,700 119.9 107.7 139.7 1,275 89.8 6.5 77.1 100.0
New Jerseyd 38,700 2.0 37,200 40,200 515.0 495.2 534.7 34,282 88.6 2.0 85.4 92.2
New Mexico 4,300 4.5 3,900 4,700 244.0 222.2 265.7 3,754 87.4 4.6 80.2 95.9
New York 132,800 0.9 130,400 135,200 802.1 787.4 816.8 123,173 92.7 0.9 91.1 94.5
North Carolina 37,900 1.6 36,700 39,100 427.3 413.7 440.9 32,577 86.0 1.6 83.4 88.9
North Dakota 740 14.3 530 950 117.7 84.7 150.8 486 65.6 15.5 51.3 91.3
Ohio 26,900 2.0 25,800 27,900 272.7 262.1 283.2 22,874 85.1 2.0 81.9 88.5
Oklahoma 7,800 3.9 7,300 8,400 239.9 221.8 258.0 6,321 80.5 3.9 74.9 87.1
Oregon 8,000 3.4 7,500 8,600 222.8 207.9 237.7 7,183 89.6 3.4 84.0 96.0
Pennsylvaniad 39,800 1.7 38,500 41,100 363.9 351.9 375.8 35,721 89.8 1.7 87.0 92.9
Puerto Ricod 17,300 3.1 16,200 18,300 614.0 576.6 651.3 15,556 90.1 3.1 85.0 96.0
Rhode Island 2,900 5.8 2,600 3,200 313.1 285.4 349.0 2,611 91.2 5.1 81.8 100.0
South Carolina 20,500 2.4 19,600 21,500 470.7 448.7 492.7 17,236 84.0 2.4 80.2 88.1
South Dakota 800 12.5 640 1,000 110.3 87.4 137.4 636 79.2 11.7 63.6 100.0
Tennessee 20,700 2.3 19,700 21,600 359.6 343.5 375.6 17,641 85.3 2.3 81.7 89.3
Texas 113,300 1.0 111,100 115,500 478.8 469.6 488.0 94,185 83.1 1.0 81.6 84.8
Utah 3,700 5.4 3,300 4,100 145.1 129.8 160.3 3,055 83.0 5.4 75.1 92.8
Vermont 750 10.2 690 900 137.8 127.5 165.4 694 92.5 6.3 77.1 100.0
Virginia 26,900 2.1 25,800 28,000 372.9 357.9 388.0 23,253 86.4 2.1 83.1 90.0
Washington 15,800 2.5 15,000 16,600 246.5 234.2 258.8 13,788 87.3 2.6 83.1 91.9
West Virginiac 2,600 7.2 2,300 3,000 170.7 146.6 194.7 1,990 75.7 7.3 66.4 88.2
Wisconsin 7,400 3.7 6,900 8,000 150.5 139.5 161.6 6,376 86.0 3.8 80.1 92.8
Wyoming 390 15.5 340 510 80.1 70.2 104.5 340 87.6 9.6 67.2 100.0
Table 13. Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and Puerto Rico
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2020 (COVID-19 Pandemic)c
Alabama 16,600 2.7 15,700 17,500 392.3 371.5 413.0 13,992 84.4 2.7 80.1 89.1
Alaska 850 11.7 720 1,000 141.4 120.1 173.8 721 84.9 9.3 69.1 100.0
Arizona 20,700 2.4 19,800 21,700 343.1 327.1 359.0 17,472 84.3 2.4 80.6 88.4
Arkansas 7,500 4.2 6,800 8,100 296.5 271.8 321.2 5,948 79.8 4.3 73.7 87.1
California 152,800 0.9 150,200 155,500 460.7 452.6 468.8 133,497 87.3 0.9 85.8 88.9
Colorado 14,900 2.7 14,100 15,600 303.4 287.5 319.3 13,031 87.7 2.7 83.3 92.5
Connecticut 11,300 3.3 10,600 12,100 366.3 342.8 389.8 10,391 91.7 3.3 86.2 98.0
Delaware 3,900 5.6 3,400 4,300 457.9 407.5 508.3 3,381 87.5 5.7 78.8 98.3
District of Columbia 14,500 2.9 13,700 15,400 2462.0 2322.2 2601.7 13,655 94.0 2.9 88.9 99.6
Florida 130,900 1.0 128,400 133,400 705.9 692.4 719.4 113,398 86.7 1.0 85.0 88.3
Georgia 68,600 1.3 66,800 70,300 766.3 746.7 785.8 57,318 83.6 1.3 81.5 85.8
Hawaii 2,600 7.1 2,400 3,000 215.6 192.1 245.5 2,351 89.1 6.2 78.2 100.0
Idaho 1,700 12.2 1,300 2,100 109.2 83.2 135.3 1,244 74.7 12.9 60.3 98.1
Illinois 40,600 1.8 39,200 42,000 376.6 363.5 389.6 35,390 87.2 1.8 84.3 90.3
Indiana 14,000 3.0 13,200 14,800 247.3 232.9 261.6 11,692 83.6 3.0 79.0 88.7
Iowa 3,400 5.5 3,000 3,800 128.4 114.4 142.3 2,887 84.4 5.6 76.1 94.7
Kansas 3,900 5.6 3,500 4,400 161.7 143.8 179.6 3,264 83.0 5.7 74.7 93.3
Kentucky 9,400 3.5 8,800 10,100 249.2 232.2 266.1 7,761 82.4 3.5 77.2 88.4
Louisiana 25,200 2.3 24,000 26,300 650.7 621.4 680.1 21,131 84.0 2.3 80.4 87.9
Maine 1,800 8.0 1,600 2,100 155.1 137.1 179.6 1,626 88.4 6.8 76.3 100.0
Maryland 36,400 1.8 35,200 37,700 701.9 677.2 726.7 32,922 90.3 1.8 87.2 93.6
Massachusetts 22,500 2.2 21,600 23,500 372.2 356.3 388.0 20,671 91.8 2.2 88.0 95.8
Michigan 19,300 2.6 18,400 20,300 226.5 215.1 238.0 16,642 86.0 2.6 81.9 90.6
Minnesota 10,000 3.1 9,400 10,700 211.0 198.0 224.0 8,858 88.1 3.2 83.0 93.9
Mississippic 11,500 3.5 10,700 12,300 466.4 434.4 498.3 9,554 83.1 3.5 77.7 89.2
Missouri 14,600 2.8 13,800 15,400 282.4 266.7 298.0 12,755 87.4 2.8 82.8 92.5
Montana 740 10.2 680 890 80.3 73.9 96.4 680 92.0 6.5 76.7 100.0
Nebraska 2,700 6.4 2,400 3,000 167.1 146.2 188.0 2,287 84.8 6.5 75.4 97.0
Nevada 13,300 3.0 12,600 14,100 510.4 480.6 540.1 10,889 81.6 3.0 77.1 86.6
New Hampshire 1,400 8.6 1,300 1,700 119.4 107.9 139.4 1,295 90.4 6.4 77.4 100.0
New Jerseyd 38,700 2.0 37,200 40,200 493.6 474.0 513.2 34,376 88.9 2.0 85.5 92.5
New Mexico 4,400 4.6 4,000 4,800 248.1 225.5 270.7 3,867 87.5 4.7 80.2 96.3
New York 131,600 1.0 129,100 134,100 767.8 753.3 782.3 122,311 92.9 1.0 91.2 94.7
North Carolina 38,300 1.7 37,000 39,500 433.3 419.0 447.5 33,118 86.5 1.7 83.8 89.5
North Dakota 760 15.0 540 980 118.6 83.8 153.5 515 67.7 16.4 52.4 95.9
Ohio 27,300 2.0 26,200 28,300 274.4 263.5 285.3 23,327 85.6 2.0 82.3 89.1
Oklahoma 8,100 4.0 7,400 8,700 246.7 227.3 266.1 6,550 81.0 4.0 75.1 87.9
Oregon 8,100 3.5 7,500 8,700 223.7 208.3 239.2 7,269 89.6 3.5 83.8 96.3
Pennsylvaniad 39,900 1.7 38,500 41,200 359.4 347.2 371.6 35,860 90.0 1.7 87.0 93.1
Puerto Ricod 17,100 3.2 16,000 18,200 588.2 551.4 624.9 15,496 90.6 3.2 85.3 96.7
Rhode Island 2,900 6.0 2,600 3,200 303.3 276.1 338.9 2,617 91.0 5.2 81.5 100.0
South Carolina 20,900 2.5 19,800 21,900 480.0 456.9 503.2 17,568 84.3 2.5 80.4 88.5
South Dakota 860 12.9 680 1,100 118.5 93.2 148.5 679 78.7 12.1 62.8 100.0
Tennessee 21,100 2.3 20,100 22,100 362.1 345.6 378.6 18,158 86.0 2.3 82.3 90.2
Texas 115,900 1.0 113,600 118,200 485.1 475.4 494.7 96,755 83.5 1.0 81.9 85.2
Utah 3,900 5.4 3,400 4,300 147.8 132.0 163.6 3,232 83.8 5.5 75.7 93.8
Vermont 750 10.4 700 900 134.0 124.3 161.4 697 92.8 6.3 77.0 100.0
Virginia 27,200 2.1 26,000 28,300 373.0 357.5 388.5 23,563 86.7 2.1 83.3 90.5
Washington 16,100 2.6 15,300 16,900 247.9 235.2 260.6 14,110 87.5 2.6 83.3 92.3
West Virginiac 2,800 7.6 2,400 3,200 181.3 154.2 208.4 2,099 75.4 7.8 65.6 88.7
Wisconsin 7,600 3.9 7,000 8,200 152.9 141.3 164.5 6,534 85.7 3.9 79.6 92.7
Wyoming 390 16.2 350 520 81.4 72.1 107.3 348 88.5 9.5 67.2 100.0
Table 13. Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and Puerto Rico
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2021c
Alabama 17,000 2.8 16,100 17,900 399.6 377.7 421.5 14,313 84.3 2.8 79.9 89.2
Alaska 860 12.1 740 1,100 142.3 123.3 176.1 743 86.7 8.8 70.0 100.0
Arizona 21,400 2.5 20,300 22,400 347.1 330.3 363.9 18,056 84.6 2.5 80.7 88.9
Arkansas 7,800 4.4 7,100 8,400 306.2 279.7 332.7 6,178 79.7 4.5 73.3 87.3
California 154,300 0.9 151,500 157,100 466.4 457.9 474.8 135,306 87.7 0.9 86.1 89.3
Colorado 15,300 2.8 14,400 16,100 308.7 291.9 325.4 13,328 87.3 2.8 82.9 92.3
Connecticut 11,400 3.3 10,600 12,100 366.0 342.1 389.9 10,466 92.0 3.3 86.4 98.5
Delaware 3,900 5.8 3,500 4,400 461.0 408.7 513.2 3,471 87.9 5.9 78.9 99.1
District of Columbia 14,300 3.0 13,500 15,200 2505.5 2361.2 2652.0 13,504 94.2 3.0 89.0 100.0
Florida 133,000 1.0 130,400 135,600 708.9 695.0 722.8 115,906 87.1 1.0 85.4 88.9
Georgia 70,100 1.4 68,200 72,000 775.1 754.4 795.7 58,899 84.0 1.4 81.8 86.3
Hawaii 2,700 7.3 2,400 3,000 218.3 194.4 249.4 2,369 89.1 6.3 78.0 100.0
Idaho 1,700 12.9 1,300 2,100 107.8 81.6 135.2 1,285 75.7 13.4 60.4 100.0
Illinois 40,500 1.8 39,000 42,000 377.8 364.2 391.5 35,388 87.4 1.8 84.3 90.7
Indiana 14,500 3.0 13,700 15,400 255.5 240.4 270.6 12,208 84.0 3.0 79.3 89.2
Iowa 3,500 5.7 3,200 3,900 132.6 117.8 147.5 3,009 84.8 5.8 76.2 95.5
Kansas 4,100 5.7 3,700 4,600 168.6 149.7 187.5 3,446 83.8 5.8 75.3 94.4
Kentucky 9,800 3.6 9,100 10,400 257.1 238.8 275.4 8,066 82.7 3.7 77.2 89.1
Louisiana 25,300 2.4 24,200 26,500 657.3 626.5 688.2 21,376 84.4 2.4 80.6 88.5
Maine 1,900 8.2 1,700 2,200 156.6 139.3 181.8 1,670 89.0 6.7 76.6 100.0
Maryland 36,400 1.8 35,000 37,700 699.0 673.6 724.3 32,944 90.6 1.9 87.4 94.0
Massachusetts 22,600 2.2 21,600 23,600 374.6 358.3 390.8 20,793 92.0 2.2 88.1 96.1
Michigan 19,800 2.6 18,800 20,800 231.8 219.9 243.7 17,115 86.4 2.6 82.2 91.1
Minnesota 10,200 3.2 9,600 10,900 214.4 200.8 228.0 9,086 88.7 3.2 83.4 94.7
Mississippic 11,700 3.7 10,900 12,600 475.5 441.3 509.8 9,764 83.2 3.7 77.6 89.6
Missouri 14,800 2.9 14,000 15,700 285.7 269.6 301.9 12,999 87.6 2.9 82.9 92.9
Montana 780 10.1 720 930 83.0 76.3 99.5 717 91.9 6.5 76.7 100.0
Nebraska 2,800 6.7 2,400 3,100 170.7 148.4 193.0 2,348 84.8 6.8 75.0 97.6
Nevada 13,800 3.1 13,000 14,700 521.5 489.6 553.3 11,336 82.0 3.1 77.3 87.3
New Hampshire 1,500 8.6 1,300 1,700 121.8 110.4 142.4 1,339 90.6 6.3 77.5 100.0
New Jerseyd 39,000 2.1 37,400 40,600 497.0 476.8 517.3 34,636 88.8 2.1 85.3 92.6
New Mexico 4,600 4.7 4,100 5,000 254.6 230.9 278.3 3,990 87.7 4.8 80.2 96.7
New York 131,100 1.0 128,500 133,600 775.3 760.3 790.3 122,136 93.2 1.0 91.4 95.0
North Carolina 38,900 1.7 37,600 40,200 435.3 420.7 450.0 33,947 87.2 1.7 84.4 90.3
North Dakota 800 16.0 550 1,100 125.3 85.9 164.6 533 66.5 17.8 50.6 97.0
Ohio 27,700 2.1 26,600 28,900 278.8 267.3 290.3 23,842 86.0 2.1 82.6 89.6
Oklahoma 8,400 4.1 7,700 9,100 254.5 233.9 275.2 6,878 81.7 4.2 75.6 88.9
Oregon 8,300 3.7 7,700 8,900 227.6 211.3 243.9 7,433 89.6 3.7 83.6 96.6
Pennsylvaniad 40,100 1.8 38,700 41,500 361.3 348.9 373.8 36,287 90.5 1.8 87.5 93.8
Puerto Ricod 17,100 3.2 16,000 18,200 587.9 550.5 625.3 15,579 91.1 3.3 85.7 97.3
Rhode Island 2,900 6.1 2,700 3,300 305.8 280.3 342.3 2,663 91.6 5.0 81.9 100.0
South Carolina 21,200 2.6 20,100 22,300 480.8 456.5 505.0 17,914 84.5 2.6 80.5 89.0
South Dakota 910 13.5 710 1,100 122.8 96.0 155.4 708 78.1 12.5 61.7 100.0
Tennessee 21,400 2.4 20,400 22,400 363.7 346.6 380.8 18,554 86.6 2.4 82.7 90.9
Texas 119,000 1.0 116,500 121,400 490.6 480.5 500.7 99,947 84.0 1.0 82.3 85.8
Utah 4,000 5.6 3,600 4,500 151.1 134.5 167.7 3,409 84.4 5.7 76.0 94.8
Vermont 760 10.4 710 920 135.1 126.4 162.8 714 93.5 6.1 77.6 100.0
Virginia 27,600 2.2 26,500 28,800 378.1 362.1 394.2 24,143 87.3 2.2 83.8 91.2
Washington 16,500 2.7 15,600 17,300 251.5 238.1 264.9 14,445 87.8 2.7 83.3 92.7
West Virginiac 2,900 8.3 2,400 3,300 186.3 156.1 216.6 2,172 76.1 8.5 65.4 90.8
Wisconsin 7,800 4.0 7,200 8,400 156.4 144.3 168.6 6,753 86.2 4.0 79.9 93.5
Wyoming 420 16.2 370 550 85.4 75.6 112.4 368 88.6 9.4 67.2 100.0

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect model uncertainty

a Reported to the National HIV Surveillance System.
b Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
c Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.
d Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.

Table A1. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Initiative Phase I jurisdictions
No. RSE (%) 95% CI Ratea 95% CI
2017
Arizona
      Maricopa County 570 15.7 390 740 15.9 11.0 20.7
California
      Alameda County 190 25.7 90 280 13.2 6.5 19.8
      Los Angeles County 1,500 9.0 1,200 1,800 17.8 14.6 20.9
      Orange County 290 20.5 170 410 10.9 6.5 15.3
      Riverside County 270 21.5 150 380 13.5 7.8 19.2
      Sacramento County 220 23.6 120 320 17.3 9.3 25.3
      San Bernardino County 270 21.1 160 390 15.7 9.2 22.3
      San Diego County 430 16.8 290 580 15.6 10.4 20.7
      San Francisco County 170 26.8 80 260 21.5 10.2 32.8
District of Columbia 230 24.8 120 340 38.6 19.8 57.4
Florida
      Broward County 650 13.4 480 820 39.5 29.1 49.9
      Duval County 270 20.8 160 380 34.4 20.4 48.5
      Hillsborough County 300 19.8 180 410 24.9 15.2 34.6
      Miami-Dade County 1,100 10.1 910 1,400 49.3 39.5 59.0
      Orange County 430 16.5 290 560 37.4 25.3 49.5
      Palm Beach County 260 21.2 150 360 20.2 11.8 28.6
      Pinellas County 160 26.6 80 250 19.1 9.1 29.1
Georgia
      Cobb County 190 26.1 90 280 29.8 14.5 45.1
      DeKalb County 360 18.8 230 490 58.0 36.6 79.4
      Fulton County 590 14.7 420 760 67.1 47.7 86.5
      Gwinnett County 160 27.9 70 250 21.9 9.9 33.9
Illinois
      Cook County 910 11.3 710 1,100 20.9 16.3 25.5
Indiana
      Marion County 220 22.2 130 320 28.8 16.3 41.4
Louisiana
      East Baton Rouge Parish 170 26.3 80 250 44.7 21.6 67.7
      Orleans Parish 150 27.9 70 230 44.1 19.9 68.2
Maryland
      Baltimore City 200 26.9 90 300 38.0 17.9 58.0
      Montgomery County 100 *37.8 30 170 11.2 2.9 19.6
      Prince George’s County 200 26.3 100 310 26.7 12.9 40.5
Massachusetts
      Suffolk County 120 26.0 60 180 17.2 8.4 25.9
Michigan
      Wayne County 280 20.1 170 390 18.9 11.5 26.4
Nevada
      Clark County 480 16.3 330 630 26.5 18.0 34.9
New Jersey
      Essex Countyc 310 21.4 180 440 46.9 27.2 66.7
      Hudson Countyc 160 29.7 70 250 27.9 11.7 44.2
New York
      Bronx County 400 17.2 270 540 34.3 22.7 45.8
      Kings County 470 15.8 330 620 22.1 15.2 28.9
      New York County 350 18.4 220 470 23.9 15.3 32.5
      Queens County 330 18.7 210 460 17.0 10.8 23.3
North Carolina
      Mecklenburg County 290 18.7 180 390 32.1 20.3 43.9
Ohio
      Cuyahoga County 130 *30.4 50 210 12.2 4.9 19.4
      Franklin County 190 25.0 100 280 17.8 9.1 26.5
      Hamilton County 150 27.9 70 230 22.3 10.1 34.5
Pennsylvania
      Philadelphia County 390 16.1 270 520 29.7 20.3 39.1
Puerto Rico
      San Juan Municipioc 100 *35.2 30 170 33.4 10.4 56.5
Tennessee
      Shelby County 240 20.0 150 340 31.9 19.3 44.4
Texas
      Bexar County 300 20.2 180 420 19.1 11.5 26.6
      Dallas County 830 12.3 630 1,000 39.3 29.8 48.7
      Harris County 1,100 10.4 910 1,400 30.6 24.3 36.8
      Tarrant County 300 20.6 180 420 17.8 10.6 25.0
      Travis County 210 24.7 110 310 20.2 10.4 29.9
Washington
      King County 210 25.8 100 310 11.1 5.5 16.7
Table A1. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Initiative Phase I jurisdictions
No. RSE (%) 95% CI Ratea 95% CI
2018
Arizona
      Maricopa County 550 18.5 350 750 15.0 9.5 20.4
California
      Alameda County 190 28.5 80 300 13.5 5.9 21.0
      Los Angeles County 1,500 10.3 1,200 1,800 17.4 13.9 20.9
      Orange County 280 23.6 150 410 10.3 5.5 15.1
      Riverside County 290 23.4 150 420 14.3 7.7 20.8
      Sacramento County 220 26.8 100 330 17.0 8.0 25.9
      San Bernardino County 260 24.5 140 390 14.9 7.8 22.1
      San Diego County 420 19.1 270 580 15.1 9.5 20.8
      San Francisco County 160 *31.5 60 260 20.0 7.6 32.3
District of Columbia 230 26.7 110 350 38.2 18.2 58.3
Florida
      Broward County 530 17.1 350 700 31.9 21.2 42.6
      Duval County 240 25.0 120 370 31.0 15.8 46.2
      Hillsborough County 270 23.8 140 400 22.2 11.8 32.6
      Miami-Dade County 1,100 12.1 800 1,300 45.5 34.6 56.3
      Orange County 410 19.5 250 560 34.9 21.5 48.3
      Palm Beach County 260 24.5 130 380 19.9 10.3 29.5
      Pinellas County 140 *33.4 50 230 15.9 5.5 26.4
Georgia
      Cobb County 160 *33.0 60 260 25.2 8.9 41.5
      DeKalb County 390 20.9 230 560 63.0 37.1 88.9
      Fulton County 620 16.8 410 820 69.5 46.6 92.3
      Gwinnett County 150 *34.3 50 250 19.6 6.4 32.7
Illinois
      Cook County 890 13.1 660 1,100 20.3 15.1 25.6
Indiana
      Marion County 220 25.0 110 330 28.5 14.5 42.5
Louisiana
      East Baton Rouge Parish 180 28.5 80 280 47.8 21.1 74.6
      Orleans Parish 150 *30.6 60 240 45.6 18.2 72.9
Maryland
      Baltimore City 210 27.2 100 330 41.8 19.5 64.0
      Montgomery County 90 *41.1 20 170 10.8 2.1 19.5
      Prince George’s County 260 24.8 130 380 33.6 17.2 50.0
Massachusetts
      Suffolk County 120 27.5 60 190 17.4 8.0 26.8
Michigan
      Wayne County 270 23.8 140 390 18.2 9.7 26.7
Nevada
      Clark County 520 18.3 330 700 27.9 17.9 37.9
New Jersey
      Essex Countyc 220 29.9 90 340 32.7 13.5 51.8
      Hudson Countyc 150 *35.7 50 260 26.8 8.0 45.5
New York
      Bronx County 390 19.4 240 540 33.7 20.8 46.5
      Kings County 450 18.4 290 610 21.0 13.4 28.6
      New York County 310 22.1 170 440 21.2 12.0 30.4
      Queens County 320 21.5 190 460 16.7 9.7 23.8
North Carolina
      Mecklenburg County 240 23.6 130 350 26.3 14.1 38.6
Ohio
      Cuyahoga County 130 *33.7 40 220 12.5 4.2 20.8
      Franklin County 200 27.5 90 310 18.4 8.5 28.3
      Hamilton County 140 *32.9 50 230 20.6 7.3 33.9
Pennsylvania
      Philadelphia County 410 17.4 270 550 30.7 20.2 41.1
Puerto Rico
      San Juan Municipioc 70 *48.4 0 130 24.2 1.2 47.1
Tennessee
      Shelby County 250 21.9 140 360 33.2 18.9 47.4
Texas
      Bexar County 320 22.5 180 460 19.6 10.9 28.2
      Dallas County 820 14.1 600 1,100 38.7 28.0 49.3
      Harris County 1,100 12.0 860 1,400 29.8 22.8 36.8
      Tarrant County 280 23.8 150 420 16.9 9.0 24.7
      Travis County 240 26.0 120 360 22.6 11.1 34.2
Washington
      King County 260 25.0 130 390 13.9 7.1 20.7
Table A1. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Initiative Phase I jurisdictions
No. RSE (%) 95% CI Ratea 95% CI
2019
Arizona
      Maricopa County 510 22.2 290 730 13.6 7.7 19.5
California
      Alameda County 200 *31.9 80 330 14.1 5.3 22.9
      Los Angeles County 1,400 12.1 1,100 1,700 16.6 12.7 20.5
      Orange County 230 29.8 90 360 8.5 3.5 13.4
      Riverside County 260 27.8 120 410 13.0 5.9 20.1
      Sacramento County 210 *31.4 80 330 16.0 6.1 25.9
      San Bernardino County 310 25.5 160 470 17.7 8.9 26.6
      San Diego County 420 22.1 240 600 14.8 8.4 21.3
      San Francisco County 120 *41.7 20 210 14.8 2.7 26.8
District of Columbia 190 *33.5 70 320 32.0 11.0 53.0
Florida
      Broward County 540 19.0 340 750 32.8 20.5 45.0
      Duval County 220 *30.1 90 350 27.4 11.2 43.7
      Hillsborough County 240 28.7 100 370 19.3 8.4 30.1
      Miami-Dade County 980 14.2 700 1,200 42.2 30.4 53.9
      Orange County 450 20.9 270 640 38.7 22.8 54.6
      Palm Beach County 240 28.7 100 370 18.5 8.1 28.9
      Pinellas County 150 *36.6 40 250 17.0 4.8 29.3
Georgia
      Cobb County 190 *34.7 60 320 30.1 9.6 50.6
      DeKalb County 320 26.7 150 490 51.4 24.4 78.3
      Fulton County 530 21.0 310 750 58.7 34.5 82.9
      Gwinnett County 190 *34.4 60 330 25.4 8.3 42.6
Illinois
      Cook County 810 15.9 560 1,100 18.6 12.8 24.4
Indiana
      Marion County 230 28.5 100 360 29.3 12.9 45.8
Louisiana
      East Baton Rouge Parish 160 *34.2 50 280 44.7 14.7 74.7
      Orleans Parish 130 *38.4 30 230 39.0 9.6 68.3
Maryland
      Baltimore City 130 *40.4 30 240 26.2 5.4 47.0
      Montgomery County 100 *47.6 10 180 10.9 0.7 21.1
      Prince George’s County 230 *30.3 90 370 30.7 12.4 49.0
Massachusetts
      Suffolk County 120 *31.1 50 190 16.7 6.5 26.9
Michigan
      Wayne County 280 25.8 140 420 19.2 9.5 28.9
Nevada
      Clark County 490 22.4 270 700 25.6 14.3 36.9
New Jersey
      Essex Countyc 200 *35.9 60 330 29.5 8.7 50.3
      Hudson Countyc 110 *48.0 10 210 19.1 1.1 37.1
New York
      Bronx County 370 23.1 200 540 32.0 17.5 46.5
      Kings County 400 22.2 230 580 18.9 10.7 27.2
      New York County 270 26.8 130 420 18.8 8.9 28.7
      Queens County 250 28.2 110 390 13.0 5.8 20.2
North Carolina
      Mecklenburg County 290 23.2 160 420 31.5 17.2 45.9
Ohio
      Cuyahoga County 130 *38.9 30 230 12.3 2.9 21.7
      Franklin County 210 *30.7 80 330 18.9 7.5 30.2
      Hamilton County 130 *39.3 30 220 18.3 4.2 32.5
Pennsylvania
      Philadelphia County 410 19.4 250 560 30.7 19.0 42.5
Puerto Rico
      San Juan Municipioc 80 *47.1 10 150 27.0 2.0 52.0
Tennessee
      Shelby County 280 23.3 150 400 36.1 19.6 52.6
Texas
      Bexar County 370 23.9 200 540 22.6 12.0 33.1
      Dallas County 650 17.9 420 880 30.6 19.8 41.4
      Harris County 1,200 13.5 850 1,500 30.4 22.3 38.4
      Tarrant County 380 23.5 210 560 22.2 12.0 32.5
      Travis County 180 *34.4 60 300 16.5 5.4 27.7
Washington
      King County 220 *33.2 80 360 11.4 4.0 18.8
Table A1. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Initiative Phase I jurisdictions
No. RSE (%) 95% CI Ratea 95% CI
2020 (COVID-19 Pandemic)b
Arizona
      Maricopa County 470 28.9 200 740 12.8 5.5 20.0
California
      Alameda County 150 *42.5 30 280 10.6 1.8 19.4
      Los Angeles County 1,400 14.2 980 1,700 16.0 11.5 20.4
      Orange County 280 *31.5 110 450 10.3 3.9 16.6
      Riverside County 280 *31.3 110 450 13.9 5.4 22.5
      Sacramento County 180 *39.2 40 320 13.6 3.1 24.1
      San Bernardino County 310 29.8 130 490 17.5 7.2 27.7
      San Diego County 370 27.2 170 570 13.3 6.2 20.4
      San Francisco County 120 *47.0 10 240 15.9 1.2 30.5
District of Columbia 140 *47.9 10 280 24.3 1.5 47.1
Florida
      Broward County 510 23.7 270 740 30.8 16.4 45.1
      Duval County 280 *32.0 100 450 33.5 12.4 54.6
      Hillsborough County 290 *31.3 110 470 23.7 9.1 38.2
      Miami-Dade County 850 18.3 550 1,200 37.0 23.7 50.3
      Orange County 440 25.5 220 670 36.9 18.4 55.3
      Palm Beach County 300 *30.8 120 480 23.3 9.2 37.4
      Pinellas County 160 *42.3 30 290 18.7 3.2 34.2
Georgia
      Cobb County 170 *45.1 20 330 26.9 3.1 50.7
      DeKalb County 290 *34.5 100 490 46.4 14.9 77.9
      Fulton County 590 24.5 300 870 64.3 33.4 95.3
      Gwinnett County … … … … … … …
Illinois
      Cook County 830 18.8 520 1,100 18.6 11.7 25.4
Indiana
      Marion County 240 *33.4 80 400 29.9 10.3 49.6
Louisiana
      East Baton Rouge Parish 120 *49.2 0 240 32.0 1.1 63.0
      Orleans Parish 110 … 0 220 33.2 0.0 67.1
Maryland
      Baltimore City 180 *40.4 40 310 35.4 7.3 63.5
      Montgomery County … … … … … … …
      Prince George’s County 170 *41.6 30 300 20.5 3.8 37.2
Massachusetts
      Suffolk County 120 *33.9 40 200 17.3 5.8 28.8
Michigan
      Wayne County 270 *31.1 110 440 18.4 7.2 29.6
Nevada
      Clark County 530 25.7 260 800 28.1 13.9 42.2
New Jersey
      Essex Countyc 230 *38.6 60 400 32.2 7.8 56.6
      Hudson Countyc 140 *48.7 10 280 23.6 1.1 46.1
New York
      Bronx County 390 26.0 190 580 32.2 15.8 48.5
      Kings County 380 26.2 180 570 16.7 8.1 25.3
      New York County 300 29.4 130 470 19.9 8.4 31.4
      Queens County 290 *30.0 120 460 14.0 5.8 22.3
North Carolina
      Mecklenburg County 250 *31.2 100 400 26.3 10.2 42.5
Ohio
      Cuyahoga County 160 *38.6 40 290 15.3 3.7 26.9
      Franklin County 180 *37.1 50 310 16.3 4.4 28.1
      Hamilton County 120 *44.7 10 230 17.7 2.2 33.2
Pennsylvania
      Philadelphia County 280 *30.7 110 440 20.5 8.1 32.8
Puerto Rico
      San Juan Municipioc … … … … … … …
Tennessee
      Shelby County 210 *32.6 80 350 27.9 10.0 45.8
Texas
      Bexar County 380 28.5 170 600 23.1 10.2 36.1
      Dallas County 730 20.5 440 1,000 34.5 20.6 48.4
      Harris County 1,100 16.9 730 1,400 28.3 18.9 37.7
      Tarrant County 360 29.2 150 570 20.9 8.9 32.9
      Travis County 170 *42.7 30 310 15.4 2.5 28.3
Washington
      King County 210 *39.6 50 370 10.7 2.4 19.0
Table A1. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Initiative Phase I jurisdictions
No. RSE (%) 95% CI Ratea 95% CI
2021b
Arizona
      Maricopa County 460 *31.9 170 750 12.2 4.6 19.8
California
      Alameda County 170 *45.5 20 320 11.9 1.3 22.6
      Los Angeles County 1,200 17.1 790 1,600 14.2 9.5 19.0
      Orange County 230 *38.7 60 410 8.7 2.1 15.3
      Riverside County 240 *37.9 60 430 12.0 3.1 20.9
      Sacramento County … … … … … … …
      San Bernardino County 280 *35.5 80 470 15.5 4.7 26.3
      San Diego County 410 29.3 170 640 14.6 6.2 23.1
      San Francisco County 140 *49.9 0 280 19.3 0.4 38.1
District of Columbia 150 *46.8 10 300 26.9 2.2 51.7
Florida
      Broward County 500 26.2 240 760 30.3 14.7 45.9
      Duval County 230 *38.9 50 400 27.1 6.4 47.8
      Hillsborough County 180 *44.2 20 330 14.1 1.9 26.4
      Miami-Dade County 870 19.8 530 1,200 38.2 23.3 53.1
      Orange County 460 27.4 210 700 37.9 17.5 58.3
      Palm Beach County 230 *38.3 60 410 18.0 4.5 31.6
      Pinellas County … … … … … … …
Georgia
      Cobb County … … … … … … …
      DeKalb County 320 *37.1 90 550 50.4 13.7 87.0
      Fulton County 530 28.7 230 830 58.5 25.5 91.4
      Gwinnett County … … … … … … …
Illinois
      Cook County 780 21.4 450 1,100 17.8 10.3 25.3
Indiana
      Marion County 210 *39.7 50 370 26.1 5.7 46.4
Louisiana
      East Baton Rouge Parish … … … … … … …
      Orleans Parish … … … … … … …
Maryland
      Baltimore City 150 *48.0 10 280 29.7 1.7 57.6
      Montgomery County … … … … … … …
      Prince George’s County 200 *41.1 40 360 24.7 4.8 44.7
Massachusetts
      Suffolk County 120 *38.7 30 210 17.8 4.3 31.3
Michigan
      Wayne County 220 *39.7 50 390 14.9 3.3 26.6
Nevada
      Clark County 460 *32.2 170 740 23.6 8.7 38.6
New Jersey
      Essex Countyc 270 *34.3 90 450 37.8 12.4 63.3
      Hudson Countyc 130 *49.0 0 260 21.9 0.8 43.0
New York
      Bronx County 380 29.1 160 600 32.4 13.9 50.9
      Kings County 360 *30.0 150 570 16.3 6.7 25.8
      New York County 260 *35.1 80 440 18.6 5.8 31.4
      Queens County 270 *34.7 80 450 13.4 4.3 22.5
North Carolina
      Mecklenburg County 190 *37.9 50 330 20.3 5.2 35.3
Ohio
      Cuyahoga County 160 *46.8 10 300 14.8 1.2 28.3
      Franklin County 150 *47.3 10 300 14.1 1.0 27.2
      Hamilton County … … … … … … …
Pennsylvania
      Philadelphia County 290 *31.3 110 470 21.8 8.4 35.3
Puerto Rico
      San Juan Municipioc … … … … … … …
Tennessee
      Shelby County 220 *33.6 80 370 29.3 10.0 48.7
Texas
      Bexar County 310 *35.2 90 520 18.4 5.7 31.1
      Dallas County 750 22.5 420 1,100 35.4 19.7 51.0
      Harris County 1,000 19.0 660 1,400 27.2 17.1 37.4
      Tarrant County 320 *34.6 100 530 18.2 5.8 30.5
      Travis County 190 *45.1 20 350 16.8 1.9 31.6
Washington
      King County 200 *46.3 20 390 10.5 1.0 20.1

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk (*), should be used with caution.
Estimates with an RSE > 50% are not shown and are replaced with an ellipsis (…).

a Rates are per 100,000 population.
b Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of diagnoses reported during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
c Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table A2. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase 1 Jurisdictions
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2017
Arizona
      Maricopa County 13,000 2.7 12,300—13,600 362.1 342.7—381.5 10,672 82.4 2.7 78.2—87.0
California
      Alameda County 6,700 4.0 6,200—7,200 475.6 438.5—512.8 5,813 86.8 4.0 80.5—94.2
      Los Angeles County 54,300 1.4 52,800—55,800 639.7 622.2—657.2 47,840 88.1 1.4 85.7—90.5
      Orange County 8,100 3.6 7,600—8,700 304.7 283.0—326.3 6,719 82.5 3.6 77.0—88.8
      Riverside County 9,600 2.6 9,100—10,100 483.8 459.1—508.6 8,455 88.4 2.6 84.1—93.2
      Sacramento County 5,000 4.3 4,500—5,400 392.7 359.5—425.8 4,173 84.1 4.3 77.5—91.8
      San Bernardino County 5,300 4.3 4,800—5,700 304.1 278.4—329.8 4,092 77.4 4.3 71.3—84.5
      San Diego County 14,900 2.6 14,100—15,600 533.4 506.4—560.4 12,848 86.4 2.6 82.2—91.0
      San Francisco County 12,800 3.4 12,300—13,700 1,629.7 1,558.5—1,738.4 12,279 95.6 2.8 89.7—100.0
District of Columbia 15,100 2.7 14,300—15,900 2,523.3 2,391.2—2,655.5 14,039 93.0 2.7 88.4—98.1
Florida
      Broward County 21,400 2.1 20,600—22,300 1,307.5 1,253.2—1,361.8 19,045 88.8 2.1 85.3—92.7
      Duval County 7,100 3.9 6,500—7,600 905.6 836.6—974.6 5,834 82.4 3.9 76.6—89.2
      Hillsborough County 7,900 3.6 7,300—8,500 661.1 613.9—708.4 6,628 83.8 3.7 78.2—90.2
      Miami-Dade County 29,500 2.0 28,400—30,700 1,280.5 1,230.0—1,330.9 25,649 86.8 2.0 83.5—90.4
      Orange County 10,100 3.2 9,500—10,700 885.3 830.0—940.6 8,298 82.3 3.2 77.5—87.8
      Palm Beach County 8,900 3.6 8,300—9,600 702.9 653.4—752.4 7,724 86.6 3.6 80.9—93.1
      Pinellas County 5,200 4.3 4,800—5,700 610.7 559.6—661.8 4,488 85.8 4.3 79.2—93.7
Georgia
      Cobb County 3,700 4.6 3,400—4,000 592.2 538.3—646.0 2,994 80.9 4.7 74.1—89.0
      DeKalb County 9,600 3.1 9,000—10,200 1,551.6 1,456.1—1,647.1 8,108 84.1 3.2 79.3—89.7
      Fulton County 16,800 2.4 16,000—17,600 1,917.6 1,828.0—2,007.2 14,230 84.9 2.4 81.1—89.0
      Gwinnett County 3,400 4.5 3,100—3,700 460.3 419.8—500.8 2,716 79.4 4.5 73.0—87.1
Illinois
      Cook County 28,300 2.0 27,200—29,400 648.1 622.8—673.5 24,537 86.6 2.0 83.3—90.1
Indiana
      Marion County 5,300 4.2 4,900—5,700 680.9 624.7—737.0 4,475 84.6 4.2 78.1—92.2
Louisiana
      East Baton Rouge Parish 4,500 4.8 4,000—4,900 1,204.2 1,090.8—1,317.6 3,788 84.9 4.8 77.6—93.7
      Orleans Parish 5,300 5.1 4,800—5,900 1,601.6 1,442.5—1,760.7 4,729 88.5 5.1 80.5—98.3
Maryland
      Baltimore City 11,800 3.3 11,000—12,500 2,281.1 2,132.0—2,430.3 10,855 92.2 3.3 86.5—98.6
      Montgomery County 4,200 4.7 3,900—4,600 487.5 442.2—532.8 3,770 88.8 4.8 81.2—97.9
      Prince George’s County 8,800 3.3 8,200—9,400 1,158.4 1,084.4—1,232.4 7,579 86.0 3.3 80.9—91.9
Massachusetts
      Suffolk County 6,100 4.2 5,700—6,600 868.3 808.0—939.0 5,671 93.1 3.8 86.0—100.0
Michigan
      Wayne County 7,500 4.1 6,900—8,100 513.6 471.9—555.3 6,357 84.8 4.2 78.4—92.3
Nevada
      Clark County 9,800 3.0 9,200—10,400 540.9 509.1—572.6 7,935 80.9 3.0 76.4—86.0
New Jersey
      Essex Countyd 9,900 3.9 9,100—10,600 1,500.5 1,386.3—1,614.7 8,879 89.7 3.9 83.4—97.1
      Hudson Countyd 5,400 5.1 4,900—6,000 959.1 863.0—1,055.3 4,752 87.2 5.2 79.3—97.0
New York
      Bronx County 28,300 1.8 27,300—29,300 2,406.9 2,323.7—2,490.1 26,493 93.6 1.8 90.5—96.9
      Kings County 27,700 2.0 26,600—28,800 1,288.8 1,238.1—1,339.5 25,567 92.4 2.0 88.9—96.2
      New York County 28,200 2.1 27,000—29,300 1,936.2 1,855.6—2,016.7 26,536 94.2 2.1 90.5—98.3
      Queens County 16,900 2.5 16,100—17,800 867.3 825.0—909.7 15,303 90.4 2.5 86.2—95.0
North Carolina
      Mecklenburg County 6,500 3.8 6,000—7,000 730.6 676.8—784.4 5,598 85.9 3.8 80.0—92.7
Ohio
      Cuyahoga County 5,300 4.2 4,900—5,700 498.8 457.6—540.0 4,557 86.0 4.2 79.5—93.8
      Franklin County 5,500 4.1 5,100—6,000 516.7 475.6—557.8 4,704 85.0 4.1 78.7—92.3
      Hamilton County 3,600 5.1 3,200—3,900 526.2 473.1—579.3 2,856 80.1 5.2 72.7—89.1
Pennsylvania
      Philadelphia County 18,300 2.4 17,400—19,100 1,380.3 1,316.2—1,444.3 16,746 91.7 2.4 87.6—96.1
Puerto Rico
      San Juan Municipiod,e 3,600 7.1 3,200—4,100 1,223.8 1,088.8—1,395.5 3,207 89.0 6.3 78.0—100.0
Tennessee
      Shelby County 7,100 3.8 6,500—7,600 925.5 855.7—995.3 6,031 85.2 3.9 79.2—92.2
Texas
      Bexar County 7,300 3.6 6,800—7,900 461.5 428.6—494.5 6,074 82.7 3.7 77.2—89.1
      Dallas County 20,800 2.2 19,900—21,700 984.9 943.1—1,026.8 17,319 83.2 2.2 79.8—86.9
      Harris County 29,700 1.9 28,600—30,700 792.8 763.5—822.0 24,623 83.0 1.9 80.1—86.2
      Tarrant County 6,600 3.7 6,100—7,100 397.6 368.5—426.6 5,405 81.7 3.7 76.1—88.2
      Travis County 5,600 4.2 5,200—6,100 547.2 502.1—592.3 4,693 83.4 4.2 77.1—90.9
Washington
      King County 7,700 3.7 7,200—8,300 413.4 383.2—443.6 6,745 87.1 3.7 81.2—93.9
Total 604,200 0.4 599,200—609,200 801.5 794.9—808.1 528,428 87.5 0.4 86.7—88.2
Table A2. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase 1 Jurisdictions
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2018
Arizona
      Maricopa County 13,400 2.8 12,700—14,100 366.7 346.9—386.5 11,101 82.8 2.8 78.6—87.6
California
      Alameda County 6,900 4.0 6,300—7,400 483.8 446.1—521.6 5,984 87.3 4.0 81.0—94.7
      Los Angeles County 54,900 1.4 53,400—56,400 646.7 628.8—664.6 48,646 88.6 1.4 86.2—91.1
      Orange County 8,200 3.7 7,600—8,800 307.4 285.3—329.6 6,824 82.8 3.7 77.3—89.3
      Riverside County 10,100 2.6 9,600—10,600 504.7 479.3—530.0 9,000 88.8 2.6 84.6—93.5
      Sacramento County 5,100 4.3 4,700—5,600 402.2 368.0—436.3 4,303 83.8 4.4 77.3—91.6
      San Bernardino County 5,600 4.2 5,200—6,100 320.1 293.5—346.6 4,422 78.7 4.3 72.7—85.8
      San Diego County 15,100 2.6 14,300—15,900 538.0 510.5—565.5 13,032 86.3 2.6 82.1—90.9
      San Francisco County 12,600 3.5 12,100—13,400 1,591.0 1,530.2—1,700.2 12,093 96.2 2.7 90.0—100.0
District of Columbia 14,900 2.7 14,100—15,700 2,473.5 2,340.8—2,606.3 13,917 93.2 2.7 88.5—98.5
Florida
      Broward County 21,700 2.1 20,800—22,600 1,312.8 1,257.6—1,367.9 19,334 89.2 2.1 85.6—93.1
      Duval County 7,200 3.9 6,700—7,800 915.5 845.4—985.5 6,018 83.1 3.9 77.2—90.0
      Hillsborough County 8,000 3.7 7,500—8,600 658.9 611.3—706.5 6,775 84.2 3.7 78.5—90.8
      Miami-Dade County 29,800 2.0 28,600—31,000 1,289.8 1,238.2—1,341.5 25,960 87.1 2.0 83.8—90.7
      Orange County 10,300 3.2 9,700—11,000 886.6 830.5—942.6 8,555 83.0 3.2 78.1—88.6
      Palm Beach County 9,000 3.7 8,300—9,600 699.0 649.0—749.1 7,779 86.8 3.7 81.0—93.5
      Pinellas County 5,200 4.4 4,800—5,700 606.9 554.9—658.9 4,524 86.5 4.4 79.7—94.7
Georgia
      Cobb County 3,900 4.7 3,500—4,200 613.9 557.8—669.9 3,162 81.7 4.7 74.8—89.9
      DeKalb County 10,000 3.1 9,400—10,600 1,602.4 1,503.7—1,701.1 8,455 84.4 3.2 79.5—89.9
      Fulton County 17,600 2.4 16,800—18,400 1,982.8 1,891.3—2,074.3 15,043 85.5 2.4 81.7—89.6
      Gwinnett County 3,500 4.6 3,200—3,900 470.9 428.6—513.2 2,843 80.2 4.6 73.6—88.1
Illinois
      Cook County 28,500 2.0 27,400—29,700 654.9 628.9—680.9 24,833 87.1 2.0 83.7—90.7
Indiana
      Marion County 5,400 4.2 5,000—5,900 693.7 636.1—751.2 4,605 84.7 4.3 78.2—92.3
Louisiana
      East Baton Rouge Parish 4,500 4.9 4,100—5,000 1,226.1 1,108.7—1,343.4 3,852 85.1 4.9 77.7—94.1
      Orleans Parish 5,400 5.1 4,900—5,900 1,621.3 1,459.7—1,782.9 4,822 89.1 5.1 81.1—99.0
Maryland
      Baltimore City 10,900 3.6 10,200—11,700 2,139.9 1,987.4—2,292.3 10,034 91.8 3.7 85.6—98.8
      Montgomery County 4,300 4.8 3,900—4,700 489.2 443.1—535.4 3,829 89.6 4.9 81.9—98.9
      Prince George’s County 9,000 3.3 8,400—9,600 1,184.9 1,109.0—1,260.8 7,839 86.9 3.3 81.7—92.9
Massachusetts
      Suffolk County 6,000 4.3 5,600—6,500 852.9 796.4—924.1 5,620 93.4 3.8 86.2—100.0
Michigan
      Wayne County 7,800 4.1 7,100—8,400 532.3 489.5—575.0 6,656 85.8 4.1 79.4—93.3
Nevada
      Clark County 10,400 3.0 9,800—11,000 560.4 527.6—593.1 8,448 81.3 3.0 76.8—86.3
New Jersey
      Essex Countyd 9,800 4.0 9,100—10,600 1,482.3 1,366.9—1,597.8 8,843 90.1 4.0 83.6—97.7
      Hudson Countyd 5,500 5.2 4,900—6,000 960.3 862.2—1,058.5 4,768 87.5 5.3 79.4—97.4
New York
      Bronx County 28,400 1.8 27,400—29,400 2,427.4 2,342.8—2,512.1 26,690 93.9 1.8 90.7—97.3
      Kings County 27,700 2.0 26,600—28,800 1,296.8 1,245.3—1,348.4 25,727 92.8 2.0 89.2—96.6
      New York County 28,100 2.1 26,900—29,300 1,930.0 1,848.9—2,011.1 26,527 94.4 2.1 90.6—98.6
      Queens County 17,100 2.5 16,200—17,900 881.3 837.9—924.6 15,528 91.0 2.5 86.8—95.7
North Carolina
      Mecklenburg County 6,700 3.7 6,200—7,200 740.0 685.5—794.5 5,800 86.3 3.8 80.4—93.1
Ohio
      Cuyahoga County 5,400 4.2 4,900—5,800 509.7 467.4—552.0 4,670 86.6 4.3 80.0—94.5
      Franklin County 5,600 4.1 5,100—6,000 517.1 475.0—559.1 4,758 85.1 4.2 78.7—92.6
      Hamilton County 3,600 5.3 3,200—3,900 523.6 468.7—578.5 2,889 81.2 5.4 73.5—90.7
Pennsylvania
      Philadelphia County 18,200 2.4 17,300—19,000 1,367.7 1,303.0—1,432.5 16,688 91.8 2.4 87.7—96.4
Puerto Rico
      San Juan Municipiod,e 3,600 7.2 3,200—4,100 1,274.0 1,146.2—1,454.2 3,248 90.0 6.0 78.8—100.0
Tennessee
      Shelby County 7,300 3.8 6,800—7,800 953.2 881.9—1,024.5 6,291 86.2 3.8 80.2—93.1
Texas
      Bexar County 7,500 3.7 7,000—8,100 465.5 431.7—499.2 6,253 83.2 3.7 77.6—89.7
      Dallas County 21,500 2.2 20,600—22,400 1,009.6 966.5—1,052.6 17,966 83.6 2.2 80.2—87.3
      Harris County 30,400 1.9 29,200—31,500 806.2 776.3—836.2 25,422 83.7 1.9 80.7—86.9
      Tarrant County 6,900 3.7 6,300—7,400 405.6 375.8—435.4 5,636 82.3 3.8 76.6—88.8
      Travis County 5,900 4.2 5,400—6,300 559.1 513.2—604.9 4,883 83.3 4.2 77.0—90.7
Washington
      King County 7,800 3.8 7,200—8,400 410.1 379.4—440.7 6,805 87.5 3.8 81.4—94.5
Total 612,300 0.4 607,200—617,400 807.3 800.5—814.0 537,700 87.8 0.4 87.1—88.6
Table A2. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase 1 Jurisdictions
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2019
Arizona
      Maricopa County 13,900 2.8 13,100 14,600 370.5 350.2 390.9 11,561 83.4 2.8 79.0 88.2
California
      Alameda County 6,900 4.1 6,300 7,400 484.6 445.9 523.3 6,038 87.6 4.1 81.1 95.2
      Los Angeles County 55,500 1.4 54,000 57,100 655.4 637.0 673.8 49,420 89.0 1.4 86.5 91.5
      Orange County 8,300 3.7 7,700 8,900 310.0 287.2 332.7 6,917 83.2 3.8 77.5 89.8
      Riverside County 10,500 2.6 10,000 11,000 516.4 490.3 542.5 9,367 89.3 2.6 85.0 94.0
      Sacramento County 5,300 4.4 4,800 5,700 409.8 374.5 445.1 4,412 83.5 4.4 76.9 91.3
      San Bernardino County 5,900 4.3 5,400 6,400 333.8 305.9 361.7 4,692 79.4 4.3 73.3 86.7
      San Diego County 15,300 2.7 14,500 16,100 542.9 514.6 571.1 13,176 86.3 2.7 82.1 91.1
      San Francisco County 12,400 3.6 12,000 13,200 1,564.4 1,515.3 1,674.3 11,972 96.9 2.5 90.5 100.0
District of Columbia 14,800 2.8 14,000 15,700 2,446.9 2,313.0 2,580.9 13,882 93.5 2.8 88.7 99.0
Florida
      Broward County 22,000 2.2 21,000 22,900 1,324.3 1,268.0 1,380.6 19,650 89.4 2.2 85.7 93.4
      Duval County 7,300 4.0 6,700 7,900 914.8 843.4 986.2 6,152 84.1 4.0 78.0 91.2
      Hillsborough County 8,200 3.7 7,600 8,800 664.1 615.9 712.3 6,989 84.8 3.7 79.1 91.4
      Miami-Dade County 29,900 2.1 28,700 31,200 1,293.3 1,240.3 1,346.3 26,186 87.4 2.1 84.0 91.2
      Orange County 10,500 3.3 9,800 11,200 895.4 837.6 953.3 8,759 83.3 3.3 78.2 89.0
      Palm Beach County 9,100 3.7 8,400 9,700 699.2 648.5 749.9 7,864 86.8 3.7 80.9 93.6
      Pinellas County 5,400 4.4 4,900 5,900 624.4 571.0 677.7 4,731 87.6 4.4 80.7 95.7
Georgia
      Cobb County 4,000 4.8 3,700 4,400 635.8 576.4 695.3 3,324 82.1 4.8 75.1 90.6
      DeKalb County 10,400 3.2 9,700 11,000 1,644.5 1,542.7 1,746.3 8,823 85.1 3.2 80.1 90.7
      Fulton County 18,100 2.4 17,300 19,000 2,007.1 1,913.8 2,100.5 15,572 85.9 2.4 82.1 90.1
      Gwinnett County 3,700 4.7 3,400 4,100 488.4 443.0 533.8 3,039 81.5 4.8 74.6 89.9
Illinois
      Cook County 29,100 2.0 27,900 30,200 669.5 642.7 696.3 25,486 87.6 2.0 84.3 91.3
Indiana
      Marion County 5,500 4.4 5,000 5,900 693.1 633.4 752.8 4,605 84.2 4.4 77.6 92.2
Louisiana
      East Baton Rouge Parish 4,600 5.0 4,100 5,000 1,241.4 1,119.6 1,363.2 3,886 85.0 5.1 77.4 94.3
      Orleans Parish 5,500 5.1 4,900 6,000 1,638.1 1,473.6 1,802.5 4,913 89.8 5.2 81.6 99.8
Maryland
      Baltimore City 10,900 3.7 10,100 11,700 2,151.4 1,995.6 2,307.3 10,025 92.3 3.7 86.0 99.5
      Montgomery County 4,300 4.9 3,900 4,700 487.7 440.9 534.8 3,868 90.4 5.0 82.4 100.0
      Prince George’s County 9,100 3.4 8,500 9,700 1,189.2 1,110.9 1,267.4 7,929 87.5 3.4 82.1 93.6
Massachusetts
      Suffolk County 6,000 4.3 5,600 6,500 847.3 793.1 919.0 5,624 93.6 3.7 86.3 100.0
Michigan
      Wayne County 8,000 4.1 7,300 8,600 547.8 503.8 591.9 6,868 86.3 4.1 79.9 93.8
Nevada
      Clark County 10,900 3.0 10,200 11,500 572.5 538.5 606.6 8,893 81.8 3.0 77.2 86.9
New Jersey
      Essex Countyd 9,800 4.0 9,000 10,600 1,475.2 1,357.9 1,592.4 8,853 90.4 4.1 83.8 98.2
      Hudson Countyd 5,500 5.3 4,900 6,000 957.5 857.9 1,057.1 4,808 88.2 5.4 79.9 98.4
New York
      Bronx County 28,700 1.8 27,700 29,700 2,472.7 2,386.0 2,559.4 27,121 94.4 1.8 91.2 97.8
      Kings County 27,700 2.1 26,600 28,800 1,301.3 1,248.7 1,353.9 25,730 93.0 2.1 89.4 96.9
      New York County 27,800 2.2 26,600 29,000 1,910.8 1,829.0 1,992.5 26,340 94.6 2.2 90.7 98.8
      Queens County 17,200 2.5 16,300 18,000 893.5 849.2 937.9 15,728 91.7 2.5 87.3 96.5
North Carolina
      Mecklenburg County 7,000 3.8 6,500 7,500 752.7 697.1 808.2 6,023 86.4 3.8 80.5 93.3
Ohio
      Cuyahoga County 5,400 4.3 5,000 5,900 516.6 473.0 560.2 4,752 87.3 4.3 80.5 95.3
      Franklin County 5,800 4.1 5,300 6,300 533.1 489.7 576.4 4,991 85.8 4.2 79.3 93.4
      Hamilton County 3,600 5.4 3,300 4,000 534.2 477.5 590.9 3,024 83.0 5.5 75.0 92.8
Pennsylvania
      Philadelphia County 18,300 2.4 17,400 19,200 1,376.5 1,310.5 1,442.4 16,848 92.1 2.4 87.9 96.7
Puerto Rico
      San Juan Municipiod,e 3,700 7.2 3,300 4,200 1,294.5 1,170.8 1,477.0 3,309 90.4 5.8 79.3 100.0
Tennessee
      Shelby County 7,400 3.9 6,800 7,900 959.8 886.4 1,033.1 6,332 86.0 3.9 79.9 93.2
Texas
      Bexar County 7,800 3.7 7,200 8,400 476.7 441.6 511.7 6,500 83.3 3.8 77.6 89.9
      Dallas County 21,900 2.2 21,000 22,900 1,024.7 980.5 1,069.0 18,499 84.4 2.2 80.9 88.2
      Harris County 31,200 1.9 30,100 32,400 821.5 790.7 852.4 26,367 84.4 1.9 81.3 87.7
      Tarrant County 7,200 3.8 6,600 7,700 418.5 387.3 449.8 5,882 82.1 3.8 76.4 88.7
      Travis County 6,000 4.2 5,500 6,500 558.0 511.8 604.1 5,024 83.7 4.3 77.3 91.2
Washington
      King County 7,900 3.9 7,300 8,500 412.5 381.2 443.8 6,969 88.0 3.9 81.8 95.2
Total 621,000 0.4 615,800 626,300 814.3 807.4 821.2 547,723 88.2 0.4 87.5 88.9
Table A2. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase 1 Jurisdictions
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2020 (COVID-19 Pandemic)c
Arizona
      Maricopa County 14,200 2.9 13,400 15,000 382.9 361.0 404.7 11,926 84.0 2.9 79.5 89.1
California
      Alameda County 6,800 4.3 6,200 7,400 473.5 433.9 513.0 5,965 87.9 4.3 81.1 95.9
      Los Angeles County 55,700 1.5 54,100 57,300 657.6 638.6 676.6 49,814 89.4 1.5 86.9 92.0
      Orange County 8,400 3.8 7,800 9,000 311.9 288.3 335.5 7,034 83.6 3.9 77.8 90.5
      Riverside County 10,800 2.6 10,300 11,400 542.0 514.0 569.9 9,709 89.5 2.6 85.1 94.4
      Sacramento County 5,400 4.5 4,900 5,900 409.7 373.6 445.8 4,534 83.8 4.5 77.0 91.9
      San Bernardino County 6,000 4.5 5,500 6,600 339.1 309.4 368.8 4,803 79.7 4.5 73.3 87.4
      San Diego County 15,400 2.7 14,600 16,200 552.3 522.8 581.7 13,299 86.4 2.7 82.1 91.3
      San Francisco County 12,100 3.7 11,800 13,000 1,551.0 1,507.4 1,663.2 11,781 97.2 2.5 90.6 100.0
District of Columbia 14,500 2.9 13,700 15,400 2,462.0 2,322.2 2,601.7 13,655 94.0 2.9 88.9 99.6
Florida
      Broward County 22,100 2.2 21,100 23,100 1,340.4 1,281.8 1,399.0 19,811 89.6 2.2 85.8 93.7
      Duval County 7,400 4.1 6,800 8,000 893.9 821.8 966.1 6,266 84.4 4.1 78.1 91.8
      Hillsborough County 8,400 3.8 7,800 9,000 683.8 632.9 734.6 7,176 85.2 3.8 79.3 92.1
      Miami-Dade County 30,000 2.2 28,700 31,200 1,303.0 1,247.8 1,358.1 26,269 87.6 2.2 84.1 91.5
      Orange County 10,600 3.4 9,900 11,400 882.4 823.0 941.9 8,892 83.5 3.5 78.2 89.5
      Palm Beach County 9,200 3.8 8,500 9,900 710.9 658.0 763.8 7,925 86.3 3.8 80.3 93.3
      Pinellas County 5,500 4.5 5,000 6,000 643.6 586.9 700.2 4,836 88.3 4.5 81.1 96.8
Georgia
      Cobb County 4,200 5.0 3,800 4,600 656.2 592.4 719.9 3,481 82.5 5.0 75.2 91.4
      DeKalb County 10,500 3.3 9,800 11,200 1,649.4 1,543.2 1,755.5 8,964 85.5 3.3 80.3 91.4
      Fulton County 18,500 2.5 17,600 19,400 2,034.9 1,936.9 2,132.8 15,937 86.1 2.5 82.2 90.5
      Gwinnett County 3,800 5.0 3,400 4,200 487.9 440.2 535.5 3,177 83.2 5.0 75.8 92.2
Illinois
      Cook County 29,200 2.1 28,000 30,400 656.2 629.1 683.4 25,639 87.8 2.1 84.3 91.6
Indiana
      Marion County 5,600 4.5 5,100 6,100 701.8 639.4 764.1 4,726 84.2 4.6 77.3 92.4
Louisiana
      East Baton Rouge Parish 4,700 5.0 4,200 5,200 1,237.6 1,115.3 1,359.8 4,051 86.0 5.1 78.3 95.4
      Orleans Parish 5,400 5.3 4,900 6,000 1,656.8 1,490.0 1,828.0 4,886 89.9 5.2 81.5 100.0
Maryland
      Baltimore City 10,500 3.9 9,700 11,300 2,128.1 1,966.7 2,289.6 9,725 92.2 3.9 85.7 99.8
      Montgomery County 4,200 5.1 3,800 4,600 475.3 431.3 523.2 3,825 90.7 4.9 82.4 100.0
      Prince George’s County 9,000 3.5 8,400 9,600 1,117.3 1,041.5 1,193.1 7,973 88.3 3.5 82.7 94.7
Massachusetts
      Suffolk County 6,000 4.4 5,600 6,500 859.3 804.2 932.9 5,632 93.6 3.8 86.2 100.0
Michigan
      Wayne County 8,000 4.2 7,400 8,700 541.3 496.6 585.9 6,940 86.3 4.2 79.7 94.1
Nevada
      Clark County 11,300 3.2 10,600 12,000 596.7 559.7 633.7 9,252 81.5 3.2 76.8 86.9
New Jersey
      Essex Countyd 9,700 4.2 8,900 10,500 1,356.5 1,244.6 1,468.5 8,768 90.6 4.2 83.7 98.7
      Hudson Countyd 5,400 5.5 4,800 6,000 887.3 791.5 983.1 4,799 88.5 5.6 79.9 99.3
New York
      Bronx County 28,400 1.8 27,400 29,400 2,364.6 2,279.1 2,450.2 26,797 94.3 1.8 91.0 97.9
      Kings County 27,400 2.1 26,200 28,500 1,208.9 1,158.6 1,259.1 25,541 93.3 2.1 89.6 97.4
      New York County 27,400 2.2 26,200 28,600 1,820.5 1,740.5 1,900.5 25,945 94.7 2.2 90.7 99.0
      Queens County 17,100 2.6 16,200 17,900 836.2 793.5 878.8 15,716 92.1 2.6 87.6 97.0
North Carolina
      Mecklenburg County 7,100 3.9 6,500 7,600 758.2 700.5 815.9 6,127 86.7 3.9 80.5 93.8
Ohio
      Cuyahoga County 5,500 4.4 5,000 6,000 513.7 469.4 558.1 4,850 87.7 4.4 80.8 96.0
      Franklin County 5,900 4.2 5,400 6,400 541.2 496.3 586.0 5,132 86.5 4.3 79.9 94.3
      Hamilton County 3,700 5.6 3,300 4,100 534.3 476.0 592.5 3,083 83.4 5.6 75.2 93.6
Pennsylvania
      Philadelphia County 18,000 2.5 17,100 18,900 1,340.0 1,273.6 1,406.5 16,651 92.4 2.5 88.0 97.2
Puerto Rico
      San Juan Municipiod,e 3,700 7.2 3,400 4,200 1,222.1 1,115.4 1,394.3 3,392 91.3 5.6 80.0 100.0
Tennessee
      Shelby County 7,200 4.1 6,600 7,800 947.6 871.2 1,024.1 6,246 86.7 4.1 80.3 94.4
Texas
      Bexar County 8,100 3.9 7,500 8,700 489.8 452.5 527.0 6,727 83.3 3.9 77.4 90.2
      Dallas County 22,300 2.3 21,300 23,300 1,050.5 1,003.6 1,097.3 18,953 84.9 2.3 81.3 88.8
      Harris County 31,800 2.0 30,500 33,000 829.1 797.0 861.3 26,897 84.7 2.0 81.5 88.1
      Tarrant County 7,400 3.9 6,900 8,000 431.2 397.8 464.5 6,144 82.6 4.0 76.6 89.5
      Travis County 6,100 4.3 5,600 6,600 555.0 507.8 602.1 5,138 84.3 4.4 77.7 92.1
Washington
      King County 8,000 4.0 7,300 8,600 410.4 378.3 442.4 7,024 88.1 4.0 81.7 95.6
Total 624,000 0.4 618,600 629,500 809.9 802.9 817.0 551,833 88.4 0.4 87.7 89.2
Table A2. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase 1 Jurisdictions
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE (%) 95% CI Ratea 95% CI No.b % RSE (%) 95% CI
2021c
Arizona
      Maricopa County 14,500 3.0 13,700 15,400 384.8 362.0 407.6 12,286 84.6 3.0 79.8 89.9
California
      Alameda County 6,800 4.4 6,200 7,300 478.7 437.1 520.3 5,950 88.0 4.5 81.0 96.4
      Los Angeles County 55,800 1.5 54,200 57,500 666.3 646.5 686.2 50,182 89.9 1.5 87.3 92.7
      Orange County 8,500 3.9 7,900 9,200 316.6 292.1 341.1 7,181 84.2 4.0 78.1 91.3
      Riverside County 11,200 2.7 10,600 11,800 549.9 521.0 578.8 10,089 90.0 2.7 85.5 94.9
      Sacramento County 5,400 4.6 4,900 5,900 409.7 372.3 447.1 4,610 84.8 4.7 77.7 93.3
      San Bernardino County 6,200 4.6 5,600 6,800 346.2 314.8 377.7 5,009 80.6 4.7 73.9 88.7
      San Diego County 15,600 2.8 14,700 16,400 558.8 528.1 589.4 13,442 86.3 2.8 81.8 91.3
      San Francisco County 11,900 3.8 11,600 12,800 1,628.2 1,587.0 1,749.7 11,601 97.5 2.4 90.7 100.0
District of Columbia 14,300 3.0 13,500 15,200 2,505.5 2,361.2 2,652.0 13,504 94.2 3.0 89.0 100.0
Florida
      Broward County 22,400 2.3 21,400 23,400 1,359.5 1,298.6 1,420.3 20,137 90.0 2.3 86.1 94.2
      Duval County 7,500 4.2 6,900 8,100 899.8 825.0 974.7 6,413 85.3 4.3 78.8 93.0
      Hillsborough County 8,500 3.9 7,900 9,200 682.3 630.5 734.2 7,379 86.7 3.9 80.6 93.8
      Miami-Dade County 30,500 2.2 29,200 31,800 1,337.3 1,279.6 1,394.9 26,875 88.1 2.2 84.4 92.0
      Orange County 11,100 3.5 10,300 11,800 916.9 853.9 980.0 9,252 83.7 3.5 78.3 89.9
      Palm Beach County 9,300 3.9 8,500 10,000 712.1 657.7 766.6 8,034 86.8 3.9 80.7 94.0
      Pinellas County 5,500 4.6 5,000 6,000 646.7 588.5 704.9 4,895 88.9 4.6 81.5 97.7
Georgia
      Cobb County 4,300 5.1 3,900 4,800 668.6 601.4 735.8 3,623 83.8 5.2 76.1 93.1
      DeKalb County 10,600 3.5 9,800 11,300 1,667.5 1,554.6 1,780.4 9,064 85.8 3.5 80.4 92.0
      Fulton County 18,900 2.5 17,900 19,800 2,075.5 1,971.8 2,179.2 16,290 86.3 2.6 82.2 90.9
      Gwinnett County 3,900 5.2 3,500 4,300 494.9 444.1 545.8 3,315 84.6 5.3 76.7 94.3
Illinois
      Cook County 29,000 2.2 27,800 30,300 660.8 632.2 689.3 25,493 87.9 2.2 84.3 91.9
Indiana
      Marion County 5,800 4.6 5,300 6,300 729.1 663.1 795.0 4,927 84.8 4.7 77.7 93.2
Louisiana
      East Baton Rouge Parish 4,700 5.2 4,200 5,200 1,242.0 1,115.6 1,368.4 4,086 86.7 5.2 78.7 96.5
      Orleans Parish 5,400 5.5 4,800 5,900 1,655.7 1,490.8 1,833.9 4,822 90.0 5.3 81.3 100.0
Maryland
      Baltimore City 10,900 3.8 10,100 11,700 2,224.6 2,059.1 2,390.1 10,109 92.5 3.8 86.1 100.0
      Montgomery County 4,300 5.2 3,900 4,700 480.7 439.1 529.9 3,889 91.3 4.8 82.9 100.0
      Prince George’s County 9,000 3.6 8,400 9,600 1,119.7 1,040.6 1,198.8 7,959 88.5 3.6 82.7 95.3
Massachusetts
      Suffolk County 6,000 4.5 5,600 6,500 878.6 822.6 955.8 5,594 93.6 3.8 86.1 100.0
Michigan
      Wayne County 8,300 4.2 7,600 8,900 559.4 512.9 606.0 7,180 87.0 4.3 80.3 94.9
Nevada
      Clark County 11,700 3.3 11,000 12,500 609.9 570.3 649.5 9,630 82.0 3.3 77.0 87.7
New Jersey
      Essex Countyd 9,700 4.3 8,800 10,500 1,361.4 1,246.0 1,476.9 8,723 90.2 4.4 83.2 98.6
      Hudson Countyd 5,500 5.5 4,900 6,100 924.6 824.0 1,025.2 4,884 88.7 5.6 80.0 99.5
New York
      Bronx County 28,100 1.9 27,100 29,200 2,399.6 2,309.9 2,489.4 26,554 94.4 1.9 91.0 98.0
      Kings County 27,300 2.2 26,100 28,400 1,241.1 1,188.4 1,293.7 25,538 93.6 2.2 89.8 97.7
      New York County 27,200 2.3 26,000 28,400 1,935.4 1,848.8 2,022.1 25,805 94.8 2.3 90.8 99.3
      Queens County 17,200 2.6 16,300 18,100 863.3 818.6 908.0 15,909 92.5 2.6 88.0 97.6
North Carolina
      Mecklenburg County 7,100 4.0 6,600 7,700 756.9 697.5 816.3 6,227 87.6 4.0 81.2 95.0
Ohio
      Cuyahoga County 5,600 4.6 5,100 6,100 524.1 477.2 570.9 4,923 88.0 4.6 80.8 96.6
      Franklin County 6,000 4.4 5,500 6,500 545.6 498.8 592.4 5,214 87.1 4.4 80.2 95.3
      Hamilton County 3,700 5.7 3,300 4,100 540.4 479.5 601.3 3,135 84.1 5.8 75.5 94.7
Pennsylvania
      Philadelphia County 17,900 2.6 17,000 18,800 1,345.8 1,277.1 1,414.6 16,546 92.6 2.6 88.1 97.6
Puerto Rico
      San Juan Municipiod,e 3,900 6.9 3,600 4,500 1,299.0 1,198.8 1,474.7 3,622 92.3 5.2 81.3 100.0
Tennessee
      Shelby County 7,400 4.2 6,800 8,000 973.0 893.7 1,052.2 6,482 87.8 4.2 81.2 95.6
Texas
      Bexar County 8,200 4.0 7,600 8,900 492.8 453.7 531.9 6,875 83.7 4.1 77.5 90.9
      Dallas County 22,900 2.3 21,800 23,900 1,080.7 1,031.0 1,130.4 19,505 85.3 2.4 81.6 89.4
      Harris County 32,400 2.0 31,100 33,700 842.3 808.6 876.0 27,585 85.2 2.0 81.9 88.7
      Tarrant County 7,700 4.1 7,100 8,300 440.1 404.7 475.5 6,346 82.7 4.1 76.5 89.9
      Travis County 6,200 4.5 5,600 6,700 554.1 505.1 603.2 5,229 84.9 4.6 78.0 93.1
Washington
      King County 8,100 4.1 7,400 8,700 417.1 383.4 450.8 7,127 88.4 4.1 81.8 96.2
Total 629,700 0.5 624,100 635,400 821.2 813.9 828.6 559,049 88.8 0.5 88.0 89.6

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC through December 2022.
Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect model uncertainty.

aRates are per 100,000 population.
bReported to the National HIV Surveillance System.
cEstimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of diagnoses reported during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes for more information.
dEstimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.
eEstimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Top of Page